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ABSTRACT OF DISSERTATION 
 
 
 
 
MULTI-COMPONENT MICROPARTICULATE/NANOPARTICULATE DRY 
POWDER INHALATION AEROSOLS FOR TARGETED PULMONARY DELIVERY 
 
The aim of the work was to design, manufacture, and characterize targeted 
multi-component dry powder aerosols of (non-destructive) mucolytic agent (mannitol), 
antimicrobial drug (tobramycin or azithromycin), and lung surfactant mimic 
phospholipids (DPPC:DPPG=4:1 in molar ratio). The targeted dry powder for inhalation 
formulation for deep lung delivery with a built-in rationale of specifically interfering 
several disease factors of chronic infection diseases in deep lungs such as cystic fibrosis, 
pneumonia, chronic bronchitis, and etc. The dry powder aerosols consisting of selected 
chemical agents in one single formulation was generated by using spray drying from 
organic solution. 
The physicochemical properties of multi-component dry powder inhaler (DPI) 
formulation were characterized by a number of techniques. In addition, the in vitro 
aerosol dispersion performance, storage stability test, and in vitro drug release of selected 
spray-dried (SD) multi-component systems were conducted. 
The physicochemical study revealed that multi-component aerosol particles possessed 
essential particle properties suitable for deep lung delivery. In general, the 
multi-component particles (typically 0.5 to 2 µm) indicated that the designed SD aerosol 
particles could potentially penetrate deep lung regions (such as respiratory bronchiolar 
and alveolar regions) by sedimentation and diffusion, respectively. The essential particle 
properties including narrow size distribution, spherical particle and smooth surface 
morphologies, and low water content (or water vapor sorption) could potentially 
minimize interparticulate interactions. The study of in vitro aerosol dispersion 
performance showed that majority of SD multi-component aerosols exhibited low values 
(less than 5µm) of MMAD, high values (approximately above 30% up to 60.4%) of FPF, 
and high values (approximately above 90%) of ED, respectively. The storage stability 
study showed that azithromycin–incorporated multi-component aerosol particles stored at 
11 and 40% RH with no partial crystallization were still suitable for deep lung delivery. 
Compared to SD pure azithromycin particles, the azithromycin-incorporated 
multi-component particles exhibited an enhanced initial release. 
The targeted microparticulate and nanoparticulate multi-component dry powder aerosol 
formulations with essential particle properties for deep lung pulmonary delivery were 
successfully produced by using spray drying from organic solution. The promising 
experimental data suggest the multi-component formulations could be further 
investigated in in vivo studies for the purpose of commercialization. 
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Chapter 1 General Introduction 
 
1.1 Characteristics of the Lung 
1.1.1 Anatomy of the Airways 
The lungs are the major respiratory organs in human body. The lungs are divided into two 
parts, including one on the right and the other on the left as shown in Figure 1.1. 
Respiratory system is responsible for transporting oxygen to the blood and removing 
carbon dioxide from the blood. It has two airway tracts, including upper and lower 
respiratory parts. The upper respiratory tract is defined as the region, starting from nose 
or mouth passages, through pharynx and larynx, to the trachea. The lower respiratory 
tract includes bronchi, bronchioles (including terminal bronchioles and respiratory 
bronchioles), and gas-exchanging regions (including alveolar ducts and alveolar sacs). 
However, based on functionality, airways can also be categorized into conducting and 
respiratory parts. The conducting airways do not involve in gas exchange, and consist of 
regions from the trachea to the terminal bronchioles. The respiratory airways, responsible 
for gas exchange, are respiratory bronchioles, alveolar ducts, and alveolar sacs. 
 
Figure 1.1. Schematic of the respiratory system. Adapted from [1]. 
The lung airways are recognized as a bronchial tree in structure[2]. Analogous to the 
trunk and branches of a tree, the trachea bifurcates to form bronchi and bronchioles. The 
sac-like alveoli could be viewed as the leaves of a tree. Weibel airway model[3] (Figure 
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1.2) is used to characterize airway structure and represents the airway divisions before 
alveolar sacs are reached. Up to 24 airway generations are proposed in the Weibel model, 
with trachea and alveolar sacs being generation 0 and 23, respectively. Compared to the 
previous generation, the number of airways at each generation is doubled. Each airway 
generation exhibits a characteristic range of sizes in lengths and diameters of the 
branches[4]. 
 
Figure 1.2. Schematic of Weibel airway model. Adapted from [2]. 
Two characteristics of the lungs exhibit important influences in airway function. The first 
characteristic is that airway diameters decrease with increasing generations (in Weibel 
model). For instance, with an alveolar diameter being 0.04 cm, a tracheal diameter in the 
adult is on the order of 1.8 cm[5]. During inspiration, this physical characteristic permits 
easy air penetration into the lower airway regions. The second characteristic is that 
surface area in airways increases dramatically with each succeeding generation. With a 
presence of ~ 600 millions alveoli, the total surface area in the alveolar region is 
estimated to be ~ 140 m2 in an adult human[5] Alveoli are the main region for gas 
exchange between air and blood. Each alveolus is surrounded and separated from one 
another by thin blood capillaries. An exchanging gas molecule in an alveolus has to travel 
a distance of approximately being 500 nm, from the alveolar epithelium, through 
capillary endothelium, and to basement membrane before arriving into the blood[5]. 
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1.1.2 Physiology of the Airways 
Lining on the luminal surface is the epithelium of the airways. The epithelial cells are the 
barrier of absorption into the bloodstream. The cell productions are markedly different 
depending on locations in the lungs. As shown in Figure 1.3, the epithelial cells are 
drawn at the corresponding relative sizes. In the bronchial airways, a wide range of cells 
make up the epithelium[2]: the basal cells are the stem cells for the epithelium, 
differentiating to form the other cells in the case of injury or apoptosis; the goblet cells 
secret the mucus; the ciliated cells provide the mechanism for moving the mucus; the 
brush cells participate in drug metabolism. The gradually thinning epithelium, with many 
mucus and ciliated cells, acts as so called “mucociliary escalator”. Absorptive epithelium 
becomes thinner until alveoli are reached. All the above listed types of cells exist in the 
smaller airways, but as a thinner layer.  
 
Figure 1.3. Comparison of the lung epithelium at different airways. Adapted from [2]. 
However, as different to bronchial airways, alveolar epithelium is a monolayer of cells. 
The alveolus mainly consists of Type I and Type II alveolar cells as shown in Figure 1.4. 
Type I cells are very broad and extremely thin (< 0.1 µm) squamous cells that form most 
(about 95 %) of the surface of the alveoli. The exchange of oxygen and carbon dioxide 
takes place through the cell membranes and cytoplasm of Type I cells. As numerous as 
Type I cells, Type II cells are locate among the Type I cells and cover only 5% of the 
alveolar surface. Type II cells possess three main functions[6]: 1) secretion of pulmonary 
surfactant; 2) control of alveolar fluid levels; 3) act as the stem cells to replace both Type 
I and II cells after injury. On average, about 12-14 alveolar macrophages range over the 
air-side of 500 alveoli spaces[2]. A morphometric study of human lung tissue indicated 
that 90% of alveolar macrophages are observed at or near alveolar septal junctional 
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zones[7]. Alveolar macrophages engulf and ingest any foreign particles and infectious 
microorganisms that may exist in the alveoli. The indigestible materials are frequently 
transported to the lymph nodes of the lungs[6]. 
 
Figure 1.4. Structure of an alveolus. Adapted from [8]. 
Released by Type II alveolar cells, pulmonary surfactant is a mixture of surface-active 
lipids (90% by weight) and proteins (10% by weight). The lipids and proteins have both a 
hydrophilic region and a hydrophobic regions. Pulmonary surfactant adsorbs to the 
air-water interface of alveoli with the hydrophilic head groups in the water and the 
hydrophobic tails facing towards the air. Therefore, it reduces the surface tension of 
interface. Dipalmitoylphosphophatidylcholine (DPPC), a predominant lipid (40% by 
weight) with saturated fatty acid chains, contributes substantially to the unique properties 
of pulmonary surfactant.[9] In addition to DPPC, pulmonary surfactant also contains 
unsaturated phosphatidylcholine (~35%), phosphatidylglycerol (~10%), 
phosphatidylinositol (~2%), phosphatidylethanolamine (~3%), sphingomyelin (~2.5%), 
and cholesterol (~3%).[10] The proteins are comprised of a highly variable amount of 
serum proteins and four apoproteins (surfactant protein A (SP-A), surfactant protein B 
(SP-B), surfactant protein C (SP-C), and surfactant protein D (SP-D)). Associated with 
lipids, the proteins contribute to specific functions of pulmonary surfactant.[9] Pulmonary 
surfactant stabilizes the alveoli during the respiratory cycle by reducing surface tension of 
water-air interface. Therefore, it prevents the tendency of alveolar collapse in expiration 
and makes lung inflation easy in inspiration.[10] The function of host defense in alveoli 
replies on the nature of SP-A and SP-D.[9] In addition, surfactant also possesses 
anti-inflammatory functions[11], promotes mucus clearance[12], prevents pulmonary 
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infection[11], and eliminates extracellularly generated oxyradicals and enhances 
intracellular antioxidant enzyme content[13]. 
 
1.1.3 Blood Circulation 
Pulmonary and systemic circulation both exist in the lungs. Drug delivered to the lower 
airways could be absorbed into body through both of the circulations. Pulmonary 
circulation conducts the blood from the heart to the lungs for oxygen. Oxygen-depleted 
blood travels through capillaries on alveoli, removing carbon dioxide and absorbing 
oxygen into the blood. The alveoli provide the tremendous surface for gas exchanging 
during respiration. Thereafter, the oxygenated blood leaves the lungs through pulmonary 
vein and returns to the left atrium of heart. Pulmonary circulation operates on a 
low-pressure and low-resistance vascular bed with a flow rate of 5 L/min[10]. 
Systemic circulation is the blood movement from the heart through the body to provide 
oxygen and nutrients. During systemic circulation oxygen in the blood diffuses into the 
respiratory cells, while waste and carbon dioxide are carried into the blood. In addition, 
systemic circulation assists in the humidification and warming of inspired air in the 
trachea and bronchi[10]. Moreover, it also plays a key role in anti-inflammation of lungs 
by mucosal swelling and delivery of inflammatory cells and mediators to the airways[10]. 
 
1.2 Aerosol Particle Deposition Mechanisms in Human Lungs 
Local delivery of drugs to the lungs attracts tremendous attention for the treatment of a 
variety of pulmonary diseases. The therapeutic efficacy by dry powder for inhalation is 
highly influenced the dose delivered to the target regions. Given the characteristics of the 
lungs and respiratory pattern, aerosol particle properties (e.g. particle size and size 
distribution, particle morphology, hygroscopicity, and etc.) mainly determine the airways 
deposition[14]. There are three major particle deposition mechanisms[14] in the lungs, 
including inertial impaction, sedimentation, and Brownian diffusion. Other mechanisms, 
including interception, electrostatic precipitation, and hygroscopic particle growth, have 
also been reported[10]. Various deposition mechanisms may be involved simultaneously 
for one particular aerosol formulation. 
Inertial impaction is the main deposition mechanism for particles more than 5 µm in 
diameter with high velocity[14]. These particles are unable to follow the air streamlines 
due to high inertia. It takes place commonly in extrathoracic and large conducting 
airways, where air flow velocities are high and airway directional changes are fast. The 
probability of inertial impaction of aerosol particles increases with increasing air flow 
velocity, rate of breathing, particle size (> 5 µm) and particle density[10]. Stokes number 
(Stk) influences the particle deposition by inertial impaction[15]: 
Stk = ρpdp
2V
18µD
  (Equation 1.1) 
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Where ρp is the particle mass density, dp is the particle diameter, V is the air flow velocity, 
µ is the dynamic viscosity of the surrounding air, and D is a characteristic dimension of 
the obstacle obstructing air flow (usually in a daughter airway). 
Sedimentation (gravitational settling) is deposition mechanism for particles (typically 1-5 
µm) in the small conducting airways where air flow velocity is slow[14]. The deposition 
is high for large particles (gravitational drag) with long residence time[14]. However, it 
decreases with increasing breathing rate[10]. As similar to inertial impaction, 
sedimentation is dependent on the relaxation time of the particles (the time required for 
the particle to respond to a change of the air flow velocity; τ)[16]. 
τ = ρpdp
2
18µ
  (Equation 1.2) 
Where ρp is the particle density, dp is the particle diameter, and µ is the dynamic viscosity 
of the surrounding air. 
Brownian diffusion dominates the deposition of particles with submicron in size 
(typically 0.5-1 µm)[14]. Brownian diffusion results from random motion of particles 
impacted by the surrounding air molecules. It occurs in the deep lungs, especially 
respiratory bronchial and alveolar regions where air flow is minimal. Stokes-Einstein 
equation (for diffusion of spherical particle through medium with low Reynolds number) 
defines the diffusion constant (D) of Brownian motion: 
D =  kBT
6πηr
 (Equation 1.3) 
Where kB is Boltzmann’s constant, T is the absolute temperature, η is viscosity, and r is 
the radius of the spherical particle. 
Interception is mainly relevant to particles with high aspect ratio (elongated particles) 
such as fibers and aggregates. The use of elongated particles for deep lung delivery has 
been attracting attentions due to the characteristic aerodynamic behaviors (such as an 
increase in fine particle fraction (FPF))[17-19]. Elongated particles preferably align with 
the long axis in air streamlines when penetrating into airways. Therefore, the short axis of 
elongated particle is mainly related to the aerodynamic diameters. Moreover, once 
deposited, elongated particles are less rapidly cleared by macrophages due to the long 
length[20]. However, the aerosol dispersion of elongated particles relies on the form of 
loose agglomeration of the particles. Low aerosol performance arises as the particles are 
in contact with long axis[21]. In addition, powder flow and content uniformity could be 
problematic with elongated particles in dry powder formulations[16].  
Electrostatic precipitation could occur on charged particles generated by mechanical 
forces. However, this electrostatic attraction/repulsion between charging in particles and 
airway surface only is a minor contributor to particle deposition[22].  
Particle growth of hygroscopic aerosols at elevated relative humidity and temperature in 
the respiratory tracts may affect particle deposition[23].  
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1.3 Pulmonary Aerosol Drug Delivery 
Efficiency of pulmonary drug delivery is dependent upon both the aerosol formulation 
and inhalation device. Modern inhalation devices can be divided into four principle 
categories: nebulizers, pressurized metered-dose inhalers (pMDIs), dry powder inhalers 
(DPIs), and soft-mist inhalers (SMIs). Each class possesses its unique strengths and 
weaknesses. 
1.3.1 Nebulizers 
Two typical nebulizers are commercially available, including air jet and ultrasonic 
nebulizers. Marketed respiratory solutions are usually drug in isotonic aqueous solutions. 
In addition, these solutions may contain preservative to inhibit microbial growth.  
Jet nebulizers (Figure 1.5), the most commonly used nebulizers, are also named as 
“atomizers”[24]. Jet nebulizers are connected to a compressor used as a source of gas. 
The compressed air or oxygen in a compressor flows at high velocity through a liquid. It 
turns the liquid into aerosol droplets inhaled by patients. Approximately 50 to 60% of the 
aerosols produced by jet nebulizers are in the respirable range (< 10 µm)[10]. 
 
 
Figure 1.5. Schematic of a jet nebulizer. Adapted from [25]. 
Ultrasonic nebulizers (Figure 1.6) use an electronic oscillator to generate a high 
frequency ultrasonic wave, causing a mechanical vibration of a piezoelectric transducer. 
The vibration provides the energy to aerosolize the liquid. The frequency of the vibrating 
piezoelectric transducer determines the droplet size for a given solution. Generated by 
ultrasonic nebulizers, approximately 70% of the particles exhibit particle size in range 
from 1 to 5 µm[10]. However, heat generated from frictional forces by movement of the 
transducer may be detrimental to thermolabile formulations[10]. 
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Figure 1.6. Schematic of an ultrasonic nebulizer. Adapted from [25]. 
Commonly used in hospital, the old models of both jet and ultrasonic nebulizers usually 
generate a lot of noise and are not portable due to a heavy weight. Advances in 
technology have led to the development of novel nebulizers. These miniaturized novel 
nebulizers are portable with high-output, generating small droplets capable of penetrating 
deeply into the lungs (< 5 µm). New techniques in liquid spray delivery devices are 
employed including high pressure micro-spray nozzle systems and electrostatic 
generation of aerosol clouds[26]. Some of the commonly available drug solutions 
delivered by nebulizers are Ventolin® (salbutamol, beta 2-mimetic bronchodilator), 
Bricanyl® (terbutaline, beta 2-mimetic bronchodilator), Atrovent® (ipratropium, 
anticholinergic bronchodilator), Pulmozyme® (dornase alpha, mucolytic), and Tobi® 
(tobramycin, antibiotic)[10]. 
In general, the advantages of using nebulizers are: 1) constant output of delivering 
aerosols; 2) large dose delivery; 3) low requirement on coordination between aerosol 
generation and breathing of patients. However, well-documented disadvantages of using 
nebulizers are: 1) time-consuming; 2) high cost; 3) inefficiency[27]; 4) poor 
reproducibility and great variability; 5) risk of bacterial contamination; 6) constant 
cleaning[28]; 7) inconvenient (bulky)[29]; 8) waste of active ingredient (dead volume of 
solution)[30]. 
 
1.3.2 Pressurized Metered-Dose Inhaler (pMDIs) 
Pressurized metered-dose inhalers (pMDIs) can deliver a specific amount of drug to the 
lungs in the form of a short aerosol burst. pMDIs are usually self-administered by the 
patient. These devices are commonly used in treatment of asthma, chronic obstructive 
pulmonary disease (COPD), and other respiratory diseases. 
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pMDIs (Figure 1.7) are composed of three major components[5, 31]: 1) a canister made 
of aluminum or stainless steel, where the formulation resides; 2) a metering valve 
allowing a metered quantity of the formulation to be dispensed with each actuation; 3) an 
actuator (or mouthpiece) allowing the release of aerosols and directing the aerosols into 
the patient’s lungs. The formulation itself consists of the medication (either dissolved or 
suspended in the propellant), a liquefied gas propellant, and possibly stabilizing 
excipients. Actuation of the device releases a single metered dose of the formulation 
liquid through the control valve. With expansion and evaporation of propellant in 
formulation liquid, it leaves the drug in the form of aerosols at a high velocity. The 
liquefied propellant are used both as an energy source for expelling the formulation from 
the valve and a dispersion medium for the drug and other excipients. 
 
Figure 1.7. Schematic of a pressurized metered-dose inhaler. Adapted from [32]. 
Particle size and size distribution of aerosols from a pMDI are dependent on the 
physicochemical properties of the formulation. Size of aerosol droplets from suspension 
formulation in pMDIs could be reduced by using a low drug concentration, or small drug 
particles, or a system with high vapor pressure[33]. In addition, low concentration of a 
surfactant helps the dispersion of suspended particles or dissolution of a partially soluble 
drug, and lubricates the metering system[34]. Antioxidant or chelating agent may be 
added to enhance chemical stability of the formulation[10]. Unpleasant taste of 
formulations might be masked by adding flavors or sweeteners[10]. Some of the 
commercially available pMDIs include Flixotide® (fluticasone, corticosteroid), Atrovent® 
(ipratropium bromide, anticholinergic bronchodilator), Ventolin® (salbutamol, beta 
2-mimetic bronchodilator), and Combivent® (ipratropium bromide and salbutamol, 
anticholinergic and beta 2-mimetic bronchodilator). 
There are several disadvantages of drug delivery by pMDIs. Chlorofluorocarbons (CFCs) 
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as a propellant have been banned by 2000 by “Montreal Protocol” (due to the 
contribution to ozone depletion and health effects)[35]. The replacement propellant, 
hydrofluoroalkane (HFA), is an extremely poor solvent. Therefore, formulation 
surfactants are totally insoluble in HFA, resulting in physical stability issue of drug 
particles. Numerous approaches are employed to overcome the issues associated with 
HFA propellants, including addition of a co-solvent, development of a new surfactant, 
and particle engineering[10].  
In general, only a small fraction of drug dose (approximately 10 to 20% of emitted dose) 
could be delivered by pMDIs to the lungs. A well-known issue, so-called “cold–Freon 
effect”, can be experienced by using pMDIs. It is attributed to the evaporation of 
propellant when the aerosols impact on the back of the throat, causing patients to stop 
inhaling[36]. Poor hand-mouth coordination is another issue associated with the use of 
pMDIs[37]. However, the introduction of breath-actuated pMDIs (such as Autohaler®) 
provides a convenient means to overcome the poor coordination[10]. 
 
1.3.3 Dry Powder Inhalers (DPIs) 
Dry powder inhalers (DPIs) are devices that deliver drug to the lungs as a dry powder. 
The emergence of DPIs was largely driven by the “Montreal Protocol” that addressed 
elimination of CFCs from traditional pMDIs[38, 39]. DPI products combine powder 
technology and device design in order to disperse dry aerosol particles in the lungs of 
patients. Commercially available DPI devices range from single-dose devices (e.g., 
Aerolizer® (Novartis) and Handihaler® (Boehringer Ingelheim)) to multi-dose devices in 
form of a blister pack (e.g., Diskhaler® and Diskus® (GlaxoSmithKine)) or reservoir-type 
system (e.g., Turbuhaler® (AstraZeneca))[5]. For instance, a schematic of the 
Handihaler® DPI device (open state) from Boehringer Ingelheim (Germany) is shown in 
Figure 1.8. Drug particles in a capsule (placed in center chamber (#6 in Figure 1.8)) are 
released via a rumbling motion once the capsule is pierced by two pins (placed inside of 
the piercing button (#5 in Figure 1.8)). The drug particles are dispersed through the 
turbulent air flow generated by a stainless grid (placed inside of the mouthpiece (#2 in 
Figure 1.8)) at the time of inhalation[10]. 
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Figure 1.8. Schematic of the Handihaler® DPI device. Adapted from [40]. 
DPIs have three basic features including device, formulation, and dose-metering 
system[16]. The pre-metered (single-dose or multi-dose) devices are further classified 
into active (device actuated) and passive (breath actuated) DPIs. As to passive DPIs, the 
inspiration is the only energy source for particle resuspension from static powder state. 
The device itself is designed to allow efficient particle resuspension through powder 
fluidization and deaggregation[41]. DPI formulation could either be lactose carrier-free 
(respirable drug particles alone with aerodynamic diameter about 1-5 µm depending on 
the target site)[42-44] or lactose carrier-based (blends of respirable drug particles and 
lactose particles)[45]. α-lactose monohydrate is commonly used as carrier particles. In 
addition to acting as a bulking agent for uniform capsule filling, the carrier particles 
(typically > 30 µm in diameter) are used to increase powder flow and facilitate the release 
of respirable drug aerosols[16]. Dose-metering system includes the pre-metered 
individual capsules, multiple dose blisters or strips, and dose reservoirs. 
Efficiency and reproducibility of aerosols reaching the desired site of action are 
determined by DPIs device, formulation, and inspiratory maneuver of patients[45]. The 
new generation of DPIs under developments includes extra mechanisms (such as the 
employment of impellors, compressed air assistance, vibration, and impact hammers) to 
enhance aerosolization of drug particles[16]. Recently novel DPIs, standardized 
entrainment tubes (SETs; a series DPIs with unique features and design, but different 
turbulent shear forces), have been developed, leading to prediction, modeling, and 
fundamental understanding of particle resuspension from static powder state[46-48].  
 
1.3.4 Soft-Mist Inhalers (SMIs) 
Soft-mist inhaler (SMI; Respimat®), as shown in Figure 1.9, is a new generation inhaler 
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invented by Boehringer Ingelheim in 1997[49]. This device provides a metered dose to 
the users. As the bottom of the inhaler is rotated clockwise 180 degrees by hand, a 
tension is built up into a spring around the flexible liquid container. Upon activation, the 
release of energy from the spring imposes pressure on the flexible liquid container. It 
produces two fine jets of liquid that converge at a pre-set angle through precisely 
engineered nozzle (in uniblock), forming a soft inhalable mist. With no propellant and no 
need for a battery, the device employs only mechanical energy. The relatively long 
generation time of aerosol cloud (approximately 1.5 s) facilitates coordination of 
actuation and inhalation which is a major problem with pMDIs. With the slow velocity of 
the soft mist, it results in larger amounts of the drug deposited in the lungs and less 
deposited in the oropharynx compared with either pMDIs and DPIs[49]. In general, the 
soft mist contains a high fine particle fraction of approximately 65 to 80%[49].  
 
 
Figure 1.9. Schematic of the Respimat® soft-mist inhaler. Adapted from [49]. 
 
1.4 Interparticulate Forces 
Dry powder aerosol particles prepared in respirable sizes exhibit unique properties based 
on the forces of interaction. The interparticulate forces need to be overcome before the 
inhalable aerosol particles generated in circumstance of either carrier-free or 
carrier-based DPI formulations. Interparticulate or surface forces (adhesive and cohesive 
forces) in the dry powder formulations are a result of complex combination of physical 
forces including van der Waals forces, electrostatic forces, capillary forces[16, 50]. In 
addition, other forces, such as mechanical interlocking, frictional forces, and hydrogen 
bonding, are not frequently mentioned, but still important[41]. Particle aggregation is a 
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result of interparticulate forces. The contribution of each force to the particle aggregation 
is dependent on numerous factors such as surface morphology, crystallinity, intrinsic 
material properties, and environmental conditions[41]. The calculated magnitude of 
interparticulate forces (van der Waals, electrostatic, and capillary forces between ideal 
binary system) was previously reported[41, 51]. In general, at normal environmental 
conditions, the strength of van der Waals forces is about two orders of magnitude higher 
than electrostatic and capillary forces. However, capillary forces would dominate at 
condition of high relative humidity[16]. 
van der Waals forces (Fvdw) can be defined as below[16]: 
Fvdw =  
A
6h2
∗ R1R2
R1+R2
=  AR
12h2
 (R1 = R2 = R, for two identical spheres) (Equation 1.4) 
Fvdw =  
AR
6h2
 (R1 << R2, for sphere and surface) (Equation 1.5) 
Where A is the Hamaker constant (typically ~10-19 J) dependent on the molecular 
properties of the materials, R is the particle radius (m), and h is the separation distance 
(m). As compared to van der Waals force, gravitational forces are lowered greater when 
size of drug particles becomes small[16]. Therefore, the dry particles, with size less than 
10 µm, become adhesive/cohesive as van der Waals forces become predominant[16]. 
Based on the Equation 1.4 and 1.5, van der Waals forces, effective within a separation 
distance < 100 µm[16], diminish rapidly with increasing separation distance. Therefore, 
van der Waals forces are sensitive to the change of particle shape and surface 
morphology[52]. The magnitude of van der Waals forces is greatly affected by the 
number of mutual points of contact known as the coordination number[41]. The van der 
Waals forces of particles could be also influenced by surface roughness (such as kinks 
and defects) by several orders of magnitude. The surface roughness of particles can be 
evaluated by mathematical models (e.g. Fourier, fractal, and chaos analysis) in terms of 
irregular oscillations around a mean value[53]. 
Electrostatic forces (including contact charging, coulombic interaction, and induced 
charging) could be either attractive or repulsive[16]. Contact charging involves the 
contact of a charged object to a neutral object until electron transfer reaches equilibrium. 
The contact charging force (Fc) is defined as[16, 50]: 
Fc =  
2πq2
A
  (Equation 1.6) 
Where q is charge detachment between two objects, A is the contact area between two 
objects. 
Coulombic interaction occurs in two charged objects. Dependent upon the sign of 
electrical charge, it could be either attraction or repulsion. Coulombic force (Fq) is 
expressed as[16]: 
Fq =  
q1q2
4πεh2
  (Equation 1.7) 
Where q1 and q2 are the charge on two objects, respectively, ε is the permittivity, and h is 
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the separation distance. 
Induced charging appears when a charged object approaches an uncharged object. 
Induced charging (Fe) is calculated as[16]: 
Fe = q2 �1 −
h
(R2+h2)0.5
� ∗ 1
16πεh2
 (Equation 1.8) 
Where q is the charging on charged object, h is the separation distance, R is the radius of 
uncharged object, and ε is the permittivity. 
As LaPlace pressure develops, capillary forces cause capillary condensation of water 
vapor. The formation of liquid bridge formation between solid particles due to water 
vapor condensation brings particles together. Capillary forces take places because of 
intermolecular forces between the liquid and surrounding solid surfaces. The capillary 
forces (Fcp) between two spherical particles are described as[16, 50]: 
Fcp = 4πR∗γLcosθ + 4πR∗γSL  (Equation 1.9) 
Where R* is the harmonic mean of radii of the particles, γL is the surface tension of water, 
γSL is the solid-liquid interfacial energy, and θ is the contact angle of liquid film to 
particle surface. 
Mechanical interlocking arises with an increase in surface roughness. Mechanical 
interlocking of the particles is a prominent mechanism preventing particle dispersion for 
carrier-based DPI formulations. Moreover, surface roughness may also alter van der 
Waals forces, surface charging density, water vapor condensation in dry powders[54]. It 
has been reported that increased surface smoothness of carrier particles enhanced the fine 
particle fraction (FPF) of the DPI formulations[55-57]. In addition, dependent on the 
physicochemical and viscoelastic properties, aerosol particles may deform, which 
changes the effective contact area[16]. 
In reality, the forces of interaction between pharmaceutical particles are difficult to 
characterize or be controlled due to the heterogeneity in particle composition and 
physicochemical characteristics. Therefore, it is not practical to consider each of the 
forces independently. Nonetheless, key features of inhalation powders that critically 
influence interparticulate forces could be evaluated, including particle size and size 
distribution, particle shape, surface asperities (roughness), crystallinity, particle density, 
and presence of impurities[10]. Adhesion/cohesion of dry powder for inhalation could be 
indirectly estimated by using inverse gas chromatography (IGC)[58-64] and contact 
angle[65], and directly measured by using atomic force microscopy (AFM)[66, 67]. The 
efficiency of deaggregation in aerosolization is highly influenced by existing 
adhesive/cohesive forces in formulations. For instance of carrier-based dry powder 
formulation for inhalation, strong adhesive (drug-carrier) interaction may prevent the 
release of respirable drug particles from the surface of carriers, leading into a high 
deposition in upper airways. Therefore, the adhesive forces between respirable drug 
particles and large carrier particles strongly influences the delivered dose, since only drug 
particles separated from carrier surface are able to reach to the deep lungs. Similarly, 
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excessive cohesive forces could lead to agglomerate formation, affecting powder 
fluidization and dispersion characteristics of formulations[66]. The balance of these 
forces is very critical in drug-carrier blending, drug particle deaggregation, and drug 
particle resuspension. 
 
1.5 Spray Drying 
There are several methods available to make respirable particles for dry powder 
inhalation, including micronization, freeze drying, and spray drying, and etc.[68-70]. 
Micronization, a simple and easy process by particle-particle and particle-solid collisions, 
is a classical approach in particle size reduction. However, in addition to produce 
cohesive particle aggregates, it is difficult to the control of particle size, size distribution, 
and morphology[45]. Many particles (e.g. protein drug) are produced by freeze drying 
due to stability issue. However, in addition to formation of undesired particles which are 
not suitable for inhalation, it is time and energy consuming[71]. 
Spray drying is a one-step continuous particle process operation. It exhibits a high ability 
to produce particles in a controlled manner, such as directing particle size and size 
distribution, particle shape, and particle morphology, which are important particle 
features for pulmonary drug delivery by inhalation. The process of spray drying converts 
a liquid feed (such as solutions, suspension, emulsions and etc.) to dried particles. A 
schematic of spray dryer is shown in Figure 1.10. Some key components of a spray dryer 
include: 1) electric device that elevates the temperature of drying gas; 2) nozzle that 
atomizes liquid feed into droplets by compressed air; 3) spray drying glass chamber for 
primary drying of droplets with drying gas; 4) cyclone that separates dried particles from 
drying gas; 5) filter that removes fine particles (not collected by cyclone); 6) aspirator 
that generates air flow in system; 7) liquid collecting system (not show in Figure 1.10) 
that condenses water vapor, organic vapor, or both into liquid state.  
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Figure 1.10. Schematic of a spray dryer. Adapted from [72]. 
In general, the process of spray drying involves three stages, including atomization, 
drying, and separation[30]. Atomization is the process of droplet generation from liquid 
feed. A spray of millions of droplets is formed when a liquid feed is forced through a 
nozzle by a pressurized atomizing gas at high velocity. The nozzle dimensions influence 
the size of produced droplet, and thus the size of resultant dry particle. In addition, pump 
feeding rate, liquid feed concentration, liquid feed type (i.e. solution, suspension, or an 
emulsion), solvent type (i.e. aqueous vs organic liquid), liquid viscosity, atomizing gas 
type, and aspiration rate may impact the particle size of final powder. However, regarding 
to the role of viscosity, opposite views has been expressed. It is suggested[30] that an 
increase in viscosity of feed increase the size of droplet and its dried particle. It is also 
reported[73, 74] that smaller particles are generated by using liquid with higher viscosity 
and faster feeding rate. These conditions are thought to generate a larger back-pressure in 
a nozzle, producing a finer spray due to an increase in sheer during atomization. 
Drying of droplets takes place when contacting heated gas in the primary drying chamber. 
The type of drying gas with the associated moisture level may affect particle 
properties.[30]The rate of drying is mainly influenced by drying temperatures (both 
independent inlet and dependent outlet temperatures) and the flow rate of drying air[75]. 
The thermal efficiency of spray drying is generally defined as[75, 76]. 
ηoverall = 100 ∗ �
Tin−Tout
Tin−Troom
� (Equation 1.10) 
Where ηoverall is overall thermal efficiency, Tin is the inlet temperature, Tout is the outlet 
temperature, and Troom is the room temperature. Using a low airflow rate exhibit a high 
efficient drying for dried particles due to a long resident time. However, a low airflow 
rate during spray drying associate with a low yield and possible large final particles[75]. 
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Separation of dried particles from air stream is achieved by using a cyclone. With an 
application of centrifugal force, particles impact on the wall of cyclone. Particles are 
eventually collected in a bottom vial as removed from the cyclone wall. The effective 
particle collection is dependent upon geometry of the cyclone. With a given cyclone, the 
particle collection efficiency is enhanced with increasing airflow rate and powder mass 
loading[30].  
 
1.6 Chronic Infections in the Deep Lungs (Cystic Fibrosis/Pulmonary Infections) 
Chronic infection diseases in lower respiratory regions[77] include cystic fibrosis (CF), 
pneumonia, chronic bronchitis, and etc. Chronic bronchitis, a type of chronic obstructive 
pulmonary disease (COPD), is highly caused cigarette smoking[78]. However, 
environment, occupation, and social class have also been associated to the development 
of chronic bronchitis[79-81]. Both bacterial (about 90%)[82] and viral (about 10%)[83] 
infections were observed in sputum of patients with chronic bronchitis. Pneumonia is an 
infectious lung disease, primarily in alveoli, with an inflammatory condition. Pneumonia 
is often caused by bacteria or virus such as pneumococcus, klebsiella, Hemophilus 
influenza, staphylococcus or rhinoviruses, influenza virus and etc.[77, 84].  
 
1.6.1 Disease Background 
As a disease example of deep lung chronic infections, only CF is focused in details in this 
section. CF is an inherited life-shortening autosomal recessive disease, affecting about 
30,000 children and adults in the United States (70,000 worldwide). The defective gene, 
CF transmembrane conductance regulator (CFTR), results in dysfunction of apical 
membrane CFTR protein. CFTR protein disrupts ion (chloride and sodium) transport in 
systems, including pulmonary airways, pancreatic ducts, sweat ducts, and intestine[85, 
86]. Therefore, it results in the production of an abnormally viscous secretion[87].  
The clinical consequences of this multi-system disease are characterized by progressive 
pulmonary damage leading to respiratory failure, pancreatic dysfunction, liver disease 
progressing to cirrhosis, gut motility problems, infertility and elevated sweat 
eletrolytes[87, 88]. Nevertheless, the major causes of morbidity and mortality in patients 
with CF are obstruction of pulmonary airways and bronchiectasis[89].  
CF originates from the deep lungs such as respiratory bronchiolar and alveolar regions. 
The lower airways of CF lungs are coated with thick and tenacious secretions, resulting 
in diminished function of mucociliary clearance. This creates an ideal environment for 
chronic lung infections, leading to cardiopulmonary failure. There are several bacterial 
species, such as Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia 
cepacia, that appear to be especially well-adapted to cause chronic lung infections in CF 
lungs[90]. In young children of CF, Staphylococcus aureus and Haemophilus influenza 
are the two predominant pathogens. As increasing age, most patients will eventually 
progress to infection with Pseudomonas aeruginosa or a variety of other gram-negative 
organisms, including Alcaligenes xylosoxidans, Stenotrophomonas maltophilia, and ect. 
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Even in adult CF patients, the bacterial pathogens may change gradually with time. 
However there is one constant: endobronchial bacterial infection, once established, can’t 
be completely eradicated. The therapeutic advances over the last several decades largely 
responsible for the dramatic increase in life expectancy in CF have been aimed primarily 
at decreasing the density of endobronchial Pseudomonas aeruginosa infection, thereby 
reducing the local inflammatory reaction that accounts for the progressive airway 
destruction characteristic of CF[91].  
A proportion of CF patients are also affected by allergic bronchopulmonary aspergillosis 
(ABPA). This is a disease characterized by lung hypersensitivity due to endobronchial 
colonization with Aspergillus fumigatus[92]. The strains of Aspergillus have been 
isolated from the sputum of more than 20% and up to 52% of CF patients[93, 94]. ABPA 
is associated with an accelerated decline in lung function of CF patients[95]. The reported 
prevalence of ABPA in CF patient is around 10%, which is much higher than the non-CF 
population[94-96]. Many of the findings of ABPA overlap with common manifestation of 
the lung disease of CF. Scedosporium apiospermum is the second-most-frequent genus of 
fungi isolated from the sputa of CF patients. It exhibits a pathogenicity similar to that of 
Aspergillus species[97].  
Patients suffering from CF are probably at particular risk of losing the ability of the 
surfactant to maintain airway potency. The disease is associated with inflammation, 
which cause a leakage of plasma proteins into the airway lumen. This is a likely cause of 
a disturbed function of the pulmonary surfactant[98, 99]. However, it is probably a more 
important reason that surfactant dysfunction is caused by a Pseudomonas aeruginosa 
infection in CF patients, in which Pseudomonas aeruginosa bacteria can synthesize and 
release phospholipase C (PLC) to the lung lumen[100-104]. This enzyme can catalyze a 
hydrolysis of phosphotidylcholine (PC), the main and most active surfactant component.  
 
1.6.2 Disease Treatment 
Cystic fibrosis (CF) is a multisystem disorder disease. However, pulmonary disease is the 
predominant cause of morbidity and mortality. The treatment of CF is directed toward 
alleviation of symptoms and correction of organ dysfunction due to disease complications. 
Advances in research and medical treatments have enhanced and extended life for 
children and adults with CF. Many patients with CF are expected to live into their 30s, 
40s, or beyond. In 2009, the median predicted age of survival was in the mid-30s[105]. 
There are some standard therapies and advanced treatments for CF patients, including 
restoration of airway surface liquid, mucus alteration, antimicrobial therapy, lung 
transplantation, and etc.  
 
1.6.2.1 Restoration of Airway Surface Liquid 
Hydration of airway secretion offers an approach to improve mucociliary transport by 
using osmotic agents. A study[106] has suggested that twice-daily inhalation of a 
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hypertonic saline solution (osmotic agent) over 48 weeks has positive effects on two 
important aspects (improvement of lung function and reduction in the frequency of 
pulmonary exacerbations) of CF lung disease, compared to the control group of inhaled 
normal saline. Moreover, the study provided the evidence of long-term efficacy in 
patients with CF. In addition, mannitol, another osmotic agent, is being evaluated. 
Mannitol can be administered as a dry powder by metered-dose inhaler, which offering a 
less time-consuming alternative to hypertonic saline[107]. In addition, hypertonic saline 
and dry-powder mannitol are also considered as non-destructive mucolytic agents[108]. 
These two osmotic agents hydrate the mucus matrix, breaking upon ionic and hydrogen 
bonds, rather than covalent bonds, in mucous gel. Without reducing polymer chain length 
in mucus matrix, these osmotic agents alter the crosslink density of mucus, decreasing the 
physical entanglement. It results into a reduction in both elasticity and viscosity of mucus, 
a preferential improvement in mucociliary clearance. The detailed mechanism of 
action[108] is discussed in the literature. Hypertonic saline (known as MucoClearTM)[109] 
has been marketed. Mannitol dry powder for inhalation (known as BronchitolTM) is in 
phase III clinical trial in the US[105]. 
 
1.6.2.2 Mucolytics (Destructive) 
 
To alter the physical properties of the viscous and rigid mucus, the direct strategy is 
mucolysis (destructive). Normally, it is desirable to reduce the crosslinking and 
viscoelasticity in the mucus in order to improve mucus clearance. Mucins, generally, are 
secreted as heavily glycosylated peptide oligomers, holding together by –S-S- bridges 
derived from unpaired cysteine units near the non-glycosylated C-terminus end of the 
mucin peptide[110, 111]. Classical mucolytic, N-acetylcysteine (NAC; a thiol reducing 
agent), degrades the three-dimensional network that forms the mucous gel by breaking 
macromolecular backbone. Although not in the USA or Canada, NAC has been widely 
used as a mucolytic agent in many countries[108]. It is suggested that there is a risk of 
bronchospasm in hyper-reactive patients by using NAC.  
Mucus also contains products of inflammation including cellular debris, neutrophil 
derived DNA, and filamentous actin (F-actin). DNA and F-actin co-localize in mucus to 
form a rigid network entangled with the mucins[112]. Dornase alfa (a recombinant 
human enzyme DNase I) and gelsolin (F-actin depolymerizing agent) reduces mucus 
viscosity and tenacity, leading to a reduction in frequency of pulmonary exacerbation and 
an improvement in measured quality of life for CF patients[108]. At present, dornase alfa 
(Pulmozyme®) is an only FDA-approved mucolytic medication in the US. 
 
1.6.2.3 Antimicrobial Therapies 
 
Chronic bacterial infection induces inflammation of the airways, obstructive airways 
disease, and bronchiectasis. Antibiotic therapies for patients with CF have remained as a 
cornerstone of treatment. Indeed, the advance in development of potent broad-spectrum 
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antibiotics, particularly antipseudomonal antibiotics, impact on the increasing survival 
rate of CF patient[113]. Pseudomonas aeruginosa is not able to be eradicated. However, 
the burden of infection usually can be reduced by antibiotic therapy, with improvement in 
symptoms and lung function[114]. Antibiotics can be administrated via oral, parenteral, 
and pulmonary deliveries. The aminoglycoside (e.g., tobramycin)[115], macrolide (e.g., 
azithromycin)[116], and quinolone (e.g., ciprofloxacin)[117] antibiotic drugs are often 
administrated to CF patient with improvement of pulmonary functions. Administration of 
antibiotics by inhalation offers an attractive way to deliver high dose to the site of 
infection. It minimizes the systemic effects which are often observed when antibiotics are 
administrated in other delivery routes. For instance, the therapeutic plasma concentration 
of tobramycin may cause severe ototoxicity and nephrotoxicity in a long-term 
therapy[115]. Studies have shown that inhalation of antibiotics increased the therapeutic 
index of the drugs[118]. The inhaled tobramycin (solution), TIP® (tobramycin inhaled 
powder), azithromycin (tablet), and Cayston® (inhaled aztreonam solution) are available 
on the market[105]. 
Allergic bronchopulmonary aspergillosis (ABPA), due to lung hypersensitivity to 
Aspergillus, has been reported to occur in some CF patients. Steroids remain the mainstay 
of treatment for ABPA[119]. An oral antifungal agent, itraconazole, has been reported to 
be of benefit in patients when used in addition to prednisone treatment[120]. 
 
1.6.2.4 Lung Transplantation 
 
In terms of facing of incipient death due to respiratory failure, attention has been directly 
at ensuring comfort and minimizing distress of CF patients. The development of 
successful lung transplantation brings a new hope for CF patient with severe respiratory 
disease. Lung transplantation offers an opportunity to prolong the duration and to 
significantly improve the quality of patients’ lives[121, 122]. However, Infectious, 
pharmacologic, and nutritional issues inherent to CF add some complexity to the care of a 
given lung transplant patients. The 5-year survival rate of lung transplantation is 
48%[123, 124]. 
 
1.6.2.5 Advanced Therapies 
1.6.2.5.1 Gene Therapies 
Currently, an intense research effort is underway to develop more specific therapies for 
CF patients. These specific therapies target the underlying pathophysiology of the disease. 
The new approaches could address the underlying pathophysiological defects resulting 
from the mutated CFTR at several levels[119]. Rather than only treating the symptoms, 
gene therapies treat the disease by tackling the root cause of CF. The basic concept 
behind gene therapies is to identify the defective gene and replace the defect with a 
normal one. There are two forms of gene therapies, including germ line gene therapy 
(inheritable to future generations) and somatic gene therapy (not inheritable to future 
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generations)[125]. Several promising clinical trials of using virus and non-viral vectors 
have been carried out, supporting gene transfer to the airway epithelium is feasible[126]. 
However, gene therapy studies have revealed safety and efficiency issues in gene transfer 
in the lungs[127]. Additionally, it has been shown that the immune system of CF patient 
posed a significant barrier, hampering the efforts of vector administration[127].   
 
1.6.2.5.2 CFTR modulation 
Unlike gene therapy which replacing defective gene, the CFTR modulation approaches 
either repair the defective gene or play a role in fixing CFTR proteins. This approach is 
directed at the ion transport defects in CF, including the use of amiloride and 
uridine-5’-triphosphate (UTP). The approach of CFTR modulation normalizes ion 
transport by inhibiting excessive sodium absorption and enhancing defective chloride 
secretion[128]. Amiloride blocks the excessive sodium transport into CF airway epithelia. 
UPT stimulates chloride secretion via the alternative (not the CFTR) chloride channel. 
The studies have shown that inhaled amiloride[129, 130] and UTP[131, 132] improved 
mucociliary clearance in healthy subjects and CF patients. Several CFTR modulation 
therapies are currently in clinical trials, such as Ataluren, VX-809 + ivacaftor, VX-661 + 
ivacaftor, and N6022[105]. KalydecoTM is currently in market in the US[105]. 
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Chapter 2 Statement of Aims 
 
2.1 Statement of Problem 
Chronic infection diseases in the deep lungs (such as cystic fibrosis (CF), pneumonia, and 
etc.) are characterized by accumulation of thick and sticky mucus, chronic lung infections, 
and compromised lung surfactant composition. These multi-factored diseases, originating 
in the deep lungs (respiratory bronchiolar and alveolar regions), mainly contributes to the 
death of patients in the early ages. However, the unmet medical needs in the chronic deep 
lungs infections are not fulfilled. This is mainly due to a lack of a multiple-component 
formulation specifically targeting the deep lung regions with co-deposition of medicines 
and effectively interfering several disease factors simultaneously. As a consequence, 
patients with chronic infections in the deep lungs massively are under threats of 
progressive pulmonary damage and respiratory failure. 
This dissertation is designed to test whether the proposed multi-component dry powder 
formulation for inhalation could be produced with essential particle properties suitable 
for deep lung delivery. Specifically, microparticulate and nanoparticulate aerosol 
particles (typically 0.5 to 2 µm) are required to have efficient particle deposition in 
respiratory bronchiolar and alveolar regions by sedimentation and diffusion, respectively. 
In addition, in the proposed multi-component particles, mannitol, azithromycin or 
tobramycin, dipalmitoylphosphatidylcholine (DPPC):dipalmitoylphosphatidylglycerol 
(DPPG)=4:1 (molar ratio) are used as (non-destructive) mucolytic agent, antimicrobial 
drug, lung surfactant mimic phospholipids, respectively.  
 
2.2 Goal of Dissertation and Specific Aims 
2.2.1 Goal of Dissertation 
The overall goal of this dissertation is to manufacture and characterize multi-component 
inhalable microparticulate and nanoparticulate aerosol particles with essential particle 
properties suitable for deep lung delivery by spray drying from organic solution.  
2.2.2 Specific Aims 
In order to achieve the goal of this dissertation in Section 2.2.1, there are five specific 
aims for this dissertation: 
1) Produce multi-component microparticulate and nanoparticulate aerosols in 
solid-state with particle properties of narrow size distribution, and spherical and 
smooth surface morphologies (Chapter 3) 
2) Characterize physicochemical properties of aerosol particles (Chapter 4) 
3) Conduct in vitro aerosol dispersion performance of aerosol particles (Chapter 5) 
4) Evaluate storage stability of aerosol particles (Chapter 6) 
5) Assess in vitro drug release of aerosol particles (Chapter 7) 
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2.3 Significance 
It is envisioned that successful completion of this work can provide a novel and targeted 
multi-component dry powder aerosol formulation for the treatment of chronic infection in 
the deep lungs. The multi-component therapies in a single inhalation aerosol formulation 
(co-deposition) of targeting deep lung regions could potentially enhance the therapeutic 
outcome in CF treatment. Administration by multi-component formulations would likely 
reduce the total dosing frequencies with a single therapy, lowering the burden of diseased 
lungs and improving the quality-of-life for patients. Moreover, understanding of 
physicochemical properties and pharmaceutical performance of the formulations may aid 
formulation scientist in more rationally selecting the components to achieve desired 
performance of multi-component dry powder formulations in future. 
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Chapter 3 Aerosol Particle Design and Manufacturing 
 
3.1 Introduction 
In order to deliver aerosol particles to the lower respiratory tract and small peripheral 
airways[133], nano and microparticles (~0.5-2µm)[134-136] are required. Moreover, 
with a relatively narrow (unimodel) size distribution (~0.5-2µm) of aerosol particles, 
reproducibility of deposition in a specific deep lung region may be ensured. 
Interparticulate forces in dry powders[64] are illustrated in Figure 3.1. Interparticulate 
forces including cohesive/adhesive van der Waals, electrostatic, capillary forces, and 
mechanical interlocking, impact particle interactions during aerosol dispersion[41, 63, 
64]. van der Waals forces dominate interparticulate forces at low relative humidity (RH) 
< 65%, while capillary forces may exhibit a major influence at RH > 65%[41]. The extent 
of the forces is dependent on the particle properties (size, shape, geometry, and etc.) and 
ambient conditions (humidity, electrostatics, and etc.)[41, 63, 64]. The magnitude of 
interparticulate forces could be lowered by producing spherical particles with smooth 
surface and low water content[63, 64]. For example, spherical particles enable one-point 
contact, lowering van der Waals forces. Moreover, the curvature of particles decreases 
surface charge density, leading to a drop in electrostatic forces[63, 64]. In addition, 
relatively smooth surface morphology of particles could minimize the potential of 
mechanical interlocking, as well as further decrease van der Waals and electrostatic 
forces. Reproducibility of dosing in specific regions in lungs is a primary advantage of 
spherical particles with narrow size distribution. Capillary forces, forming high tensile 
liquid bridges between particles, are lowered by decreasing the condensation of water 
vapor. For the purpose of flow of dissertation, water content determination will be coverd 
in Chapter 4. 
 
Figure 3.1. Illustration of interparticulate forces in static dry powder. Adapted from [64]. 
There are several methods available to make respirable particles, including micronization, 
precipitation, supercritical fluids, and spray drying[68-70]. Spray drying (SD) is a 
one-step high through-put process with the ability to produce particles in a controlled 
manner, such as directing particle size and size distribution, particle shape, and particle 
morphology, which are important particle features for pulmonary drug delivery by 
inhalation. Co-spray drying a solution containing two APIs is a potential alternative to 
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produce particles with uniform drug composition[137]. Several studies of co-spray drying 
of two drugs have been reported, including inhaled corticosteroid (ICS)/short-acting 
β2-agonist[138, 139], antibiotics[140, 141], terbutaline sulfate and beclomethasone 
propionate[139]. Alcohols, such as methanol (which is regarded as a “green chemical”), 
have lower surface tension in the range of 22 to 25 mN/m with comparison to water (72 
mN/m). Due to the lower surface tension, spray drying from an alcohol solution 
efficiently reduces the size of droplets during atomization and results in small particle 
size of powders. Furthermore, the moisture % in the SD powders could be minimized by 
employing organic solvents. 
Particle morphology and surface morphology of spray-dried (SD) particles are examined 
by microscopy. Scanning electron microscopy (SEM) employs electrons, instead of light, 
for particle viewing by scanning a focused beam of electrons on a sample. Electrons 
interact with the sample, producing secondary electrons. The secondary electrons are 
collected, converted to voltage, and amplified. Depending upon the topography of the 
sample, a SEM image consists of countless spots with various signal intensities. In order 
to have electrically conductive, most organic substances require a thin coating of 
conductive material (e.g., gold, platinum, and etc.). With a resolution better than 1 
nanometer, SEM is an excellent technique to evaluate particle structure and characteristic 
surface appearance of SD particles.  
Laser diffraction is commonly used for the determination of particle size and distribution 
of a sample. The measurement is based on the scattering light with an intensity pattern at 
various angles after particles are passing through a beam of a monochromatic light laser. 
An algorithm, based on Fraunhofer or Mie theory, is used to calculate particle size and 
distribution from the diffraction pattern. Laser diffraction analysis yields volume-average 
size and distribution in volume, based upon the theory of “equivalent spherical diameter”. 
Besides the media of particle size, a series of distribution parameters from laser 
diffraction could be calculated: DV10 = 10% of particles are below this size; DV50 = 50% 
of particles are smaller (volumetric median diameter); DV90 = 90% of particles are below 
this size. Thereafter, size distribution of samples could be expressed by span value as 
below: 
span value = (DV90 − DV10)/DV50  (Equation 2.1) 
The laser diffraction is conducted through a wet sampling system in this study, requiring 
spray-dried particles to be dispersed in an appropriate dispersant. Occasionally, due to the 
lack of an appropriate dispersant, image size analysis is used as an alternative method. 
SigmaScanTM is used to determine primary particle size (projected geometric diameter) 
and distribution for some particular formulations to which laser diffraction approach is 
not applicable. To determine the projected geometric particle size, a line is drawn, across 
the center, on a primary particle on SEM micrograph. The mean particle size (projected 
mean geometric diameter) and size range are determined by measuring over 100 primary 
particles to get statistically meaningful data. 
In this chapter, the effects of spray-drying conditions (such as pump rate) of 
one-component and multi-component systems on particles size, particle morphology and 
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surface morphology of SD particles will be examined.  
 
3.2 Materials and Methods 
3.2.1 Materials 
Tobramycin (TOB) (U.S.P. grade) (C18H37N5O9; MW.: 467.515 g/mol) was obtained 
from Spectrum (New Brunswick, New Jersey). Azithromycin (AZI) (U.S.P. grade) 
(C38H72N2O12; MW.: 748.984 g/mol) was purchased from APAC pharmaceutical LLC 
(Hangzhou, China) with purity of 98%. Dipalmitoylphosphatidylcholine (DPPC) 
(C40H80NO8P; MW.: 734.05g/mol) and dipalmitoylphosphatidylglycerol sodium (DPPG) 
(C38H74NO10PNa; MW.: 744.96g/mol) were purchased from Avanti Polar Lipids, Inc. 
(Alabaster, Alabama). D-Mannitol (MAN) (SigmaUltra) (C6H14O6; MW.: 182.17 g/mol) 
was from Sigma-Aldrich (France). The chemical structures of the compounds are shown 
in Figure 3.2. Methanol (HPLC grade, ACS-certified grade, purity 99.9%) was obtained 
from Fisher Scientific (Fair Lawn, New Jersey). All nitrogen gas used for experiments 
was an ultra-high purity (UHP) nitrogen gas manufactured by Scotts Gross (Lexington, 
Kentucky). TOB and AZI were stored in the sealed glass desiccators over Indicating 
Drierite/DrieriteTM desiccant at 4oC under ambient pressure. DPPC and DPPG were 
stored in the sealed glass desiccators over Indicating Drierite/DrieriteTM desiccant at 
-20oC under ambient pressure. MAN was stored under room conditions. All materials 
were used as received.  
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(c) 
 
(d) 
 
(e) 
Figure 3.2. The chemical structures for: (a) tobramycin; (b) azithromycin; (c) 
dipalmitoylphosphatidylcholine (DPPC); (d) dipalmitoylphosphatidylglycerol sodium salt 
(DPPG); and (e) D-mannitol. 
 
3.2.2 Methods 
3.2.2.1 Preparation of Spray-dried (SD) Particles by Organic Solution Spray Drying 
Neat organic solution spray-drying process was performed using a Büchi B-290 Mini 
Spray Dryer (Büchi, Switzerland) in closed-mode. With connection to a B-295 Inert Loop 
(Büchi, Switzerland), the spray dryer employed a high performance cyclone to increase 
powder yield. Dry nitrogen gas (UHP) was used as the atomizing drying gas. Feeding 
stock solution was made by dissolving as received material(s) to make a concentration of 
0.1% w/v in methanol. Inlet temperature was set at 150oC. A stainless steel nozzle with 
diameter of 0.7mm was used. Atomization rate of 600L/h and aspirate rate of 35m3/h 
were used. Spray-drying pump rates varied with formulation systems: A) one-component 
system: 3 ml/min (10%; low pump rate), 15 ml/min (50%; medium pump rate), and 30 
ml/min (100%; high pump rate); B) multi-component system (with change of formulation 
composition): 15 ml/min (50%; medium pump rate). The corresponding outlet 
temperatures for each SD formulations of tobramycin and azithromycin are summarized 
in Table 3.1 and Table 3.2, respectively. SD particles were separated from the nitrogen 
drying air in a cyclone and collected in a sample collection vial. All SD powders were 
carefully stored in sealed glass vials that were stored in sealed glass desiccators over 
Indicating Drierite/DrieriteTM desiccant at -20oC under ambient pressure.   
OH
HO
OH
OH
OH
OH
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Table 3.1. Summary of spray drying conditions of tobramcyin relevant formulations.  
Formulation System Pump Rate (%) Outlet Temperature (oC) 
 10 88 
Pure TOB 50 69 
 100 35 
TOB:MAN=1:0.1 50 63 
TOB:MAN=1:0.25 50 61 
TOB:MAN=1:0.5 50 59 
TOB:MAN=1:0.75 50 58 
TOB:MAN=1:1 50 55 
TOB:PLS=1:2 50 57 
TOB:PLS=1:1 50 54 
TOB:PLS=1:0.5 50 65 
TOB:PLS:MAN=1:0.5:0.1 50 58 
TOB:PLS:MAN=1:0.5:0.25 50 65 
TOB:PLS:MAN=1:0.5:0.5 50 54 
TOB:PLS:MAN=1:0.5:0.75 50 66 
TOB:PLS:MAN=1:0.5:1 50 61 
 
 
Table 3.2. Summary of spray drying conditions of azithromycin relevant formulations.  
Formulation System Pump Rate (%) Outlet Temperature (oC) 
 10 89 
Pure AZI 50 75 
 100 50 
AZI:MAN=1:0.1 50 67 
AZI:MAN=1:0.25 50 66 
AZI:MAN=1:0.5 50 64 
AZI:MAN=1:0.75 50 65 
AZI:MAN=1:1 50 59 
AZI:PLS=1:2 50 66 
AZI:PLS=1:1 50 60 
AZI:PLS=1:0.5 50 59 
AZI:PLS:MAN=1:0.5:0.1 50 60 
AZI:PLS:MAN=1:0.5:0.25 50 68 
AZI:PLS:MAN=1:0.5:0.5 50 67 
AZI:PLS:MAN=1:0.5:0.75 50 66 
AZI:PLS:MAN=1:0.5:1 50 58 
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3.2.2.2 Scanning Electron Microscopy (SEM) 
 
Visualization of particle morphology (or structure) and surface morphology of samples 
was achieved by using a Hitachi S-800 microscope (Tokyo, Japan). Samples were placed 
on double-sided adhesive carbon tabs (TedPella, inc.) which were adhered to aluminum 
stubs (TedPella, inc.) and coated with gold/palladium alloy thin film using a Hummer VI 
sputtering system (Technics). The coating process operated at 10 AC milliAmperes with 
8 kV of voltage for 3min. The electron beam with an accelerating voltage of 20 kV was 
used at a working distance of 30mm. SEM images were captured by Evex NanoAnalysis. 
Several magnification levels were used. 
 
3.2.2.3 Particle Sizing and Size Distribution 
3.2.2.3.1 Laser Light Diffraction  
 
Particle size and size distributions of SD particles (SD pure tobramycin and SD 
tobramycin:mannitol) were determined by laser diffraction using SALD-7101 (Shimadzu 
Scientific Instruments, Japan). Samples were dispersed in chloroform and ultrasonicated 
for 10 s in a water bath ultrasonicater Branson 5210 (Danbury, Connecticut) before 
measuring particle size. Particle dispersions of samples were immediately transferred to a 
measuring cell and kept stirring during measurement in the nano particle size analyzer. 
Due to the use of chloroform, a refractive index 1.60-0.10 was selected for the 
experiments. Volume-based dimension of particle amount distribution was obtained for 
samples. DV10, DV50, and DV90 from Shimadzu software were used as particle size 
characterization parameters. The span value was calculated using Equation 2.1. All 
experiments were done in triplicate (n=3) for each formulation. 
 
 
3.2.2.3.2 Image Size Analysis 
 
As an alternative way to determine primary particle size and size distribution, 
SigmaScanTM Pro 5 (Jandel Scientific, CA) was used due to the difficulty of samples 
being dispersed in various dispersants for laser diffraction. Image size analysis was based 
on SEM micrographs. Calibration of distance measurement was done on the scaling bar 
on micrographs. The diameter was measured for at least 100 particles and statistical data 
was calculated (mean ± S.D. & size range). 
 
3.3 Results 
3.3.1 Scanning Electron Microscopy (SEM) 
3.3.1.1 One-component System (Spray-dried Pure Drug) 
SEM micrographs of spray-dried (SD) pure tobramycin (TOB) and pure azithromycin 
(AZI) particles[43], produced from low (10%), medium (50%), and high (100%) pump 
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rates, respectively, are shown in Figure 3.3. As received particles of TOB and AZI 
possessed sharp edges and particle sizes far beyond the respiratory range for dry powder 
inhalation (DPI), a value less than 10µm[142]. In general, relatively spherical particle 
morphology and smooth surface morphology of SD particles were produced for each 
component from various pump rates. However, as shown in Figure 3.3d and 3.3h, more 
corrugated surface of SD particles generated from high pump rate was also observed.  
 
3.3.1.2 Two-component System  
3.3.1.2.1 Spray-dried Drug:Mannitol 
SEM micrographs of SD tobramycin:mannitol (TOB:MAN) and azithromycin:mannitol 
(AZI:MAN) particles[143] are shown in Figure 3.4. Under the same spray-drying 
conditions, relatively spherical particle morphology and smooth surface morphology of 
SD particles were produced for each system with various composition ratios. In addition, 
it was noticed that some AZI:MAN (e.g., Figure 3.4i and 3.4j) appeared to have  
relatively more corrugations on surface than TOB:MAN.  
 
3.3.1.2.2 Spray-dried Drug:Phospholipids 
SEM micrographs of SD tobramycin:phospholipids (TOB:PLS) and 
azithromycin:phospholipids (AZI:PLS) particles are shown in Figure 3.5. Relatively 
spherical particle morphology and smooth surface morphology of TOB:PLS were 
produced with various PLS content in the system. However, it is noticed that incomplete 
particle formation was observed for AZI:PLS=1:1 (Figure 3.5e) and AZI:PLS=1:2 
(Figure 3.5d). Contrastingly, relatively spherical particle morphology and smooth surface 
morphology of AZI:PLS were produced at molar ratio of 1:0.5 in Figure 3.5f.  
 
 
3.3.1.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol) 
SEM micrographs of SD tobramycin:phospholipids:mannitol (TOB:PLS:MAN) and 
azithromycin:phospholipids:mannitol (AZI:PLS:MAN) particles are shown in Figure 3.6. 
For the three-component systems, the ratio of antibiotics:phospholipids was fixed at 1:0.5 
in order to get a high antibiotic drug loading. The MAN content in three-component 
formulations varied from 0.1 to 1. All TOB:PLS:MAN particles possessed relatively 
spherical particle shape and smooth surface except for TOB:PLS:MAN=1:0.5:0.75 
(Figure 3.6d) with incomplete particle formation. In general, regardless of 
AZI:PLS:MAN=1:0.5:0.25 (Figure 3.6g) with some aggregation, AZI:PLS:MAN 
particles were produced with desired particle properties of relatively spherical particle 
morphology and smooth surface morphology. 
30 
 
 
               (a)                      (b)                     (c)                      (d) 
 
 
               (e)                      (f)                     (g)                      (h) 
 
 
Figure 3.3. SEM micrographs of as received particles (magnification 100X) and SD pure particles (magnification 10,000X) of 
tobramycin (TOB) and azithromycin (AZI)[43] for: (a) As received TOB; (b) SD pure TOB (10%P); (c) SD pure TOB (50%P); 
(d) SD pure TOB (100%P); (e) As received AZI; (f) SD pure AZI (10%P); (g) SD pure AZI (50%P); and (h) SD pure AZI 
(100%P).  
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         (a)                  (b)                   (c)                   (d)                 (e) 
 
         (f)                  (g)                   (h)                   (i)                 (j) 
Figure 3.4. SEM micrographs of SD tobramycin:mannitol (TOB:MAN) and SD azithromycin:mannitol (AZI:MAN) 
particles[143] (magnification 10,000X) for: (a) TOB:MAN=1:0.1; (b) TOB:MAN=1:0.25; (c) TOB:MAN=1:0.5; (d) 
TOB:MAN=1:0.75; (e) TOB:MAN=1:1; (f) AZI:MAN=1:0.1; (g) AZI:MAN=1:0.25; (h) AZI:MAN=1:0.5; (i) 
AZI:MAN=1:0.75;  and (j) AZI:MAN=1:1. 
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                             (a)                   (b)                  (c) 
 
                            (d)                    (e)                  (f) 
 
Figure 3.5. SEM micrographs of SD tobramycin:phospholipids (TOB:PLS) and SD azithromycin:phospholipids (AZI:PLS) 
particles (magnification 10,000X) for: (a) TOB:PLS=1:2; (b) TOB:PLS=1:1; (c) TOB:PLS=1:0.5; (d) AZI:PLS=1:2; (e) 
AZI:PLS=1:1; and (f) AZI:PLS=1:0.5. 
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         (a)                  (b)                   (c)                  (d)                  (e) 
 
         (f)                  (g)                   (h)                  (i)                   (j) 
Figure 3.6. SEM micrographs of SD tobramycin:phospholipids:mannitol (TOB:PLS:MAN) and SD 
azithromycin:phospholipids:mannitol (AZI:PLS:MAN) particles (magnification 10,000X) for: (a) TOB:PLS:MAN=1:0.5:0.1; 
(b) TOB:PLS:MAN=1:0.5:0.25; (c) TOB:PLS:MAN=1:0.5:0.5; (d) TOB:PLS:MAN=1:0.5:0.75; (e) TOB:PLS:MAN=1:0.5:1; 
(f) AZI:PLS:MAN=1:0.5:0.1; (g) AZI:PLS:MAN=1:0.5:0.25; (h) AZI:PLS:MAN=1:0.5:0.5; (i) AZI:PLS:MAN=1:0.5:0.75; 
and (j) AZI:PLS:MAN=1:0.5:1. 
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3.3.2 Particle Sizing and Size Distribution 
3.3.2.1 One-component System (Spray-dried Pure Drug) 
By laser diffraction, SD pure TOB particles all exhibited a unimodal size distribution. 
The detailed sizing data of SD pure TOB are summarized in Table 3.3[43]. The median 
volumetric diameter (DV50) slightly increased from 0.6µm to 0.8µm for SD pure TOB as 
spray-drying pump rates increased from 10% (low) to 100% (high). The DV90 of particles 
was in the range from 1.1 to 1.6µm for SD pure TOB, consistent with the presence of 
microsized particles. However, majority of SD pure TOB particles were under micro-size 
range. Span value of SD TOB was in the range between 1.3 and 1.4, suggesting a 
relatively narrow size distribution.  
Image sizing analysis results of SD AZI primary particles are summarized in Table 
3.4[43]. SD AZI increased projected mean geometric diameter from 0.5µm to 0.7µm as 
pump rates employed in spray drying increased from low to high. With upper limit value 
being equal or over 1µm (but less than 2µm), size range data suggests that SD AZI 
particles possessed microsized particles. In addition, size range data also indicated a 
relatively narrow size distribution for SD AZI particles. 
 
Table 3.3. Laser diffraction sizing of SD pure tobramycin particles[43] (mean ± SD, 
n=3).  
SD Drug Pump Rate (%) DV10(µm) DV50(µm) DV90(µm) Span Value 
Tobramycin 
 
10 0.4±0.0 0.6±0.0 1.1±0.0 1.3±0.0 
50 0.4±0.0 0.6±0.0 1.4±0.0 1.4±0.1 
100 0.5±0.0 0.8±0.0 1.6±0.0 1.4±0.0 
 
Table 3.4. Image sizing of SD pure azithromycin primary particles[43] (mean ± SD, 
n≥100).  
SD Drug Pump Rate (%) Particle Size (µm) Size Range (µm) 
Azithromycin 
10 0.5±0.1 0.2-1.0 
50 0.6±0.3 0.3-1.9 
100 0.7±0.3 0.2-1.8 
 
3.3.2.2 Two-component System  
3.3.2.2.1 Spray-dried Drug:Mannitol 
By laser diffraction, SD TOB:MAN particles all exhibited a unimodal distribution. 
Detailed data of TOB:MAN are summarized in Table 3.5[143]. Relatively consistent size 
was achieved with changing of composition in TOB:MAN. The DV50 (volumetric median 
diameter) was in the range from 0.6µm to 0.7µm for TOB:MAN particles. DV90 of 
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TOB:MAN indicating microparticulate particles were also present in formulations. Span 
value of TOB:MAN was in the range between 1.5 and 1.7, indicating a relatively narrow 
size distribution.  
Image sizing analysis of SD AZI:MAN primary particles are summarized in Table 
3.6[143]. With the change of composition in formulations, projected mean geometric 
diameter of AZI:MAN were constant at 0.6µm. Size range data indicates the presence of 
micropaticulate particles and a relatively narrow size distribution for AZI:MAN. 
 
 
 
Table 3.5. Laser diffraction sizing of SD tobramycin:mannitol particles[143] (mean ± 
SD, n=3).  
 Particles DV10(µm) DV50(µm) DV90(µm) Span Value 
TOB:MAN=1:0.1 0.4±0.0 0.6±0.0 1.4±0.0 1.6±0.1 
TOB:MAN=1:0.25 0.4±0.0 0.7±0.0 1.4±0.1 1.5±0.1 
TOB:MAN=1:0.5 0.4±0.0 0.7±0.0 1.4±0.1 1.5±0.0 
TOB:MAN=1:0.75 0.4±0.0 0.6±0.0 1.4±0.0 1.7±0.1 
TOB:MAN=1:1 0.4±0.0 0.7±0.0 1.5±0.1 1.6±0.0 
 
 
Table 3.6. Image sizing of SD azithromycin:mannitol primary particles[143] (mean ± 
SD, n≥100).  
Formulation Particle Size (µm) Size Range (µm) 
AZI:MAN=1:0.1 
AZI:MAN=1:0.25 
0.6±0.2 0.2-1.4 
0.6±0.2 0.2-1.3 
AZI:MAN=1:0.5 0.6±0.2 0.2-1.4 
AZI:MAN=1:0.75 0.6±0.2 0.2-1.8 
AZI:MAN=1:1 0.6±0.2 0.3-1.1 
 
 
3.3.2.2.2 Spray-dried Drug:Phospholipids 
Image size analysis of SD TOB:PLS and SD AZI:PLS primary particles are summarized 
in Table 3.7. All particles possessed mean particle size in the range from 0.6 to 0.8µm. In 
addition to the presence of micropaticulate particles, size range data indicated a relatively 
narrow size distribution for both TOB:PLS and AZI:PLS. Due to incomplete particle 
formation, size analysis of AZI:PLS=1:2 was not conducted. 
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Table 3.7. Image sizing of SD drug:phospholipids primary particles (mean ± SD, n≥100).  
Formulations  
(molar ratio) Particle Size (µm) Size Range (µm) 
TOB:PLS=1:2 0.7±0.2 0.4-1.2 
TOB:PLS=1:1 0.7±0.2 0.3-1.4 
TOB:PLS=1:0.5 0.7±0.3 0.3-1.6 
AZI:PLS=1:2 - - 
AZI:PLS=1:1 0.8±0.2 0.4-1.4 
AZI:PLS=1:0.5 0.6±0.2 0.3-1.5 
 
 
3.3.2.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol) 
Image sizing analysis of SD TOB:PLS:MAN and SD AZI:PLS:MAN primary particles 
are summarized in Table 3.8. Similar projected mean particle size in the range from 0.6 to 
0.7µm was observed for both TOB:PLS:MAN and AZI:PLS:MAN. Moreover, the 
consistent particle size range from 0.2 to 2.1µm showed the presence of microparticulate 
particles and indicated a relatively narrow size distribution for both TOB:PLS:MAN and 
AZI:PLS:MAN. Due to (partially) incomplete particle formation, particle size of 
TOB:PLS:MAN=1:0.5:0.75 and AZI:PLS:MAN=1:0.5:0.25 were not conducted. 
 
Table 3.8. Image sizing of SD drug:phospholipids:mannitol primary particles (mean ± 
SD, n≥100).  
Formulations 
(molar ratio) Particle Size (µm) Size Range (µm) 
TOB:PLS:MAN=1:0.5:0.1 0.7±0.3 0.3-2.1 
TOB:PLS:MAN=1:0.5:0.25 0.6±0.3 0.2-1.7 
TOB:PLS:MAN=1:0.5:0.5 0.7±0.3 0.2-1.6 
TOB:PLS:MAN=1:0.5:0.75 - - 
TOB:PLS:MAN=1:0.5:1 0.7±0.2 0.3-1.2 
AZI:PLS:MAN=1:0.5:0.1 0.7±0.2 0.2-1.4 
AZI:PLS:MAN=1:0.5:0.25 - - 
AZI:PLS:MAN=1:0.5:0.5 0.6±0.2 0.3-1.1 
AZI:PLS:MAN=1:0.5:0.75 0.6±0.2 0.3-1.1 
AZI:PLS:MAN=1:0.5:1 0.6±0.2 0.3-1.4 
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3.4 Discussion 
Spray drying is a continuous high through-put particle processing operation. It transforms 
a liquid feed into dried particles via four stages[144]: (a) atomization of the feed solution 
into droplets; (b) droplets-air contact; (c) drying of the droplets; and (d) separation of the 
dried product from air stream. It has been suggested that spray-drying conditions (such as 
nozzle size, aspirator rate, airflow rate, inlet temperature, concentration of feeding 
solution, solvent type and etc.) would have potential influence on particle size. Our 
research group has previous optimized the spray-drying conditions[145] for producing 
nanoparticulate and microparticulate dry powder aerosol particles as pulmonary drug 
delivery for the deep lung delivery. Effects of pump rate and formulation composition on 
particle size, particle morphology, and surface morphology of spray-dried particles were 
examined in this chapter. 
 
3.4.1 Pump Rate Effect 
The pump rate effect was studied on one-component formulations including SD pure 
tobramycin (TOB) and pure azithromycin (AZI). It appears that the pump rates resulted 
in slightly increased (medium volumetric or projected geometric mean) particle size, but 
generated relatively constant size distribution of nanoparticulate and microparticulate 
particles. In addition, relative spherical particle morphology was generated for SD TOB 
and SD AZI with various pump rates. However, as pump rate changed from low to high, 
the particle surface morphology was altered to be relatively more corrugated as shown in 
Figure 3.3d and 3.3h. It is suggested that larger droplets could be produced from high 
pump rate during atomization[75]. Consequently, given that the use of dilution 
concentration of feeding solution and high evaporation rate of organic solvent, the solid 
shells of larger particles were potentially subject to collapse on surface during drying 
process. Alternatively, it is reported[146, 147] that an increase in particle surface 
roughness could be achieved by reducing the viscosity of the feed. However, it is also 
observed[73, 74] that smaller particles are generated by using liquid with higher viscosity 
and faster feeding rate. It is speculated that this was caused by the generation of a larger 
back-pressure in a nozzle, producing a finer spray due to an increase in sheer during 
atomization. 
 
3.4.2 Formulation Composition Effect 
In general, at studied formulation compositions, the two-component and three-component 
systems were successfully produced with desired particle properties (such as nano and 
microsized particles with relatively narrow size distribution; relative spherical particle 
morphology and smooth surface morphology). It is reasonable to expect that the 
spray-dried particles exhibited similar particle size and size distribution, since a same 
total powder concentration in solvent was used in this study. The particles with undesired 
particle properties were also observed for some formulations such as AZI:PLS=1:2 
(Figure 3.5d), AZI:PLS=1:1 (Figure 3.5e), TOB:PLS:MAN=1:0.5:0.75 (Figure 3.6d), and 
AZI:PLS:MAN=1:0.5:0.25 (Figure 3.6g). As to be discussed in detail in aerosol 
dispersion chapter, the partial particle aggregation of AZI:PLS=1:2 and 1:1 formulations 
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may correlate with outlet temperature of spray drying (To) and main phase transition 
temperature of phospholipid bilayer (Tm). As a consequence, AZI:PLS=1:2 and 1:1 
exhibited an worse aerosol dispersion performance in terms of  mass median 
aerodynamic diameter (MMAD) compared to AZI:PLS=1:0.5 with desired particle 
properties (as shown inTable 5.6 in Chapter 5). In sum, it is believed that particle surface 
component(s) that undergoes phase transition during both in spray drying and storage 
plays a critical role in facilitating particle aggregation. Liao YH et al reported[148] that 
the surface morphology of spray-dried stabilized lysozyme particles was independent in 
excipient composition. However, the volume median diameter of the powders exhibited a 
dependence upon the amount of excipients. The proposed possible mechanism(s) for 
formation of spray-dried particles leading to resultant aerosol dispersion performance will 
be elaborated in Chapter 5. 
 
 
3.5 Conclusions 
Nanoparticulate and microparticulate aerosol particles with desired particle properties 
necessary for deep lung penetration by pulmonary delivery were successfully designed 
and produced from dilute organic solution by spray drying. Under optimized spray-drying 
conditions, pump rate may possibly be used to effectively tailor (volume medium or 
projected geometric mean) particle size of formulations. With change of formulation 
composition, relatively constant particle properties of spray-dried particles were obtained 
after spray drying. However, the detailed explanation on some (partially) incomplete 
particle formations by change formulation composition still remained unexplored.  
 
 
 
 
 
 
 
Portions of Chapter 3 were reproduced with kind permission from: Li, X, Vogt, F.G., 
Hayes, D. Jr., and Mansour, H.M. Physicochemical Characterization and Aerosol 
Dispersion Performance of Organic Solution Advanced Spray Dried 
Microparticulate/Nanoparticulate Antibiotic Dry Powders of Tobramycin and 
Azithromycin for Pulmonary Inhalation Aerosol Delivery. European Journal of 
Pharmaceutical Sciences, 2014, 15:191-205. Copyright © 2014 Elsevier.  
 
Copyright © Xiaojian Li 2014 
39 
 
Chapter 4 Physicochemical Characterization 
 
4.1 Introduction 
Spray-dried powders are examined in terms of particle size and size distribution, particle 
morphology, and particle surface morphology. There are, however, a number of 
important physicochemical properties[41] of aerosol particles that have an impact on the 
dispersibility in aerosolization and stability of aerosol particles intended for pulmonary 
delivery. They include crystallinity and polymorphism, solid-state phase transition, water 
content and vapor sorption, and chemical spectroscopy of component in particles. 
In general, pharmaceutical solid compounds are divided into crystalline and amorphous 
materials. Crystalline materials present structure units that are repeated in a regular 
manner and form a well-defined lattice[63]. Therefore, it possesses long-range molecular 
order. The crystalline materials could form a variety of polymorphs[149, 150] and 
pseudo-polymorphs[151]. Polymorphism describes the ability of a crystalline substance 
to exhibit different lattice structures and/or molecular conformations. Polymorphs, 
exhibiting various particle shape, solubility, and water content and hygroscopicity, may 
have an impact on particle aggregation, through mechanical interlocking, electrostatic 
charge, and capillary force[41, 63]. Pseudo-polymorphs refer to crystalline hydrate and 
solvates, having bound water and organic solvent molecules, respectively[63]. Unlike 
crystalline state, amorphous phase of a material lacks long-range molecular packing, 
present in metastable state. Therefore, it possesses a relatively higher solubility and 
molecular mobility, but a less stability over pharmaceutically relevant time scales[63]. 
Crystallinity is the degree of crystalline phase in a solid. Crystallinity of particles has an 
impact on the nature of powder mixing and aggregation through energetic forces (e.g., 
cohesion and adhesion)[41]. In addition, it has an influence on stability of solid-state 
formulations. Crystallinity of dry powder for inhalation, a main indicative of physical 
stability affecting aerosol dispersion performance, needs to be studied. Crystallinity and 
polymorphism of powder are commonly examined by x-ray powder diffraction (XRPD). 
Atoms or molecules in a crystalline material scatter x-ray beams into many specific 
directions. In some of the directions, the scattered beams are completely in phase and 
reinforce into diffracted beams. As defined by Bragg’s law[152] (Equation 4.1), 
diffraction of a x-ray beam is incident on crystalline planes, satisfying the Bragg’s law 
equation: 
                         𝑛𝜆 = 2𝑑 sin 𝜃          (Equation 4.1) 
Where n is any integer, λ is the wavelength of the beam, d is the spacing between 
diffracting planes, and θ is the incident angle. In general, XRPD pattern of a crystalline 
sample shows a series of intensive peaks measured at different incident angles. No peak 
is observed for an amorphous sample in its XRPD pattern as an amorphous sample lacks 
long-range molecular range.  
A solid particle may undergo several phase transitions when heated[63]. In general, a 
crystalline solid could melt upon heating from a solid to a liquid. This is a first-order 
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thermodynamic phase transition. Upon heating, an amorphous (non-crystalline) solid 
would possibly exhibit a characteristic reversible transition from the glassy state to the 
rubbery state with a step change in heat capacity. The temperature at which glassy state 
converts to rubbery state for an amorphous solid is defined as the glass transition 
temperature (Tg). This is a second-order phase transition. Rubbery state of a solid may 
further exhibit an exothermic crystallization or/and a melting the crystallized form with 
heating. A glassy state (low molecular mobility) of an amorphous solid is usually 
preferred than rubbery state (high molecular mobility) since physical/chemical reactivity 
and stability are minimized[153]. To understand thermal-induced phase transition(s) of 
aerosol dry powder is important, especially for a non-crystalline formulation. 
Understanding the thermal-induced phase transitions of particles, especially for surface 
component leading to solid bridge, is necessary for dry powder for inhalation. 
Differential scanning calorimetry (DSC) is a frequently used technique to monitor phase 
transition of a solid associated with heat transfer. In principle, it measures the heat flow 
difference between a sample pan and an empty pan in order to keep them at the sample 
temperature.  
Capillary forces take place as water moisture interacts with solid surface. Capillary forces 
cause formation of liquid bridge between particles by vapor condensation due to lowering 
of the LaPlace pressure which occurs between particles. Aerosol dispersion performance 
can be lowered as the result of the presence of liquid bridge between particles. In addition, 
water molecules act as a plasticizer in amorphous solids by lowering Tg. Low Tg of dry 
powder could trigger the potential physical and chemical instabilities. The equilibrium 
moisture content at ambient temperature and relative humidity is suggested to be a good 
indicator of the suitability of aerosol product[41]. Therefore, water content of powder 
needs to be assessed for dry powder formulations. Coulometric titration is commonly 
employed to determine water content of powder. Determination of water content based 
on a quantitative reaction of water (H2O) with iodine (I2), sulfur dioxide (SO2), alcohol 
(ROH; e.g. methanol), and an organic base (B; e.g. imidazole) as shown in Equation 
4.2[154]: 
SO2 + ROH + B → RSO3- + HB+ 
H2O + I2 + RSO3- + 2B → RSO4- + 2HB+ + 2I- 
-------------------------------------------------------------------------------------                                 (Equation 4.2)                            
H2O + ROH + SO2 + I2 + 3B → RSO4- + 3HB+ + 2I-    
                            
Water content of sample is determined by measuring the quantity of electric current 
required for production of I2 by electrolysis of iodine ions in reagent. 
Hygroscopicity is an intrinsic nature of a material with tendency to take up moisture from 
surrounding environment. Hygroscopic material suffers a great risk of physical and 
chemical instability. Hygroscopic aerosols are susceptible to hygroscopic growth 
resulting in larger particles in aerosolization[41]. In addition, moisture uptaking and 
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losing over a narrow range of relative humidity (RH) could result in local dissolution and 
recrystallization. This leads to an irreversible aggregation through formation of solid 
bridge, which adversely affects aerosol dispersion and lung deposition.[41, 155-157] 
Thus, it is essential to examine water vapor sorption of aerosol particles. Gravimetric 
water vapor sorption (GVS) is used to study equilibrium water content of aerosol 
particles at a series of RH %. The weight change of particle due to moisture uptake and 
loss is monitored by an integrated microbalance in GVS as exposed to increment of 
RH %. Regarding to metastable materials (e.g. amorphous), the lyotropic-induced phase 
transition would possibly be detected[43, 145, 158]. As similar to thermal-induced phase 
transition, the lyotropic-induced phase transition would also have an adverse effect on 
aerosol performance. 
Component homogeneity in powder necessarily needs to be characterized for 
multi-component aerosol particles. An indication of heterogeneity of powder has an 
impact on physical stability of molecularly mixed particles. Confocal Raman microscopy 
(CRM) has demonstrated an utility in the non-invasive and non-destructive 
microspectroscopic analysis of aerosol formulations as described in detail in the 
studies[159, 160]. Confocal Raman microscopy (CRM) and spectroscopy provides 
chemical imaging and mapping of particles[160]. These functions can reveal component 
homogeneity for molecularly mixed particles. Raman spectroscopy is a spectroscopic 
technique used to observe vibrational, rotational, and other low-frequency modes in a 
system. A laser light (in visible, near infrared, or near ultraviolet range) interacts with 
molecular vibrations, photons, or other excitations in system. It results in the energy of 
the laser photons shifts up or down. The shift in energy usually reveals information on the 
vibrational modes in a system. Infrared spectroscopy yields similar, but complementary, 
information to Raman spectroscopy. Both Raman and infrared spectroscopies are capable 
of probing molecular conformation, degree of molecular order, and polymorphic system. 
In the following sections, the physicochemical properties of crystallinity and 
polymorphism, solid-state phase transition (thermal analysis), water content and vapor 
sorption, and chemical spectroscopy of component of spray-dried aerosol particles are 
described. 
 
4.2 Materials and Methods 
4.2.1 Materials 
The spray-dried (SD) particles selected for physicochemical characterization are listed in 
Table 4.1. TOB, AZI, MAN, and PLS stand for tobramycin, azithromycin, mannitol, and 
phospholipids, respectively. All the studied particles were generated employing a 50% 
pump rate in spray drying. All SD powders were carefully stored in sealed glass vials that 
were stored in sealed glass desiccators over Indicating Drierite/DrieriteTM desiccant at 
-20oC under ambient pressure for up to one week. The outlet temperatures of SD particles 
are referred to Table 3.1 and Table 3.2 in Chapter 3. 
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Table 4.1. SD particles for physicochemical characterization. 
 
Formulation System SD TOB formulations (molar ratio) 
SD AZI formulations 
(molar ratio) 
One-component Pure TOB Pure AZI 
Two-component 
TOB:MAN=1:0.1 AZI:MAN=1:0.1 
TOB:MAN=1:0.25 AZI:MAN=1:0.25 
TOB:MAN=1:0.5 AZI:MAN=1:0.5 
TOB:MAN=1:1 AZI:MAN=1:1 
TOB:PLS=1:0.5 AZI:PLS=1:0.5 
TOB:PLS=1:1 AZI:PLS=1:1 
TOB:PLS=1:2 AZI:PLS=1:2 
 TOB:PLS:MAN=1:0.5:0.1 AZI:PLS:MAN=1:0.5:0.1 
Three-component TOB:PLS:MAN=1:0.5:0.5 AZI:PLS:MAN=1:0.5:0.5 
 TOB:PLS:MAN=1:0.5:1 AZI:PLS:MAN=1:0.5:1 
 
4.2.2 Methods 
4.2.2.1 Crystallinity and Polymorphism 
X-ray powder diffraction (XRPD) patterns of samples were collected with a Rigaku x-ray 
diffractometer (Japan) with Cu Kα radiation (40kV, 44mA, and λ = 1.5406Å) between 
5.0 – 60.0º (2θ) using a scan rate of 2.00o/min at ambient temperature as 
reported[161-164]. Samples were placed on a quartz plate in an aluminum sample holder 
without further grinding. Only one experiment was done for each formulation in this 
study.  
 
4.2.2.2 Solid-State Phase Transition 
 
Thermal properties of samples were measured using a TA Q200 differential scanning 
calorimetry (DSC; TA Instruments, New Castle, DE, USA) equipped with T-Zero® 
technology and an automated computer-controlled RSC-90 cooling accessory as 
reported[161-164]. Approximate 3mg of samples was packed into hermetic anodized 
aluminum T-Zero® DSC pan. It was then hermetically sealed with the Tzero hermetic 
sealer (TA Instruments, New Castle, DE, USA) unless otherwise specified. An empty 
hermetically sealed aluminum pan was used as a reference pan. Experiments were 
conducted under both hermetic and non-hermetic conditions. In hermetic conditions, 
hermetically sealed sample pan and reference pan were used. Whereas in non-hermetic 
conditions, both pin-holed sample pan and reference pan were used. The non-hermetic 
DSC conditions will be specially mentioned in this chapter if necessary. The use of 
non-hermetic conditions allowed the release of moisture from samples, minimizing 
moisture effect on thermal events. Ultra-high purity (UHP) nitrogen was used as a 
purging gas at a rate of 50 ml/min. Sample was heated from 10-200oC at a scanning rate 
of 5.00oC/min. The onset temperature of main phase transition (Tm) was reported for 
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phospholipid-containing powders. Detailed report methods are referred to Section 4.3.2. 
All experiments were done in triplicate (n=3). 
 
4.2.2.3 Water Content 
 
Water content of powders was assessed by Karl Fischer (KF) coulometric titration. The 
measurements were performed with a 737 KF Coulometer coupled with 703 Ti Stand 
(Metrohm Ltd., Antwerp, Belgium) as reported[161-164]. Approximately 6 to 7mg of 
sample was dissolved in AQUA STAR methanol using a 5mL volumetric. The solution 
was injected into reaction cell filled with HYDRANAL KF reagent. After obtaining the 
reading from KF coulometer, the water content of sample was obtained from simple 
calculation. The experiments were done in triplicate (n=3). 
 
4.2.2.4 Water Vapor Sorption 
Water vapor sorption isotherms of powders were measured gravimetrically using an 
automated microelectronic balance coupled to a computerized VTI SGA-CX symmetric 
vapor sorption analyzer (Hialeah, Florida) as previously reported[161, 162, 164, 165]. All 
measurements were taken at 25oC using a sample size of ～1.0 to 1.5mg. Samples were 
subjected to pre-drying treatment at 25oC under 0% relative humidity (RH) (nitrogen gas 
purging) for up to a maximum of 7h with equilibrium criterion of weight change less than 
or equal to 0.0001% in 10min interval. At the end of the pre-drying cycle, the samples 
were exposed to a sequence of increasing RH with increment of 5% RH on each step, 
which started at 5% RH until 95% RH. The criterion used to establish equilibrium during 
sorption was a weight change of less than or equal to 0.03% in 10min interval for up to 
3h. The data point was acquired at every 2min or 0.01% weight change. Standby 
temperature was set at 25oC. 
 
4.2.2.5 Chemical Spectroscopy 
 
4.2.2.5.1 Confocal Raman Microscopy and Spectroscopy for Chemical Imaging and 
Mapping 
 
Using conditions previously reported[160, 166], dispersive Raman spectra and mapping 
images of samples were obtained using an Aramis confocal Raman spectrometer and 
fluorescence microscope system (Horiba Jobin Yvon, Edison, NJ, USA). The system was 
equipped with an Olympus BX41 confocal optical microscope, an Olympus U-LH 100W 
Hg lamp, and a U-RFL-T power source used for fluorescence excitation and brightfield 
illumination (Olympus America, Inc., Chester Valley, PA). Filters were used to achieve 
fluorescence excitation in the range of 330-385nm, with emission observed using a 
425nm cutoff filter. Neutral density filters were used to adjust fluorescence intensity. 
Raman spectra were obtained using both a 785nm diode laser and a 633nm HeNe laser. 
Raman spectral maps were obtained using either a 10x or 50x objective with the stage 
moved in increments of 5 to 10µm. Each map point was acquired using 32 to 128 
accumulations each with 2s of detector exposure time. A confocal hole of 500µm with a 
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grating of 600-900 grooves/mm and a slit width of 100µm were used. Spectra were 
subjected to baseline correction and smoothing prior to further analysis. 
 
4.2.2.5.2 Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy 
 
A Varian FTS-7000e attenuated total reflectance-Fourier transform infrared spectrometer 
(ATR-FTIR; Varian Inc., CA) equipped with a DTGS detector and a PIKE MIRacle ATR 
ZnSe accessory was used. Each spectrum was collected for 32 scans at a spectral 
resolution of 8cm-1 over the wavelength number range of 4,000-700cm-1. A background 
spectrum was done under the same experimental conditions. Spectral data were acquired 
with Varian Resolutions Pro software. 
 
4.3 Results 
4.3.1 Crystallinity and Polymorphism 
4.3.1.1 One-component System (Spray-dried Pure Drug) 
X-ray powder diffraction (XRPD) pattern in Figure 4.1a indicates as received tobramycin 
(TOB) was partially crystalline as the peaks were broad and not well-defined.[43] As 
shown in Figure 4.1b, as received azithromycin (AZI) appeared to be in crystalline phase 
with intensive peaks[43]. Both SD pure TOB (Figure 4.1a) and SD pure AZI (Figure 4.1b) 
particles lacked their characteristic crystalline peaks[43]. The data indicated SD pure 
TOB and SD pure AZI lost long-range molecular order compared to the corresponding as 
received material.  
 
 
(a) 
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(b) 
Figure 4.1. X-ray powder diffractograms for: (a) SD pure and as received tobramycin 
particles (offset by 4000 counts); and (b) SD pure and as received azithromycin particles 
(offset by 7000 counts)[43]. 
 
4.3.1.2 Two-component System  
4.3.1.2.1 Spray-dried Drug:Mannitol 
The XRPD patterns suggest that SD tobramycin:mannitol (TOB:MAN) (Figure 4.2a) and 
azithromycin:mannitol (AZI:MAN) (Figure 4.2b) were lacking of long-range molecular 
order as the characteristic peaks of crystalline phase were not observed[143]. Apparently, 
at the studied molar ratios, MAN component exhibited no effect on XRPD patterns for 
both TOB:MAN and AZI:MAN. 
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(a) 
 
(b) 
Figure 4.2. X-ray powder diffraction patterns for: (a) SD tobramycin:mannitol 
formulations (offset by 500 counts between patterns); and (b) SD azithromycin:mannitol 
formulations (offset by 500 counts between patterns for the bottom four; offset by 1000 
counts between patterns for the top two)[143]. 
4.3.1.2.2 Spray-dried Drug:Phospholipids 
As shown on XRPD patterns of SD tobramycin:phospholipids (TOB:PLS) in Figure 4.3a, 
intensive characteristic peak of phospholipid bilayer structure at ~20-23o of 2 theta was 
observed with various molar ratios of PLS. In addition, the characteristic peak of 
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phospholipid bilayer structure of SD azithromycin:phospholipids (AZI:PLS) on XRPD 
patterns was observed in Figure 4.3b. In comparison, the peak intensity of phospholipid 
bilayer structure from AZI:PLS was lower than TOB:PLS at same molar ratio of PLS. 
The crystalline peaks of TOB and AZI were not observed in any TOB:PLS and AZI:PLS 
samples. 
 
 
(a) 
 
(b) 
Figure 4.3. X-ray powder diffraction patterns for: (a) SD tobramycin:phospholipids 
formulations (offset by 500 counts between patterns); and (b) SD 
azithromycin:phospholipids formulations (offset by 500 counts between patterns). 
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4.3.1.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol) 
With the incorporation of MAN, SD tobramycin:phospholipids:mannitol 
(TOB:PLS:MAN) in Figure 4.4a and SD azithromycin:phospholipids:mannitol 
(AZI:PLS:MAN) in Figure 4.4b exhibited a similar characteristic of XRPD patterns to 
the corresponding TOB:PLS=1:0.5 and AZI:PLS=1:0.5. Phospholipid bilayer structure 
was retained for both TOB:PLS:MAN and AZI:PLS:MAN. The characteristic crystalline 
peaks from other components (e.g., TOB/AZI and MAN (Appendix A)) were not 
observed. 
 
 
 
 
 
 
(a) 
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(b) 
Figure 4.4. X-ray powder diffraction patterns for: (a) SD 
tobramycin:phospholipids:mannitol formulations (offset by 500 counts between patterns); 
and (b) SD azithromycin:phospholipids:mannitol formulations (offset by 500 counts 
between patterns). 
 
4.3.2 Solid-State Phase Transition 
In order to present clear differential scanning calorimetry (DSC) data, a scheme for a 
typical glass transition of a drug and a main phase transition of phospholipid bilayer in 
spray-dried (SD) particles is shown in Figure 4.5. The two phase transitions result in an 
increased molecular mobility of the corresponding component. Glass transition is a 
second-order phase transition with a step change in heat capacity that an amorphous 
phase of drug component undergoes from the glassy state to rubbery state. The glass 
transition temperature (Tg) is the mid-point temperature at which glass transition takes 
place. The main phase transition of phospholipid bilayer is the first-order thermodynamic 
process that phospholipid bilayer changes from the gel phase (low degree of molecular 
mobility) to liquid crystalline phase (high degree of molecular mobility). The ΔHm and 
Tm are defined as the adjusted enthalpy change and the onset temperature of main phase 
transition of phospholipid bilayer. The ΔHm data in this dissertation is adjusted to the 
weight of phospholipids in a particular phospholipid containing formulation. Due to some 
baseline shift on thermograms and for purpose of consistent reporting, the peak 
tempertures are used to define the temperatures for other phase transitions. 
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Figure 4.5. Schematic of a typical glass transition of drug and a main phase transition of 
phospholipid bilayer in the spray-dried powder. 
 
4.3.2.1 One-component System (Spray-dried Pure Drug) 
Differential scanning calorimetry (DSC) thermograms of TOB and AZI one-component 
powders[43] are shown in Figure 4.6. As received TOB (Figure 4.6a) exhibited three 
major endotherms at temperatures of ~ 146oC, 156oC and 200oC, respectively. As 
expected, there was no glass transition observed for as received TOB. As shown Figure 
4.6b, SD pure TOB showed a glass transition at ~ 50oC and a major endotherm peak at ~ 
158oC.  
Only a single endothermic peak was observed at ~ 137oC for as received AZI (Figure 
4.6c). Thermogram of SD pure AZI is shown in Figure 4.6d. An evident glass transition 
was present at ~ 94oC for SD pure AZI. The glass transition was followed by an 
endotherm at temperature range between 160oC and 170oC for SD pure AZI. 
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(a)                                (b) 
   
(c)                                 (d) 
 
Figure 4.6. DSC thermograms for: (a) as received tobramycin; (b) SD pure tobramycin; 
(c) as received azithromycin; (d) SD pure azithromycin.[43] 
 
4.3.2.2 Two-component System  
4.3.2.2.1 Spray-dried Drug:Mannitol 
SD TOB:MAN (Figure 4.7) exhibited three phase transitions[143]. A glass transition was 
observed at temperature range between ~ 42oC and 69oC. It was followed by a small 
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endotherm at temperature around from 95oC to 96oC. The last phase transition with base 
line shift took place at ~ 169oC to 180oC. The detailed glass transition temperatures (Tg) 
of SD TOB:MAN were presented in Table 4.2[143]. 
 
SD AZI:MAN (Figure 4.8) showed two different thermograms as molar ratio of MAN 
increased from 1:0.1 to 1:1[143]. SD AZI:MAN with molar ratios of 1:0.1, 1:0.25, and 
1:0.75 presented similar characteristic thermograms. SD AZI:MAN=1:0.5 and 1:1 
exhibited similar thermal events with more complication than the formulations with other 
molar ratios. Glass transitions were observed for all SD AZI:MAN. DSC thermograms 
from non-hermetic conditions (Figure 4.9) revealed a similarity for AZI:MAN=1:0.1 and 
1:0.75, and AZI:MAN=1:0.5 and 1:1, respectively. Interestingly, AZI:MAN=1:0.25 
(Figure 4.9b) exhibited a characteristic thermogram under non-hermetic conditions. The 
detailed glass transition temperatures (Tg) of SD AZI:MAN from hermetic DSC studies 
were presented in Table 4.2[143]. 
 
Table 4.2. Glass transition temperatures for SD tobramycin:mannitol and SD 
azithromycin:mannitol[143] (mean ± SD, n=3). 
Molar Ratio Glass Transition Temperature (
oC) 
TOB:MAN AZI:MAN 
1:0.1 69.2±0.2 92.9±0.5 
1:0.25 66.5±0.2 93.7±0.5 
1:0.5 59.4±0.9 94.9±0.0 
1:0.75 55.2±0.9 94.0±0.2 
1:1 41.7±0.4 93.8±0.6 
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                 (a)                               (b)                               (c) 
 
(d)                              (e) 
Figure 4.7. DSC thermograms for: (a) tobramycin:mannitol=1:0.1; (b) tobramycin:mannitol=1:0.25; (c) 
tobramycin:mannitol=1:0.5; (d) tobramycin:mannitol=1:0.75; and (e) tobramycin:mannitol=1:1[143]. 
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(a)                            (b)                            (c) 
 
(d)                             (e) 
Figure 4.8. DSC thermograms for: (a) azithromycin:mannitol=1:0.1; (b) azithromycin:mannitol=1:0.25; (c) 
azithromycin:mannitol=1:0.5; (d) azithromycin:mannitol=1:0.75; and (e) azithromycin:mannitol=1:1[143].
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 (a)                           (b)                             (c) 
 
(d)                                (e) 
Figure 4.9. DSC thermograms (non-hermetic) for: (a) azithromycin:mannitol=1:0.1; (b) azithromycin:mannitol=1:0.25; (c) 
azithromycin:mannitol=1:0.5; (d) azithromycin:mannitol=1:0.75; and (e) azithromycin:mannitol=1:1[143].
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4.3.2.2.2 Spray-dried Drug:Phospholipids 
 
DSC thermograms of TOB:PLS (Figure 4.10a-c) exhibited four phase transitions, 
including a glass transition of TOB[43], a main phase transition of phospholipid 
bilayer[167], a exothermic crystallization transition, and an endothermic melting. As 
shown in DSC thermograms (Figure 4.10d-e), AZI:PLS mainly showed three phase 
transitions. It included a main phase transition of phospholipid bilayer, a glass 
transition of AZI[43], and one endothermic melting peak. The detailed DSC data of 
the formulations are summarized in Table 4.3.  
 
 
 
 
 
 
 
 
 
 
Table 4.3. Summary of glass transition temperature (Tg), main phase transition 
temperature of phospholipid bilayer (Tm), adjusted enthalpy of main phase transition 
of phospholipid bilayer (ΔHm), crystallization temperature (Tc), and melting 
temperature (Tm1) for SD tobramycin:phospholipids (TOB:PLS) and SD 
azithromyin:phospholipids (AZI:PLS) formulations in DSC (mean ± SD, n=3). 
Formulations 
(molar ratio) Tg (
oC) Tm (oC) ΔHm (J/g) Tc (oC) Tm1 (oC) 
 1:2 32.6 ± 0.9 61.9 ± 0.4 36.6 ± 2.8 143.1 ± 0.8 149.4 ± 2.2 
TOB:PLS 1:1 37.7 ± 1.1 62.6 ± 1.0 34.7 ± 1.8 141.0 ± 1.0 147.4 ± 1.5 
 1:0.5 41.9 ± 2.4 66.4 ± 0.1 27.9 ± 0.9 152.2 ± 1.1 156.2 ± 1.9 
 1:2 77.9 ± 0.9 61.2 ± 0.2 29.1 ± 0.2 - 159.2 ± 5.3 
AZI:PLS 1:1 79.9 ± 0.2 61.5 ± 0.1 22.9 ± 0.3 - 158.8 ± 7.8 
 1:0.5 76.6 ± 0.6 60.4 ± 0.1 7.6 ± 0.1 - 163.3 ± 2.8 
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(a)                              (b) 
    
(c)                              (d) 
    
(e)                              (f) 
 
Figure 4.10. DSC thermograms of SD drug:phospholipids formulations for: (a) 
tobramycin:phospholipids=1:2; (b) tobramycin:phospholipids=1:1; (c) 
tobramycin:phospholipids=1:0.5; (d) azithromycin:phospholipids=1:2; (e) 
azithromycin:phospholipids=1:1; and (f) azithromycin:phospholipids=1:0.5. 
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4.3.2.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol) 
DSC thermograms of TOB:PLS:MAN and AZI:PLS:MAN are shown in Figure 4.11 
and Figure 4.12, respectively. In Figure 4.11a-c, a glass transition of TOB, a main 
phase transition of phospholipid bilayer, and one endothermic melting peak were 
observed for TOB:PLS:MAN=1:0.5:0.1, 1:0.5:0.25, and 1:0.5:0.5. Additionally, a 
possible phase transition from lamellar to hexagonal of PLS (after main phase 
transition of phospholipid bilayer)[167] and an exothermic crystallization peak 
(before endothermic melting peak) were observed for TOB:PLS:MAN=1:0.5:0.75 
(Figure 4.11d) and 1:0.5:1 (Figure 4.11e).  
 
Similarly, AZI:PLS:MAN exhibited a main phase transition of phospholipid bilayer, a 
glass transition of AZI and one or two endothermic melting peak(s) depending on 
amount of MAN in the formulations. As shown in Figure 4.12a-c, one endothermic 
peak was observed for AZI:PLS:MAN with molar ratios from 1:0.5:0.1 to 1:0.5:0.5. 
However, additional endothermic peak was present for AZI:PLS:MAN=1:0.5:0.75 
(Figure 4.12d) and 1:0.5:1 (Figure 4.12e). Table 4.4 summarizes the detailed DSC 
data for TOB:PLS:MAN and AZI:PLS:MAN. 
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Table 4.4. Summary of glass transition temperature (Tg), main phase transition temperature of phospholipid bilayer (Tm), adjusted enthalpy of 
main phase transition of phospholipid bilayer (ΔHm), crystallization temperature (Tc), and melting temperature (Tm1 and Tm2) for 
tobramycin:phospholipids:mannitol and azithromycin:phospholipids:mannitol in DSC (mean ± SD, n=3). 
 
Formulations Tg (oC) Tm (oC) ΔHm (J/g) Tc (oC) Tm1 (oC) 
TOB:PLS:MAN 
1:0.5:0.1 37.2 ± 1.2 63.8 ± 0.1 30.6 ± 0.2 - 156.9 ± 3.9 
1:0.5:0.25 43.1 ± 0.1 61.2 ± 0.2 28.7 ± 0.9 - 163.7 ± 3.3 
1:0.5:0.5 37.0 ± 1.5 59.9 ± 0.0 39.8 ± 0.8 - 160.4 ± 3.5 
1:0.5:0.75 44.1 ± 0.2 57.6 ± 0.1 38.9 ± 1.8 156.1 ± 0.6 160.8 ± 1.3 
1:0.5:1 43.6 ± 0.1 55.8 ± 0.1 42.1 ± 1.0 158.7 ± 0.3 169.4 ± 1.2 
Formulations Tg (oC) Tm (oC) Hm (J/g) Tm1 (oC) Tm2 (oC) 
AZI:PLS:MAN 
1:0.5:0.1 80.4 ± 0.4 55.7 ± 0.1 7.7 ± 0.4 - 161.7 ± 2.3 
1:0.5:0.25 84.2 ± 0.6 50.5 ± 0.1 4.8 ± 0.1 - 158.7 ± 2.7 
1:0.5:0.5 84.6 ± 0.8 44.2 ± 0.1 7.1 ± 0.6 - 162.3 ± 5.4 
1:0.5:0.75 83.5 ± 1.3 44.0 ± 0.2 11.7 ± 1.7 142.4 ± 1.0 157.3 ± 3.0 
1:0.5:1 76.7 ± 0.1 42.2 ± 0.2 12.2 ± 0.3 147.1 ± 0.4 161.3 ± 4.9 
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 (a)                          (b) 
    
 (c)                         (d) 
 
(e) 
 
Figure 4.11. DSC thermograms of SD tobramycin three-components formulations for: 
(a) tobramycin:phospholipids:mannitol=1:0.5:0.1; (b) 
tobramycin:phospholipids:mannitol=1:0.5:0.25; (c) 
tobramycin:phospholipids:mannitol=1:0.5:0.5; (d) 
tobramycin:phospholipids:mannitol=1:0.5:0.75; and (e) 
tobramycin:phospholipids:mannitol=1:0.5:1. 
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(a)                           (b) 
    
(c)                           (d) 
 
(e) 
                                                                                                     
Figure 4.12. DSC thermograms of SD azithromycin three-components formulations 
for: (a) azithromycin:phospholipids:mannitol=1:0.5:0.1; (b) 
azithromycin:phospholipids:mannitol=1:0.5:0.25; (c) 
azithromycin:phospholipids:mannitol=1:0.5:0.5; (d) 
azithromycin:phospholipids:mannitol=1:0.5:0.75; and (e) 
azithromycin:phospholipids:mannitol=1:0.5:1. 
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4.3.3 Water Content 
The water content of all formulations (as received drugs and spray-dried powders) is 
listed in Table 4.5. SD powders exhibited water content less than 7% except for 
TOB:PLS:MAN=1:0.5:0.25 with 11%. 
 
4.3.3.1 One-component System (Spray-dried Pure Drug) 
Theoretically, the monohydrate, dihydrate, and trihydrate crystalline forms of 
TOB[168] contain 3.7, 7.1, and 10.3% (w/w) water, respectively. KF data shows as 
received TOB contained 7.47±0.18% (w/w)[43]. It suggests as received TOB was 
possibly present as a dihydrate with some moisture sorbed[43]. Monohydrate and 
dihydrate of AZI[169] possess 2.29% and 4.58% (w/w) water, respectively. 
As-received AZI was possibly present in dihydrate rich as supported by water content 
of 4.35±0.14% (w/w)[43]. Compared to the corresponding crystalline material, 
residual water content of SD pure TOB and SD pure AZI powders was lower after 
spray drying.  
 
4.3.3.2 Two-component System  
4.3.3.2.1 Spray-dried Drug:Mannitol 
As expected, the incorporation of non-hygroscopic MAN[170] lowered water content 
of TOB:MAN from 3.54% (w/w) to 0.41% (w/w) as increasing MAN from 1:0.1 to 
1:1[143]. A similar descending trend was observed for AZI:MAN with an increase in 
amount of MAN from 1:0.1 to 1:0.25[143]. However, water content of AZI:MAN 
increased as MAN further increased from 1:0.25 to 1:1[143].  
 
4.3.3.2.2 Spray-dried Drug:Phospholipids 
PLS showed an molar ratio effect on water content of TOB:PLS and AZI:PLS. With 
molar ratios of 1:2 and 1:1, the water content of TOB:PLS and AZI:PLS was 
approximately from 5% to 7%. However, it was significantly reduced down to < 2% 
in the formulations of 1:0.5. 
 
 
4.3.3.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol) 
A notable water content of 11% was observed for the TOB:PLS:MAN=1:0.5:0.25 
formulation. It is unclear as to why such high water content was observed. 
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Table 4.5. Water content for tobramycin and azithromycin formulations[43, 143] (mean ± SD, n=3). 
Tobramycin 
Formulations 
Water Content 
(% w/w) 
Azithromycin 
Formulations 
Water Content 
(% w/w) 
 
As received TOB 7.47±0.18 As received AZI 4.35±0.14  
SD pure TOB 5.24±0.12 SD pure AZI 1.30±0.21  
TOB:MAN=1:0.1 3.54±0.23 AZI:MAN=1:0.1 2.67±0.66  
TOB:MAN=1:0.25 2.79±0.87 AZI:MAN=1:0.25 0.24±0.05  
TOB:MAN=1:0.5 2.21±0.45 AZI:MAN=1:0.5 0.50±0.14  
TOB:MAN=1:0.75 0.89±0.18 AZI:MAN=1:0.75 1.50±0.52  
TOB:MAN=1:1 0.41±0.17 AZI:MAN=1:1 2.25±0.54  
TOB:PLS=1:2 6.35±1.53 AZI:PLS=1:2 4.92±1.11  
TOB:PLS=1:1 6.84±0.90 AZI:PLS=1:1 6.21±1.05  
TOB:PLS=1:0.5 1.53±0.26 AZI:PLS=1:0.5 1.42±0.72  
TOB:PLS:MAN=1:0.5:0.1 3.15±0.41 AZI:PLS:MAN=1:0.5:0.1 2.47±0.45  
TOB:PLS:MAN=1:0.5:0.25 11.00±0.86 AZI:PLS:MAN=1:0.5:0.25 5.20±0.74  
TOB:PLS:MAN=1:0.5:0.5 3.38±0.39 AZI:PLS:MAN=1:0.5:0.5 4.57±0.63  
TOB:PLS:MAN=1:0.5:0.75 4.10±0.43 AZI:PLS:MAN=1:0.5:0.75 3.28±0.38  
TOB:PLS:MAN=1:0.5:1 4.55±0.25 AZI:PLS:MAN=1:0.5:1 4.43±0.84  
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4.3.4 Water Vapor Sorption 
4.3.4.1 One-component System (Spray-dried Pure Drug) 
Equilibrated water vapor sorption isotherms at 25oC of as received TOB and AZI[43] 
with corresponding SD samples are plotted in Figure 4.13. Overall, TOB powders 
exhibited a higher water vapor sorption than AZI.  
As-received TOB slowly increased weight with RH %, exhibiting ~ 22% weight 
change at 95% RH. Water vapor isotherm was more complex for SD TOB. SD TOB 
took up relatively higher water vapor (than as received TOB) until 60% RH, reaching 
a ~ 20% weight increase. Thereafter, weight change of SD TOB started to drop to ~ 
12% at 65% RH and reached a plateau until 75% RH. The decrease in weight (at 65% 
RH) may be due to lyotropic-induced crystallization transition with expulsion of free 
water[145, 158, 171]. At the end of the study, a 65% weight increase was observed 
for SD pure TOB. As-received AZI gained approximately 4% weight. SD pure AZI 
gained 5% weight by 95% RH[43]. 
 
 
Figure 4.13. Water vapor sorption isotherms at 25oC for as received vs SD 
powders[43] (weight change % vs RH; n=1). 
 
4.3.4.2 Two-component System  
4.3.4.2.1 Spray-dried Drug:Mannitol 
Equilibrated water vapor sorption isotherms of SD TOB:MAN=1:0.5 and 
AZI:MAN=1:0.5[143] are plotted in Figure 4.14. Overall, TOB:MAN=1:0.5 took up 
more water vapor than AZI:MAN=1:0.5. TOB:MAN=1:0.5 gradually sorbed water 
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vapor until 65% RH, followed by a drop in weight (possibly lyotropic-induced 
crystallization transition) at 70% RH. A plateau region from 70% to 80% RH was 
observed, followed by a sharp increase of weight after 85% RH. Weight change of 
TOB:MAN=1:0.5 increased up to ~117% at 95% RH. As similar to the water vapor 
sorption isotherm of SD AZI, AZI:MAN=1:0.5 exhibited a slight increase in weight 
up to ~32% at 95% RH without any evident phase transition, remaining in an 
amorphous state[143]. 
 
 
 
Figure 4.14. Water vapor sorption isotherms at 25oC for SD 
tobramycin:mannitol=1:0.5 and SD azithromycin:mannitol=1:0.5[143] (weight 
change % vs RH; n=1). 
 
4.3.4.2.2 Spray-dried Drug:Phospholipids 
Equilibrated water vapor sorption isotherms of SD TOB:PLS=1:0.5 and 
AZI:PLS=1:0.5 are plotted in Figure 4.15. The profiles were similar to the 
corresponding TOB:MAN=1:0.5 and AZI:MAN=1:0.5, respectively. TOB:PLS=1:0.5 
gradually took up water vapor until 65% RH. It was followed by a drop in weight 
(possibly lyotropic-induced crystallization transition) at 70% RH. A sharp increase in 
weight change was observed after 75% RH. The weight change of TOB:PLS=1:0.5 
was ~ 57% at 95% RH. As expected, AZI:PLS=1:0.5 slightly increased weight up to 
~13% at 95% RH. 
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Figure 4.15. Water vapor sorption isotherms at 25oC for SD 
tobramycin:phospholipids=1:0.5 and SD azithromycin:phospholipids=1:0.5 (weight 
change % vs RH; n=1). 
 
4.3.4.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol) 
Equilibrated water vapor sorption isotherms of SD TOB:PLS:MAN=1:0.5:0.5 and 
AZI:PLS:MAN=1:0.5:0.5 are plotted in Figure 4.16. The profiles were similar to the 
corresponding drug:mannitol or drug:phospholipids formulation, respectively. 
TOB:PLS:MAN=1:0.5:0.5 gradually took up water vapor until 65% RH. It was 
followed by a possibly lyotropic-induced crystallization transition with a drop in 
weight change at 70% RH. A sharp increase of weight was observed after 75% RH. 
Weight change of TOB:PLS:MAN=1:0.5:0.5 was up to ~71% at 95% RH. As 
expected, weight change of AZI:PLS:MAN=1:0.5:0.5 slightly increased ~15% at 95% 
RH. 
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Figure 4.16. Water vapor sorption isotherms at 25oC for SD 
tobramycin:phospholipids:mannitol=1:0.5:0.5 and SD 
azithromycin:phospholipids:mannitol=1:0.5:0.5 (weight change % vs RH; n=1). 
 
4.3.5 Chemical Spectroscopy 
4.3.5.1 Confocal Raman Microscopy and Spectroscopy for Chemical Imaging 
and Mapping 
 
4.3.5.1.1 One-component System (Spray-dried Pure Drug) 
Confocal Raman microscopy and spectroscopy (CRM) analysis of SD pure TOB 
particles[43] is shown in Figure 4.17. In Figure 4.17a, a typical spectrum taken via 
CRM at the point indicated on the images in Figure 4.17b and Figure 4.17c is shown 
in comparison to as received TOB used as input. The Raman spectra in Figure 4.17a 
were obtained using a 785 nm laser to minimize the effects of fluorescence. However, 
to the author’s knowledge, it is not clear yet why TOB emitted fluorescence, since no 
double or triple bond(s) is present in the chemical structure. The broad vibrational 
bands in the SD TOB were characteristic of an amorphous substance. Raman spectra 
taken from several SD particles by CRM were indistinguishable, indicating no 
heterogeneity in powder, from the spectrum in Figure 4.17a[43].  
A similar result was obtained from the CRM analysis of SD AZI[43] as shown in 
Figure 4.18. Although AZI showed weaker fluorescence than TOB in the amorphous 
state, a spectrum was again taken via CRM using the 785 nm laser to avoid 
fluorescence. Spectra taken by CRM across many particles of SD AZI were 
indistinguishable, suggesting that the particles were uniformly amorphous[43].  
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(a) 
 
(b) 
 
(c) 
 
Figure 4.17. (a). Raman spectrum of SD pure tobramycin compared to that of as 
received tobramycin obtained using CRM; (b). Brightfield micrograph of SD pure 
tobramycin obtained using a 10x objective; and (c). Fluorescene micrograph of SD 
pure tobramycin obtained using a 10x objective.  The red points show the location at 
which the SD spectrum in (a) was obtained[43]. Courtesy of Dr. Frederick Vogt at 
GlaxoSmithKline. 
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(a) 
 
(b) 
 
(c) 
 
Figure 4.18. (a). Raman spectrum of SD pure azithromycin compared to that of as 
received azithromycin obtained using CRM; (b). Brightfield micrograph of SD pure 
azithromycin obtained using a 10x objective; and (c). Fluorescene micrograph of SD 
pure azithromycin obtained using a 10x objective. The red points show the location at 
which the SD spectrum in (a) was obtained[43]. Courtesy of Dr. Frederick Vogt at 
GlaxoSmithKline. 
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4.3.5.1.2 Two-component System  
4.3.5.1.3 Spray-dried Drug:Mannitol 
CRM analysis was performed for TOB:MAN=1:0.5 particles to investigate the 
physical form and homogeneity of TOB and MAN in SD particles[143]. Amorphous 
SD pure TOB was previously observed to show significant fluorescence, necessitating 
the use of a near-infrared laser wavelength (785 nm) for Raman spectroscopy of these 
materials. In Figure 4.19a, a brightfield micrograph obtained with a 10x objective is 
shown for a region of SD TOB:MAN=1:0.5 particles. Superimposed on this image is 
a 25 × 25 CRM map, with greater blue intensity indicating stronger Raman signal 
from 1425 to 1480 cm-1, a characteristic region for TOB. The CRM map indicates that 
the TOB was homogeneously distributed, with the only area of reduced signal 
corresponding to a depression in the particle surface seen primarily on the upper left 
portion of the mapped region. A fluorescence microscopy image of the particles, 
shown in Figure 4.19b, also showed no indication of heterogeneity. In Figure 4.19c, a 
comparison is shown between three representative Raman spectra obtained from the 
map in Figure 4.19a and reference spectra of SD pure TOB and alpha polymorphic 
form of MAN. The three representative spectra taken from TOB:MAN=1:0.5 particles 
were similar, showing no evidence of heterogeneity. There was no evidence of 
crystalline alpha MAN present in the spectra of SD particles. In addition, the broad 
vibrational bands observed were in good agreement with amorphous TOB[143]. 
SD pure AZI was previously observed to show less fluorescence than SD pure TOB. 
When spray dried with MAN, it was found that a higher-sensitivity Raman laser 
utilizing a shorter wavelength (633 nm) could be used for analysis of 
AZI:MAN=1:0.5 particles. In Figure 4.20, the CRM results are shown for 
AZI:MAN=1:0.5 particles using a 50x objective. In Figure 4.20a, a 25 × 25 CRM 
map is shown using a set of bands in the 845 to 900 cm-1 region (characteristic of 
alpha MAN). The distribution was seen to be relatively homogenous. This map can be 
compared with a map shown in Figure 4.20b where increasing red color 
corresponding to increasing intensity of Raman bands in the 1470 to 1550 cm-1 
(characteristic of SD pure AZI). The two maps generally agreed, suggesting that 
components of MAN and AZI were closely associated, and did not show any 
indication of heterogeneity between the two components at the high magnification 
used here. Spectra (Figure 4.20c) taken from three regions supported this conclusion. 
In addition, it also suggests that the MAN in the SD particles may possibly be 
amorphous[143].  
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   (a)                       (b) 
 
 
 
(c) 
 
Figure 4.19. (a) Brightfield micrograph of SD tobramycin:mannitol=1:0.5 particles 
obtained using a 10x objective. CRM mapping was performed in the region marked 
with the red box; increasing blue color corresponds to increasing intensity of Raman 
signal in the 1425 to 1480 cm-1 region. (b) Fluorescene micrograph of the same region. 
(c) Raman spectra from three points obtained using CRM, shown in comparison to SD 
pure tobramycin and alpha mannitol prepared as pure materials[143]. Courtesy of Dr. 
Frederick Vogt at GlaxoSmithKline. 
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(a)                      (b) 
 
 
 
(c) 
 
Figure 4.20. (a) Brightfield micrograph of SD azithromycin:mannitol=1:0.5 particles 
obtained using a 50x objective. CRM mapping was performed in the region marked 
with the red box; increasing blue color corresponds to increasing intensity of Raman 
signal in the 845 to 900 cm-1 region. (b) CRM mapping results with increasing red 
color corresponding to increasing intensity of Raman signal in the 1670 to 1750 cm-1 
region. (c) Raman spectra from three points obtained using CRM, shown in 
comparison to SD pure azithromycin and alpha mannitol prepared as pure 
materials[143]. Courtesy of Dr. Frederick Vogt at GlaxoSmithKline.   
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4.3.5.2 Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy 
 
4.3.5.2.1 One-component System (Spray-dried Pure Drug) 
 
Attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) 
spectra of TOB[43] (Figure 4.21a and Figure 4.21b (zoomed in data)) and AZI[43] 
(Figure 4.21c) indicated a loss of the peak at ~3500 cm-1 after spray drying, although 
the as received TOB did not show an strong spectrum possibly due to poor contact 
with ATR crystal. This peak may be tentatively assigned to O-H stretching vibration 
mode in the particles. Instead, the SD pure TOB and AZI particles exhibited a broad 
band at region of ~3600-3000 cm-1. In comparison to as received sample, the SD pure 
AZI showed additional spectral differences at band region of ~1400 to 1100 cm-1. 
This band region may be tentatively assigned to C-O stretching[43].  
 
 
(a) 
 
(b) 
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(c) 
Figure 4.21. ATR-FTIR spectra of: (a) SD pure and as received tobramycin particles 
(full scan range); (b) SD pure and as received azithromycin particles (zoomed in 
spectra from (a)); and (c) SD pure and as received azithromycin particles (full scan 
range)[43]. 
 
4.3.5.2.2 Two-component System  
4.3.5.2.3 Spray-dried Drug:Mannitol 
ATR-FTIR spectra of TOB:MAN[143] (Figure 4.22a) and AZI:MAN[143] (Figure 
4.22b) showed similar spectra to the corresponding SD pure TOB and AZI. No 
significant peak shift was observed in the binary systems. Similar to spectrum of SD 
pure AZI, AZI:MAN=1:0.5 and AZI:MAN=1:1 showed a slight spectral difference at 
band of ~1100 cm-1 to the other compositions. In addition, a broad peak at band 
region of ~3600-3100 cm-1, possibly reflecting water molecules in samples, was 
observed in AZI:MAN=1:0.5 and AZI:MAN=1:1. This data may possibly suggest that 
water molecules could be present with AZI component. Therefore, it would possibly 
facilitate the conversion of AZI component (in AZI:MAN=1:0.5 and AZI:MAN=1:1) 
to a hydrate form.  However, as water content data (Table 4.5) being considered, it is 
unclear why the two formulations exhibited differently to other formulations[143]. 
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(a) 
 
(b) 
Figure 4.22. ATR-FTIR spectra for: (a) SD tobramycin:mannitol formulations; and 
(b) SD azithromycin:mannitol formulations[143]. 
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4.4 Discussion 
4.4.1 Crystallinity and Polymorphism 
As shown, XRPD diffractograms indicates that both SD pure drug (Figure 4.1) and 
SD drug:mannitol (Figure 4.2) were lacking of long-range molecular order after spray 
drying. XRPD diffractograms of SD drug:phospholipids (Figure 4.3) and SD 
drug:phospholipids:mannitol (Figure 4.4) particles showed that phospholipid bilayer 
structure was retained after spray drying. However, the other component(s) in 
drug:phospholipids and drug:phospholipids:mannitol was/were lacking long-range 
molecular order.  
The presence of amorphous character in SD dry powder particles may lead to the 
physical and chemical instabilities. Therefore, stability tests are of importance to 
study the effect of storage conditions on SD dry powder formulations. Besides the 
chemical stability issue, the physical change that can occur in powders upon storage is 
expected to adversely alter the aerosol dispersion performance. 
 
4.4.2 Solid-State Phase Transition 
Understanding the thermal-induced phase transition(s) is important for a 
non-crystalline formulation intended for dry powder inhalation. Phase transitions that 
result in particle aggregation or solid-state bridging between particles may lead to the 
failure of powder delivery to the deep lungs. Therefore, solid-state phase transition of 
formulations, especially dry powders for inhalation is of importance. 
4.4.2.1 One-component System (Spray-dried Pure Drug) 
Before our work[43], the thermogram of as received TOB in hermetically sealed DSC 
pan has not been reported in the scientific literature. However, it has been done under 
non-hermetic conditions[168]. As mentioned earlier, commercially available 
crystalline TOB consists of stoichiometric hydrate forms of monohydrate, dihydrate, 
and trihydrate[168]. Compared to thermograms of TOB published previously, it 
indicates the first endothermic peak at ~146oC (in Figure 4.6a) may correspond to the 
dehydration of as received TOB dihydrate. As-received TOB presented as a dihydrate 
form was possibly supported by KF titration (Table 4.5) and thermogravimetric 
analysis (TGA) data (Figure 4.23a) with ~ 7.5% weight (water) loss when heated to 
150oC. The TGA was conducted in a pin-holed pan with a scan rate as 5oC/min. The 
dehydration was likely followed by the melting of a metastable anhydrous form at 
~156oC, and the possible melting of stable anhydrous TOB occurred at ~200oC. In 
thermal analysis from hermetically sealed DSC pan (Figure 4.6a), the formation of 
stable anhydrous from the melt by an exothermic crystallization (at the temperature 
range between ~156oC and 200oC) was not detected. However, the crystallization 
process was confirmed by hot stage microscopy (HSM) under cross-polarizer (Figure 
4.24) at ~217oC[43]. HSM study was conducted at 5oC/min. The temperature 
difference between DSC and HSM was due to open-air conditions in HSM study. The 
endothermic events at 158oC in the thermograms of SD pure TOB are suggested to be 
the melting of metastable anhydrous form. However, XRPD diffractogram (Figure 
4.1a) exhibited no crystalline peaks from SD pure TOB with some possible extent of 
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anhydrous form (or even short-rang molecular order) due to the limitation of detection. 
Therefore, it may suggest that SD pure TOB from spray drying was amorphous-phase 
rich.  
 
(a) 
 
(b) 
Figure 4.23. Thermogravimetric analysis for: (a) as received tobramycin; and (b) SD 
pure azithromycin. 
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25oC             37 oC           188 oC           197 oC 
 
217 oC            242 oC 
Figure 4.24. HSM micrographs of as received tobramycin[43]. 
As suggested by KF data (Table 4.5), as received AZI was possibly in the dihydrate 
form. The endothermic peak (Figure 4.6c) at 137oC is suggested to correspond to the 
concurrent events of dehydration and melting of as received AZI[169]. The 
endotherm at temperature from 160 to170oC from SD pure AZI (Figure 4.6d) was 
possibly the melting of low amount of metastable AZI anhydrate (or short-range 
molecular order of AZI). This conclusion was supported by TGA data (Figure 4.23b) 
since there was no weight change at the temperature range of 160 to 170oC. 
 
4.4.2.2 Two-component System   
4.4.2.2.1 Spray-dried Drug:Mannitol 
The order-to-disorder phase transition (endothermic event) of TOB:MAN (Figure 4.7) 
was observed and slightly influenced with temperature shift by the molar ratio of 
incorporated MAN. However, the existence of long-range molecular order of TOB 
and MAN in TOB:MAN system after spray drying was not suggested by XRPD in 
Figure 4.2a.  
 
Both hermetic and non-hermetic DSC conditions were studied for AZI:MAN. In 
hermetic DSC conditions, equilibrium in thermal event is established in a fast manner. 
However, non-hermetic conditions allow the release of moisture from samples, 
minimizing moisture effect on thermal events. In Figure 4.8, DSC thermograms under 
hermetic conditions of AZI:MAN=1:0.1, 1:0.25 and 1:0.75, and AZI:MAN=1:0.5 and 
1:1 exhibited similar thermal events, respectively. Under non-hermetic conditions, 
only the AZI:MAN=1:0.25 exhibited unique behavior (Figure 4.9b). In non-hermetic 
DSC studies, thermograms of AZI:MAN=1:0.1 (Figure 4.9a) and 1:0.75 (Figure 4.9d)  
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were similar to SD pure AZI (Figure 4.25). This data may suggest that the MAN 
component was probably present in amorphous phase. Similar to the discussion of SD 
pure AZI (in Section 4.4.2.1), a possible low amount of metastable AZI anhydrate (or 
short-range molecular order of AZI) may be present in AZI:MAN=1:0.1 and 1:0.75. 
In non-hermetic DSC studies, the two endothermic transition peaks in 
AZI:MAN=1:0.25 (Figure 4.9b) appeared consistent with the melting of delta and 
beta forms of MAN, respectively. Hulse, et al observed similar thermograms for the 
formulation of MAN with protein by co-spray drying[172]. As shown in Figure 4.9b, 
the beta form of MAN may result from the small exothermic event (crystallization) 
after the melting of the delta form. The possible melting of beta MAN was observed 
at 165oC. The thermograms of both formulations AZI:MAN=1:0.5 (Figure 4.9c) and 
AZI:MAN=1:1 (Figure 4.9e) exhibited a small endothermic peak at around 60oC. This 
endothermic peak could possibly be the melting/dehydration of a MAN hydrate 
form[173], although this hypothesis was not supported by XRPD data possibly due to 
the detection limit.  
 
 
Figure 4.25. DSC thermogram (non-hermetic) of SD pure azithromycin. 
 
4.4.2.2.2 Spray-dried Drug:Phospholipids 
Glass transition temperatures (Tgs) of the drugs in phospholipid incorporated 
two-component formulations (in Table 4.3) were lowered as compared to the SD pure 
drugs (~50oC for SD pure TOB and ~94oC for SD pure AZI, respectively). The 
short-range molecular order of TOB component in TOB:PLS may possibly crystallize 
at ~141-152oC as indicated by an exothermic peak. The crystallized TOB melted at 
~147-156oC. As to AZI:PLS, a possible endothermic peak of AZI was observed 
without showing an evident exothermic crystallization. It is believed that either a 
crystallization of AZI was possibly not detected under such DSC conditions or an 
endothermic peak could be a melting of the AZI component. 
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Based on the weight fraction of the components, the adjusted values of main phase 
transition of phospholipid bilayer (ΔHm) were presented in Table 4.3. The values of 
ΔHm in phospholipid containing formulations may represent the tight packing of 
phospholipid bilayer structure in particles. The values of ΔHm from TOB:PLS were 
relatively constant (between 27.94J/g and 36.63J/g). Overall, AZI:PLS exhibited a 
lower value of ΔHm than TOB:PLS at same molar ratio. Noticeably, ΔHm values were 
relatively higher for AZI:PLS=1:2 (29.11J/g) and AZI:PLS=1:1 (22.86J/g), compared 
to AZI:PLS=1:0.5 (7.58J/g). This result may indicate that the phospholipid bilayer 
structures, in AZI:PLS=1:2 and 1:1, were well organized.  AZI molecules have been 
reported to bind to phospholipids molecules and interfere with interfacial and 
hydrophobic parts of fully hydrated phospholipid bilayer[174]. Therefore, with water 
molecules associated in spray-dried particles (Table 4.5), it is expected that AZI 
molecules could interact with phospholipid molecules, possibly altering the 
organization of bilayer structure. Therefore, compared to TOB formulations, a higher 
reduction in integrity of phospholipid bilayer may be expected for AZI:PLS as a 
function of ratio composition, resulting in a lower value of ΔHm.  
 
4.4.2.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol) 
Glass transition temperatures (Tgs) of the drugs in three-component formulations were 
lowered compared to the SD pure drugs (~50oC for SD pure TOB and ~94oC for SD 
pure AZI, respectively). In addition to the main phase transition of phospholipid 
bilayer, an endothermic melting peak was observed for TOB:PLS:MAN=1:0.5:0.1, 
1:0.5:0.25, and 1:0.5:0.5 in Figure 4.11a-c. It could possibly be the melting of either 
TOB or MAN, or simply the co-melting of TOB and MAN since the two components 
exhibit very close melting points[43, 44]. In TOB:PLS:MAN=1:0.5:0.75 and 1:0.5:1 
(Figure 4.11d and 4.11e), TOB and MAN components may possibly crystallize, 
resulting in one melting peak. There was one (MAN content from 0.1 to 0.5 in the 
composition ratio) or two (MAN content from 0.75 to 1 in the composition ratio) 
melting peaks present in formulations in AZI:PLS:MAN (Figure 4.12). The additional 
endothermic peak at ~142-147oC (at relatively lower temperature) was possibly the 
melting of a thermodynamically metastable polymorph of MAN such as the delta 
form[175]. Similar to TOB:PLS:MAN, the endothermic melting peak at ~ 157-161oC 
in  AZI:PLS:MAN could possibly be the melting of either AZI or MAN, or simply 
the co-melting of MAN and AZI components. 
 
As expected, adjusted enthalpy (ΔHm) values of main phase transition of phospholipid 
bilayer for TOB:PLS:MAN were higher than AZI:PLS:MAN at various molar ratios. 
Interestingly, it appeared that the molar ratio of 1:0.5:0.25 and 1:0.5:1 for both 
formulation systems resulted in lowest and highest ΔHm, respectively. These two 
specific molar ratios in each drug formulation may possibly indicate the lowest and 
highest integrity of phospholipid bilayer structure under studied molar ratios, 
respectively. 
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4.4.3 Water Content 
Water content of a solid formulation is not only related to chemical degradation, but 
also has an impact on aerosol dispersion performance by formation of liquid bridge. 
For dry powder inhalation formulations, low water content is essential in order to 
minimize capillary forces between particles. 
In general, water content of final spray-dried powders was dependent on material 
properties and composition of components in particles. As shown in Table 4.5, water 
content of spray-dried pure drug was lowered by removing water molecules in as 
received material after spray drying from organic solution. The incorporation of 
non-hydroscopic MAN into drug:MAN and PLS with high water affinity into 
drug:PLS resulted into water content of < 4% and < 7%, respectively. Water content 
in three component drug:PLS:MAN generally was < 6% except for 
TOB:PLS:MAN=1:0.5:0.25 (~ 11% water content). This exception was possibly, in 
part, due to the hygroscopic nature of TOB[176]. 
In order to compare the water content from the worst case scenario where water is not 
removed by spray drying with the value obtained by KF, the calculation for 
theoretical values were conducted. It is assumed that water moisture is only from 
methanol solvent and as-received materials. Another assumption is that all the 
moisture is evenly distributed to the powder regardless of particle size. The water 
content of methanol is 0.01%. As-received TOB, AZI, MAN, DPPC and DPPG 
possessed water content of 7.47%, 4.35%, 0.53%, 3.76%, and 3.21%, respectively. 
The concentration of powder in methanol is 0.1%. The calculated values for KF are 
listed in Table 4.6. It is concluded that all calculated values are higher than the 
measured, possibly supporting that the spray drying process from organic solution 
does remove water under these studied spray-drying conditions. 
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Table 4.6. Calculated water content for tobramycin and azithromycin formulations (mean ± SD, n=3). 
Tobramycin 
Formulations 
Water Content 
(% w/w) 
Tobramycin 
Formulations 
Water Content 
(% w/w) 
 
SD pure TOB 14.26 SD pure AZI 11.37  
TOB:MAN=1:0.1 14.02 AZI:MAN=1:0.1 11.28  
TOB:MAN=1:0.25 13.69 AZI:MAN=1:0.25 11.17  
TOB:MAN=1:0.5 13.21 AZI:MAN=1:0.5 10.98  
TOB:MAN=1:0.75 12.80 AZI:MAN=1:0.75 10.82  
TOB:MAN=1:1 12.46 AZI:MAN=1:1 10.68  
TOB:PLS=1:2 11.57 AZI:PLS=1:2 10.94  
TOB:PLS=1:1 12.09 AZI:PLS=1:1 11.05  
TOB:PLS=1:0.5 12.95 AZI:PLS=1:0.5 11.15  
TOB:PLS:MAN=1:0.5:0.1 12.59 AZI:PLS:MAN=1:0.5:0.1 11.10  
TOB:PLS:MAN=1:0.5:0.25 12.45 AZI:PLS:MAN=1:0.5:0.25 11.02  
TOB:PLS:MAN=1:0.5:0.5 12.22 AZI:PLS:MAN=1:0.5:0.5 10.90  
TOB:PLS:MAN=1:0.5:0.75 12.02 AZI:PLS:MAN=1:0.5:0.75 10.79  
TOB:PLS:MAN=1:0.5:1 11.83 AZI:PLS:MAN=1:0.5:1 10.69  
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4.4.4 Water Vapor Sorption 
Water vapor sorption isotherms indicate the amount of water vapor uptake at 
individual RH %, providing potential practical storage guidance on dry powders for 
inhalation. Water vapor sorption data could also reveal any possible lyotropic-induced 
phase transition, impeding aerosol dispersion performance. As compared to SD pure 
TOB, the relatively smaller weight drop during possible lyotropic-induced 
crystallization in SD TOB two-component and three-component powders was due to 
either a lower TOB component loading or an incompletion of the phase transition in 
the powders. The large amount of water vapor uptaken by the particles at high RH % 
(i.e. above 80% RH) suggests a possible dissolution process[177]. Overall, due to the 
hygroscopic nature, TOB formulations exhibited water vapor sorption to a higher 
extent compared to AZI formulations, especially at high RH %. 
 
4.4.4.1 One-component System (Spray-dried Pure Drug) 
The stoichiometric plots of mole water vapor sorbed per mole dry compound vs 
relative humidity[43] (Figure 4.26), translated from water vapor sorption data (Figure 
4.13), could provide insightful molecular information. No evidence suggested that the 
“pre-dried” as-received TOB (possibly in dihydrate; thermodynamic stable) lost 
H-bonding water molecules. As-received TOB showed no evident lyotropic-induced 
phase transition. However, the SD pure TOB (possibly amorphous rich) underwent a 
lyotropic-induced phase transition to a more organized physical form. Without 
showing a glass transition, DSC data (Figure 4.27) suggest that SD pure TOB after 
water vapor sorption was possibly present as a hydrate or a mixture of hydrates. It 
showed two sharp endothermic peaks similar to the dehydration events from 
as-received TOB (Figure 4.6a). Possibly due to the high amount of sorbed free water 
vapor, approximately 4 water molecules were associated with SD TOB at 65% RH, as 
shown in Figure 4.26. In addition, SD TOB took up higher amount of water vapor at 
95% RH than as received TOB possibly due to a larger surface area.  
As-received AZI decreased weight by approximately 3.5% (shown as blue curve in 
Figure 4.28), indicating a loss of H-bonding water molecules during the pre-drying 
process at 0% RH. Upon exposure to water vapor, “pre-dried” as-received AZI gained 
approximately 1.5 water molecules per molecule and maintained this molecular ratio 
constant across the whole RH %. This may indirectly indicate as-received AZI was 
possibly dihydrate rich, which was in agreement with KF data (Table 4.5). However, 
SD pure AZI took up water vapor slowly and eventually reached ~2 molecules of 
water per molecule of AZI at 95% RH.  
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Figure 4.26. Water vapor sorption isotherms at 25oC for as received vs SD powders 
(water vapor sorbed/dry compound mole/mole vs RH; n=1)[43]. 
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Figure 4.27. DSC thermograms of SD pure tobramycin after completion of water 
vapor sorption study. 
 
 
Figure 4.28. An experimental summary graph of water vapor sorption isotherms at 
25oC for as received AZI. 
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4.4.4.2 Two-component System  
4.4.4.2.1 Spray-dried Drug:Mannitol 
As similar to SD pure TOB, a possible lyotropic-induced crystallization was observed 
for TOB in TOB:MAN=1:0.5. However, the phase transition shifted from 65% RH 
(SD pure TOB) to 70% RH (TOB:MAN=1:0.5). There was no evident phase 
transition observed for AZI:MAN=1:0.5.  
 
4.4.4.2.2 Spray-dried Drug:Phospholipids  
As similar to SD pure TOB, a possible lyotropic-induced crystallization was observed 
for TOB in TOB:PLS at 70% RH. No evident lyotropic-induced phase transition was 
observed for AZI:PLS.  
4.4.4.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol) 
With incorporation of MAN to drug:PLS, drug:PLS:MAN exhibited similar water 
vapor sorption profiles to the corresponding drug:PLS.  
 
4.4.5 Chemical Spectroscopy 
Uniformity in physical form for and homogeneity of multi-component systems are 
essential for physical stability or even drug content uniformity of SD dry powder 
formulations. Therefore, Confocal Raman microscopy (CRM) with non-invasive and 
non-destructive analysis is employed to examine the SD powders. Infrared 
spectroscopy yields similar, but complementary, information to Raman spectroscopy. 
It probes the degree of molecular order and polymorphic system. 
4.4.5.1 Confocal Raman Microscopy and Spectroscopy for Chemical Imaging 
and Mapping 
 
CRM analysis of SD pure TOB (Figure 4.17) and SD pure AZI (Figure 4.18) particles 
showed no sign of heterogeneity in physical form. The data suggest there was no 
presence of any crystalline phase in SD powder. Therefore, it may be consistent with 
the hypothesis put forth in the DSC studies that SD pure drug was amorphous rich. As 
to TOB:MAN=1:0.5 (Figure 4.19) and AZI:MAN=1:0.5 (Figure 4.20) particles, CRM 
analysis suggested no evidence of heterogeneity between the two components in SD 
binary mixture. 
 
4.4.5.2 Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy 
 
FTIR data may suggest that the crystal structure was absent in SD pure TOB (Figure 
4.21a and 4.21b) and SD pure AZI (Figure 4.21c) as the vibration of several chemical 
bonds (TOB: O-H stretching; AZI: O-H and C-O stretching) changed after spray 
drying. This is in agreement with XRPD and DSC data. 
Shown in FTIR data (Figure 4.22), no significant interaction between antibiotic drug 
and MAN is suggested as peak shifts were not observed. In addition, although CRM 
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analysis suggested no evidence of heterogeneity, FTIR data indicated that 
AZI:MAN=1:0.5 and 1:1 may possibly possess relatively more characteristic of 
crystalline AZI than other molar ratios. The unique characteristic was also supported 
by DSC data. 
 
4.5 Conclusions 
Physicochemical properties of spray-dried powders were characterized by a variety of 
techniques. In general, the spray-dried powders without incorporation of 
phospholipids were lacking of long-range molecular order or exhibited as an 
amorphous solid. With incorporation of phospholipids, the spray-dried powders 
retained phospholipid bilayer structure. However, the extent of phospholipid bilayer 
structure was mainly dependent on the antibiotic drug in formulations. The other 
component(s) in phospholipids-incorporated formulations were lacking in long-range 
molecular order or exhibited as amorphous solid. The majority of spray-dried powders 
showed low water content. In contrast to spray-dried azithromycin formulations, the 
lyotropic-induced phase transition in spray-dried tobramycin formulation may 
indicate a physical stability or even potential chemical stability issue and aerosol 
dispersion at high relative humidity conditions. Overall, no evident sign of 
heterogeneity and presence of significant amount of crystalline phase in spray-dried 
pure drug and drug:mannitol were observed by chemical spectroscopy. 
 
 
 
 
 
 
 
 
 
Portions of Chapter 4 were reproduced with kind permission from: Li, X, Vogt, F.G., 
Hayes, D. Jr., and Mansour, H.M. Physicochemical Characterization and Aerosol 
Dispersion Performance of Organic Solution Advanced Spray Dried 
Microparticulate/Nanoparticulate Antibiotic Dry Powders of Tobramycin and 
Azithromycin for Pulmonary Inhalation Aerosol Delivery. European Journal of 
Pharmaceutical Sciences, 2014, 15:191-205. Copyright © 2014 Elsevier.  
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Chapter 5 in vitro Aerosol Dispersion 
 
 
5.1 Introduction 
Inertial impactors have been employed to characterize pharmaceutical aerosol 
formulations for several decades. The results of inertial impactors often correlate with 
particle deposition within the human lungs. Several apparatuses are documented in the 
European and United States Pharmacopoeias (USP), such as twin-stage liquid 
impinger (TSLI), Anderson cascade impactor (ACI), and the next generation impactor 
(NGI). The principle of inertial impaction for aerodynamic sizing is based on the 
aerodynamic behavior of aerosol particles, as shown by a cascade inertial impactor in 
Figure 5.1. When the direction of an air flow changes, the entrained particles in air 
continue to move in the original direction of flow until they lose inertia as a result of 
friction with air[5]. A plate is placed to collect particles in the path of the original 
direction of air flow. The larger particles impact the plate, while the smaller particles 
relax into a new direction of flow without being collected. With well-defined design 
and geometry of each impactor or impinge, the collection efficiency on each 
collection stage is dependent on air flow rate and dry powder inhaler (DPI) device 
employed. 
 
Figure 5.1. Schematic representation of the principle of inertial impaction for cascade 
inertial impactors. Adapted from [178]. 
 
In the present study, the NGI is employed for in vitro aerosol dispersion performance 
of spray-dried (SD) particles. As reported, it has been extensively utilized for 
pulmonary aerosol formulations[179, 180]. The design and assembly of the NGI is 
shown in Figure 5.2. The induction port (Figure 5.2a) is used to connect the impactor 
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to a DPI inhaler. The pre-separator (Figure 5.2a) connects between the induction port 
and the impactor. When necessary, with dry powder inhalers (DPIs), a pre-separator 
can be added to avoid overloading the first stage and is used with lactose carrier DPI 
systems. In addition, a suitable mouthpiece adapter is used to provide an airtight seal 
between the DPI inhaler and the induction port.[178] The NGI is designed with seven 
stages and a micro-orifice collector (MOC) as shown in Figure 5.2b. It is stated that 
“over the design flow rate range of 30 to 100 L/minute, the 50% efficiency 
aerodynamic cutoff diameters of the stages (D50 values) range between 0.24µm to 
11.7µm, evenly spaced on a logarithmic scale”[178]. Several removable impaction 
cups (Figure 5.2b) are placed in one plane on the NGI.[178] The NGI has more 
collection stages than the TLSI[181] and is easier to use than the ACI[182]. In 
addition, “the collection efficiency curves for each stage are sharp and minimize 
overlap between stages”[178] is well known for the NGI. Therefore, the NGI allows a 
high resolution of particle deposition with an easy operation. 
 
 
 
(a) 
 
 
 
 
(b) 
 
Figure 5.2. Closed (operating) condition (a) with pre-separator and internal 
construction (b) of the next generation impactor. Adapted from [178]. 
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The deposition patterns of spray-dried (SD) particles are assessed by employing the 
NGI. The NGI data could allow the correlation of particle deposition on stages with 
various locations in human lungs based on aerodynamic size. In addition, the various 
aerosol dispersion performance parameters would be able to assess the ability and 
efficiency of aerosol penetration of SD particles to the deep lung regions. 
 
 
5.2 Materials and Methods 
5.2.1 Materials 
The fresh spray-dried (SD) particles prepared as outlined in Chapter 4 for in vitro 
aerosol dispersion performance study are listed in Table 5.1. TOB, AZI, MAN, and 
PLS stand for tobramycin, azithromycin, mannitol, and phospholipids, respectively. 
All the studied particles were generated employing a 50% pump rate during spray 
drying. The outlet temperatures of SD particles are referred to Table 3.1 and Table 3.2 
in Chapter 3. HP clear, size 3 capsule (Quali-V®) was received from Qualicaps 
(Spain). 
 
Table 5.1. SD particles for the NGI study. 
 
Formulation 
System 
SD TOB formulations 
(molar ratio) 
SD AZI formulations 
(molar ratio) 
One-component Pure TOB Pure AZI 
Two-component 
TOB:MAN=1:0.1 AZI:MAN=1:0.1 
TOB:MAN=1:0.5 AZI:MAN=1:0.5 
TOB:MAN=1:1 AZI:MAN=1:1 
TOB:PLS=1:0.5 AZI:PLS=1:0.5 
TOB:PLS=1:1 AZI:PLS=1:1 
TOB:PLS=1:2 AZI:PLS=1:2 
 TOB:PLS:MAN=1:0.5:0.1 AZI:PLS:MAN=1:0.5:0.1 
Three-component TOB:PLS:MAN=1:0.5:0.5 AZI:PLS:MAN=1:0.5:0.5 
 TOB:PLS:MAN=1:0.5:1 AZI:PLS:MAN=1:0.5:1 
 
5.2.2 Methods 
5.2.2.1 Mass Analysis 
In accordance with USP Chapter <601> specifications[178], the aerosol dispersion 
performance of the dry powder formulations were determined using the NGI (Model 
170, MSP Corporation, Shoreview, Minnesota) equipped with a stainless steel 
induction port (i.e. USP throat; MSP Corporation, Shoreview, Minnesota), stainless 
steel NGI gravimetric insert cups (MSP Corporation, Shoreview, Minnesota) and the 
HandiHaler® (a DPI device with high shear stress; Boehringer Ingelheim 
Pharmaceutics, Germany). The NGI was coupled to a Copley HCP5 vacuum pump 
(Copley Scientific, United Kingdom), and a Copley TPK 2000 critical flow controller 
(Copley Scientific, United Kingdom). Airflow rate was adjusted before each 
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experiment by a Copley DFM 2000 flow meter (Copley Scientific, United Kingdom). 
The NGI experiment was run at a controlled airflow rate at Q=60 L/min (adult air 
flow rate) with a delay time of 10 seconds. Each HP clear, size 3 capsule contained 
10mg SD powders. To start the experiment, the capsule was pierced by pins in the 
HandiHaler®. Powder in capsule was pulled out by the flow of air and deposited on 
stages in the NGI. The mass of powder deposited on each stage was quantified by a 
gravimetric method employing type A/E glass fiber filters with diameter 55mm 
(PALL Corporation, NY). In vitro aerosolization was evaluated in triplicate under 
normal lab conditions. Three capsules were used in each experiment. The 
aerosolization experiment was randomized by Design ExpertTM 8.0.7.1 software 
(Stat-Ease Corp., MN). 
 
For the NGI with Q=60 L/min, the effective aerodynamic cutoff diameter for each 
impactor stage was calibrated by the manufacturer and stated as: stage 1, 8.06μm; 
stage 2, 4.46μm; stage 3, 2.82μm; stage 4, 1.66μm; stage 5, 0.94μm; stage 6, 0.55μm; 
stage 7, 0.34μm. Emitted dose fraction (ED[%]; Equation 5.1) is determined as the 
percentage powder mass emitted from capsules relative to the total dose in capsules 
(TD). Emitted dose (ED) includes the sum of the powder mass left on inhaler device, 
USP throat, and deposited on the NGI stages. Fine particle fraction (FPF[%]; 
Equation 5.2) is expressed as a percentage of fine particle dose (FPD) to ED. FPD is 
defined as the dose deposited on stage 2 and later stages (3-7). Respirable fraction 
(RF[%]; Equation 5.3) is defined as the percentage of FPD to deposited dose (DD). 
Deposited dose (DD) is defined as the dose deposited on all stages. 
 
Emitted dose fraction (ED[%]) =  ED
TD
x 100%       (Equation 5.1) 
Fine particle fraction (FPF[%]) =  FPD
ED
x 100%      (Equation 5.2) 
Respirable fraction (RF[%]) =  FPD
DD
x 100%      (Equation 5.3) 
 
In addition, mass median aerodynamic diameter (MMAD) of aerosol particles and 
geometric standard deviation (GSD) of the distribution are determined based on a 
log-probability distribution (particle size vs particle deposition percentage) obtained 
from the NGI data. The MMAD and GSD values were computed by using 
Mathematica (Wolfram Research Inc., Champaign, IL), a calculation program written 
by Dr. Warren Finlay[183]. 
5.2.2.2 Method validation of Chemical Analysis 
As indicated above, the particle deposition pattern on the various stages of the NGI 
are evaluated gravimetrically. In one set of experiments, the amount of AZI deposited 
on each stage was examined by chemical analysis using high performance liquid 
chromatogram (HPLC). To that end, a standard AZI solution with concentration of 
~1000 ug/mL (in methanol) was used to assess possible drug adsorbance on the glass 
filter to be placed on the NGI stages. Two treatment groups (a and b) with glass filter 
were compared with the control group: 
 a) In the first treatment experiment, the glass filter was soaked in 5mL of standard 
AZI solution for ~1h;  
92 
 
b) In the second treatment experiment, the first step is that the glass filter was soaked 
in 5mL of standard AZI solution for ~1h in vial A. The solution (3mL) in the vial A 
with soaked glass filter was collected into a new vial B. The second step is that 10mL 
solvent (methanol) was added to wash off the possible adsorbed AZI on soaked glass 
filter in vial A. Eventually, a total 13mL solution was collected in vial B. 
The two solutions from two treatment experiments (a and b) were passed through 
polytetrafluoroethylene (PTFE) syringe filter (organic solvent resistant, 0.22µm pore 
size; Tisch Scientific, USA) to remove any residual fiber before injecting into HPLC 
for AZI concentration determination. The details of validated HPLC analysis is 
reported in Section 6.3.1.1 in Chapter 6. 
 
5.3 Results 
5.3.1 One-component System (Spray-dried Pure Drug) 
Aerosol dispersion performance results of spray-dried (SD) pure TOB[43] and 
AZI[43] aerosols on each stage of the NGI from the HandiHaler® under Q of 60 
L/min is shown in Figure 5.3a and 5.3b, respectively. As indicated in Figure 5.3, the 
particle deposition profiles of SD pure TOB and SD pure AZI powders differed 
markedly.  
 
5.3.1.1 SD Pure TOB 
SD pure TOB aerosols exhibited predominant particle deposition on stage 1 
(aerodynamic cutoff diameter of 8.06µm) and low particle deposition on later stages 
(2-7; aerodynamic cutoff diameter < 5µm)[43]. A majority of fine particle mass was 
observed on stage 4 (aerodynamic cutoff diameter of 1.66µm) and stage 5 
(aerodynamic cutoff diameter of 0.94µm). The deposition mode of fine particle dose 
(FPD) was on stage 5. As indicated in Table 5.2[43], the SD pure TOB aerosols 
showed 96.2%, 28.5%, and 43.7% for ED, FPF, and RF, respectively. The values of 
MMAD and GSD were 5.0µm and 3.3, respectively. Therefore, it may be concluded 
that SD pure TOB aerosols possessed an ability to penetrate into deep lung regions 
(MMAD ≤ 5µm)[64].  
 
5.3.1.2 SD Pure AZI 
In contrast to SD pure TOB aerosols, SD pure AZI aerosols showed a relatively lower 
deposition on stage 1, and higher depositions on later stages (2-7)[43]. Similarly, SD 
pure AZI aerosolized particles exhibited a majority of fine particle mass on stage 4 
and stage 5. The deposition mode of fine particle dose (FPD) was on stage 5. The 
detailed aerosol dispersion performance parameters are listed in Table 5.2[43]. The 
SD pure AZI aerosols exhibited 90.3%, 47.0%, and 68.1% for ED, FPF, and RF, 
respectively. With MMAD and GSD being 2.3µm and 2.3, respectively, it suggests 
that SD pure AZI particles were suitable for deep lung delivery (MMAD ≤ 5µm)[64]. 
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(a) 
 
(b) 
Figure 5.3. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for: (a) SD pure tobramycin powder; 
and (b) SD pure azithromycin powder (mean ± SD, n=3)[43].  
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Table 5.2. Aerosol dispersion performance parameters of SD pure tobramycin and SD 
pure azithromycin dry powders[43] (mean ± margin of error for 95% confidence, 
n=3). 
 
SD Pure Drug Aerosol Dispersion Performance Parameters 
 ED[%] FPF[%] RF[%] MMAD[µm] GSD 
TOB 96.2±0.6 28.5±3.8 43.7±4.8 5.0±1.2 3.3±0.6 
AZI 90.3±6.7 47.0±3.7 68.1±5.4 2.3±0.4 2.3±0.2 
 
5.3.2 Two-component System (Spray-dried Drug:Mannitol and 
Drug:Phospholipids) 
5.3.2.1 Spray-dried Drug:Mannitol 
Particle deposition profiles for SD TOB:MAN[143] and AZI:MAN[143] are shown in 
Figure 5.4a and 5.4b, respectively. The particle deposition of corresponding SD pure 
drug is plotted in each figure. SD TOB:MAN and SD AZI:MAN exhibited similar 
deposition patterns to the corresponding SD pure drug. 
 
5.3.2.1.1 SD TOB:MAN 
SD TOB:MAN aerosols showed a relatively higher particle deposition percentage on 
stage 1 with an average of approximately 60%, compared to particle depositions on 
later stages (2-7)[143]. The deposition modes of FPD for SD TOB:MAN aerosol 
powders were on stage 5. As indicated in Table 5.3[143], SD TOB:MAN aerosol 
powders exhibited 90.7% or higher, 15.4% or higher, and 34.2% or higher for ED, 
FPF, and RF, respectively. The MMAD and GSD values ranged from 4.6 to 7.0µm, 
and 3.2 to 3.8, respectively. Therefore, the data indicate that only TOB:MAN=1:0.1, 
with a MMAD value less than 5µm, could be able to penetrate into deep lung 
regions[64]. 
 
5.3.2.1.2 SD AZI:MAN 
Aerosol dispersion performance of SD AZI:MAN exhibited a relatively lower particle 
deposition on stage 1 with approximately 37%, compared to SD TOB:MAN 
aerosols[143]. The majority of mass of FPD were on stage 4 and 5. The deposition 
modes of FPD for SD AZI:MAN aerosol powders were on stage 5. Shown in Table 
5.4[143], ED, FPF, and RF of SD AZI:MAN were 88.1% or higher, 38.3% or higher, 
and 60.1% or higher, respectively. In addition, the aerosols showed MMAD and GSD 
values ranging from 2.0 to 2.7µm, and 2.1 to 2.5, respectively. These data suggest that 
AZI:MAN aerosol powders were suitable for deep lung penetration[64]. 
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(a) 
 
(b) 
Figure 5.4. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for: (a) tobramycin:mannitol powders; 
and (b) azithromycin:mannitol powders (mean ± SD, n=3)[143]. 
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Table 5.3. Aerosol dispersion performance parameters of SD tobramycin:mannitol 
particles[143] (mean ± margin of error for 95% confidence, n=3). 
 
System Molar Ratio 
Aerosol Dispersion Performance Parameters 
ED[%] FPF[%] RF[%] MMAD[µm] GSD 
 1:0.1 96.9±0.4 28.7±1.8 46.8±4.9 4.6±1.0 3.2±0.5 
TOB:MAN 1:0.5 90.7±7.5 25.0±3.6 39.6±7.4 6.1±1.8 3.8±0.2 
 1:1 98.7±0.7 15.4±2.9 34.2±1.5 7.0±0.5 3.7±0.2 
 
Table 5.4. Aerosol dispersion performance parameters of SD azithromycin:mannitol 
particles[143] (mean ± margin of error for 95% confidence, n=3). 
 
System Molar Ratio 
Aerosol Dispersion Performance Parameters 
ED[%] FPF[%] RF[%] MMAD[µm] GSD 
 1:0.1 92.0±3.2 38.3±0.8 60.1±1.6 2.7±0.2 2.5±0.1 
AZI:MAN 1:0.5 88.1±1.5 46.4±1.1 72.7±0.8 2.0±0.1 2.1±0.1 
 1:1 91.9±1.5 43.3±2.3 64.3±5.3 2.5±0.5 2.4±0.3 
 
5.3.2.2 Spray-dried Drug:Phospholipids 
Particle deposition profiles for SD TOB:PLS and AZI:PLS aerosols are shown in 
Figure 5.5a and 5.5b, respectively. In addition, the particle deposition of 
corresponding SD pure drug is plotted in each figure.  
5.3.2.2.1 SD TOB:PLS 
As shown in Figure 5.5a, the aerosol particle deposition profiles of TOB:PLS were 
greatly improved as compared to SD pure TOB. Upon incorporation of phospholipids, 
the powders exhibited a sharply lowered deposition on stage 1 (from approximately 
55% to 17%), and, therefore, enhanced depositions on later stages (2-7). The 
deposition modes of FPD were on stage 5 for TOB:PLS aerosols. Shown in Table 5.5, 
TOB:PLS aerosols showed 87.4% or higher, 41.7% or higher, and 73.3% or higher for 
ED, FPF, and RF, respectively. The MMAD for TOB:PLS aerosols ranged from 1.7 
to 2.0µm. The GSD remained constant at 1.9. Therefore, TOB:PLS particles were 
possibly suitable to be delivered to deep lung regions[64].  
 
5.3.2.2.2 SD AZI:PLS 
AZI:PLS aerosols appeared to have relatively similar deposition on stage 1 compared 
to SD pure AZI. Deposition modes of FPD of AZI:PLS were dependent on the 
composition of formulations. As phospholipids molar ratio increased from 1:0.5, to 
1:1, and to 1:2, the deposition mode of FPD shifted from stage 5, to stage 3, and to 
stage 2. As to AZI:PLS aerosols in Table 5.6, the values of ED, FPF, and RF were 
95.1% or higher, 27.1% or higher, and 62.4% or higher, respectively. As suggested by 
particle deposition patterns, the MMAD varied with the composition of AZI:PLS. The 
MMAD values of the aerosols shifted from 2.2µm, to 4.7µm, and to 6.7µm as the 
molar ratio changed from 1:0.5, to 1:1, and to 1:2, respectively. The GSD values were 
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from 2.1 to 2.5. The data suggest that AZI:PLS=1:0.5 and 1:1 aerosol powders would 
be expected to reach the deep lung regions[64].  
 
 
(a)    
 
(b) 
Figure 5.5. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for: (a) tobramycin:phospholipids 
powders; and (b) azithromycin:phospholipids powders (mean ± SD, n=3). 
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Table 5.5. Aerosol dispersion performance parameters of SD 
tobramycin:phospholipids particles (mean ± margin of error for 95% confidence, 
n=3). 
System Molar Ratio 
Aerosol Dispersion Performance Parameters 
ED[%] FPF[%] RF[%] MMAD[µm] GSD 
 1:0.5 86.9±1.1 47.4±3.8 82.5±7.3 1.7±0.1 1.9±0.1 
TOB:PLS 1:1 87.4±2.0 61.9±6.3 91.9±2.3 1.9±0.1 1.9±0.1 
 1:2 95.9±0.8 41.7±2.8 73.3±1.9 2.0±0.1 1.9±0.1 
 
Table 5.6. Aerosol dispersion performance parameters of SD 
azithromycin:phospholipids particles (mean ± margin of error for 95% confidence, 
n=3). 
System Molar Ratio 
Aerosol Dispersion Performance Parameters 
ED[%] FPF[%] RF[%] MMAD[µm] GSD 
 1:0.5 95.1±1.2 37.4±4.0 72.4±9.3 2.2±0.3 2.1±0.3 
AZI:PLS 1:1 97.8±0.8 36.4±1.8 62.6±3.8 4.7±0.3 2.2±0.1 
 1:2 95.1±1.5 27.1±1.8 62.4±3.6 6.7±0.5 2.5±0.2 
 
5.3.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol) 
Particle deposition profiles for SD TOB:PLS:MAN and SD AZI:PLS:MAN aerosols 
are shown in Figure 5.6a and 5.6b, respectively. The particle deposition of 
corresponding SD formulation of drug with phospholipids is plotted in each figure.  
5.3.3.1 SD TOB:PLS:MAN 
The addition of mannitol to TOB:PLS increased particle deposition on stage 1 from 
~17% to 34%. The deposition modes of FPD of TOB:PLS:MAN aerosols were on 
either stage 4 or 5. Shown in Table 5.7, ED, FPF, and RF values for TOB:PLS:MAN 
were 91.7% or higher, 38.1% or higher, and 60.6% or higher, respectively. The 
MMAD and GSD of the aerosols ranged from 2.2 to 2.7µm, and 2.0 to 2.2, 
respectively. All TOB:PLS:MAN aerosol powders were suitable for penetration into 
the deep lungs[64]. 
 
5.3.3.2 SD AZI:PLS:MAN 
The effect of mannitol incorporation to AZI:PLS was more complicated. The powders 
of AZI:PLS:MAN=1:0.5:0.1 and 1:0.5:0.5 exhibited an increased deposition on stage 
1 with an average ~45%, as compared to ~28% from two-component formulation of 
AZI:PLS=1:0.5. Interestingly, further increase of mannitol content to 1:0.5:1 in molar 
ratio of AZI:PLS:MAN highly lowered particle deposition to ~4% on stage 1. The 
deposition modes of FPD were on stage 4. The values of ED, FPF, and RF for 
AZI:PLS:MAN were 94.3% or higher, 32.6% or higher, and 48.6% or higher, 
respectively, as shown in Table 5.8. The MMAD and GSD values of AZI:PLS:MAN 
aerosols were from 2.4 to 4.9µm, and 1.8 to 2.7, respectively. It is noticeable that 
AZI:PLS:MAN=1:0.5:1 showed superior aerosol performance, in terms of FPF, RF, 
MMAD, and GSD, compared to the other two aerosol powder systems 
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(AZI:PLS:MAN=1:0.5:0.1 and AZI:PLS:MAN=1:0.5:0.5). The data suggest that 
AZI:PLS:MAN aerosolized powders are suitable to be delivered into deep lung 
regions[64]. 
 
(a) 
 
(b) 
Figure 5.6. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for: (a) 
tobramycin:phospholipids:mannitol powders; and (b) 
azithromycin:phospholipids:mannitol powders (mean ± SD, n=3). 
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Table 5.7. Aerosol dispersion performance parameters of SD 
tobramycin:phospholipids:mannitol particles (mean ± margin of error for 95% 
confidence, n=3). 
System Molar Ratio 
Aerosol Dispersion Performance Parameters 
ED 
[%] 
FPF 
[%] 
RF 
[%] 
MMAD 
[µm] GSD 
 1:0.5:0.1 91.7±1.0 44.1±5.2 70.3±5.5 2.2±0.2 2.0±0.2 
TOB:PLS:MAN 1:0.5:0.5 93.0±1.0 42.7±4.3 66.8±7.3 2.6±0.4 2.1±0.2 
 1:0.5:1 93.1±3.5 38.1±1.0 60.6±3.3 2.7±0.2 2.2±0.1 
 
Table 5.8. Aerosol dispersion performance parameters of SD 
azithromycin:phospholipids:mannitol particles (mean ± margin of error for 95% 
confidence, n=3). 
System Molar Ratio 
Aerosol Dispersion Performance Parameters 
ED 
[%] 
FPF 
[%] 
RF 
[%] 
MMAD 
[µm] GSD 
 1:0.5:0.1 96.4±0.7 36.8±2.4 60.8±2.5 3.2±0.3 2.3±0.1 
AZI:PLS:MAN 1:0.5:0.5 96.7±0.2 32.6±0.7 48.6±2.0 4.9±0.3 2.7±0.1 
 1:0.5:1 94.3±1.0 60.4±2.3 96.1±0.6 2.4±0.1 1.8±0.0 
 
5.3.4 Validation of Gravimetric Analysis Method 
An assumption made in the aerosol dispersion performance is that the mass 
distribution of deposited particles on the NGI stages is equal to chemical distribution. 
To validate this assumption for AZI, AZI:PLS=1:0.5 was selected as a representative 
sample. As a first step, a chemical analysis method must be validated. Two different 
treatments (a and b), detailed in Section 5.2.2.2, were conducted to determine the 
number of washing necessary to collect all AZI from the glass filter. As shown in 
Table 5.9, the total drug recoveries from the two glass filter washing treatments (a and 
b) were not statistically different from the control sample with values of 100.3% and 
102.6%, respectively. This method validation indicated that there was no significant 
adsorbance of AZI on glass filter after one washing. Therefore, the first treatment 
method (a) was used to determine AZI mass deposited on each stage of the NGI in 
chemical analysis. 
Table 5.9. The data for glass filter treatment experiment. 
 Standard Solution 
First Treatment  
(a) 
Second Treatment  
(b) 
Concentration 
(µg/mL) 1017.9 1021.0 401.5 
Total Drug Recovery 
(%) 100.0 100.3 102.6 
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The AZI:PLS=1:0.5 powder was selected to conduct aerosol dispersion performance. 
By employing the glass filters, the mass of powder on each stage was determined by 
gravimetric method. Thereafter, the glass filter with captured particles on each stage 
was soaked in methanol with 10mL for stage 1 and 5mL for each of later stages (2-7). 
Sonication was applied to make sure all the particles were completely dissolved. After 
passing through PTFE syringe filter, the solution was injected into HPLC for 
concentration determination. The aerosolization experiment was conducted in 
triplicate. The data comparison between mass analysis and chemical analysis are 
presented in Figure 5.7. The results indicate that there was no significant difference in 
particle deposition on each NGI stage determined by the two analytical methods. 
Therefore, it was concluded that the gravimetric method was sufficient to assess the 
AZI component distribution on NGI stages for all studies. TOB formulations were not 
tested by this approach due to the lack of appropriate HPLC assay method. 
 
 
Figure 5.7. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for azithromycin:phospholipids=1:0.5. 
The particle deposition was determined by both weight and chemical analysis (mean ± 
SD, n=3). 
 
5.4 Discussion 
It is well known that aerodynamic diameters below 5µm are considered as the cutoff 
for particles capable of penetrating into deep lung regions[184]. The respiratory 
aerosol formulation with ability of deep lung (including respirable bronchiolar and 
alveolar regions) penetration is crucial for the treatment of lung diseases such as 
pneumonia[185], chronic lung infection with cystic fibrosis (CF)[134-136] or non-CF 
bronchiectasis[186, 187]. Therefore, we defined the sum of particles deposited on 
stage 2 and later of the NGI (cutoff aerodynamic diameter of < 4.51µm) as the fine 
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particle dose.  
Formulation composition may have critical impact on the efficiency of aerosol 
dispersion performance of the powder. Adler et al[188] reported that the surface 
composition for spray-dried multi-component powders (e.g. bovine serum albumin, 
trehalose, and surfactant (polysorbate 80)) was not identical to the overall formulation 
composition. Therefore, it can be argued that the interparticulate forces may be a 
function of surface composition[63]. More importantly, it is believed that particle 
aggregation is prevalent when components that exhibit high crystallization tendency 
or phase transitions are present on the surface. Obviously such a situation would 
potentially influence particle aerosol performance. Thus, the effect of composition on 
aerosol dispersion performance of the powder is discussed below.  
5.4.1 Effect of Mannitol on Spray-Dried Drug:Mannitol 
Compared to SD pure TOB, the aerosol dispersion performance of TOB:MAN were 
independent of mannitol at molar ratios of 1:0.1 and 1:0.5. For TOB:MAN=1:1, the 
FPF and RF decreased from 28.5% to 15.4%, and from 43.7% to 34.2%, respectively. 
On the other hand, ED and MMAD of TOB:MAN=1:1 increased, compared to SD 
pure TOB.  
With other aerosol dispersion parameters statistically unchanged, only FPF and RF of 
AZI:MAN=1:0.1 were lowered from 47.0% to 38.3%, and 68.1% to 60.1%, 
respectively, compared to SD pure AZI. In comparison to SD pure AZI, aerosol 
dispersion performance parameters of AZI:MAN=1:0.5 and 1:1 were statistically 
unchanged. 
In summary, based on the obtained aerosol dispersion performance parameters, spray 
drying drug with various amount of mannitol in drug:mannitol did not appear to 
improve the aerosol dispersion performance. Lactose is reported to exhibit surface 
enrichment supported by the formation of a hollow particle at relatively high inlet 
temperature[189-191]. It is reported[192] that due to the mannitol crystallization in 
spray-dried recombinant humanized anti-lgE monoclonal antibody 
(rhuMAbE25):mannitol upon storage, the particles exhibited a significant decrease in 
FPF. As shown in our previous study[44], mannitol has a high tendency to crystallize 
after spray drying under these conditions for SD pure mannitol powders. XRPD 
(Figure 4.2 in Chapter 4) and DSC (Figure 4.7-4.9 in Chapter 4) data did not reveal 
any evidence of crystalline mannitol in the SD drug:mannitol powders. However, it is 
possible that the small amount of mannitol, not detected by the techniques employed, 
on particle surface could be present in the crystalline phase for SD drug:mannitol 
powders. Even if the mannitol component was initially in the amorphous phase, the 
low glass transition temperature of mannitol (e.g., 7.4 oC determined from 
quench-cooled mannitol without additives in DSC at 5oC/min)[193] suggests a high 
risk of crystallization of mannitol during aerosol dispersion experiments. Therefore, it 
seems likely that the crystallization of mannitol on SD particles upon certain storage 
after production would possibly impede the deaggregation of particles due to the 
formation of bridging in the solid-state. It has been reported[73] that incorporation of 
mannitol lowered the aerosol dispersion (e.g., FPF) of spray-dried three-component 
spray-dried powder consisting of albumin, dipalmitoylphosphatidylcholine (DPPC), 
and a protein stabilizer (lactose, trehalose or mannitol) compared to other sugers (such 
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as lactose and trehalose). 
5.4.2 Effect of Phospholipids on Spray-Dried Drug:Phospholipids 
Incorporation of phospholipids in TOB:PLS improved markedly the aerosol 
dispersion performance of the powders compared to SD pure TOB. The FPF and RF 
of TOB:PLS formulations increased from 28.5% to 41.7% or higher, and from 43.7% 
to 73.3% or higher, respectively. In addition, MMAD and GSD decreased 
significantly from 5.0µm to 2.0µm or lower, and from 3.3 to 1.9, respectively. 
However, with TOB:PLS=1:2 unchanged, the ED of TOB:PLS=1:0.5 and 1:1 
decreased. 
In contrast to TOB formulations, incorporation of phospholipids did not significantly 
change the ED, RF, and GSD of AZI:PLS aerosols, while FPF decreased from 47.0% 
to 37.4% or lower. With the exception of AZI:PLS=1:0.5, MMAD increased 
significantly from 2.3µm to 4.7µm or higher for the other compositions. 
In summary, incorporation of phospholipids into formulations exhibited remarkably 
different effects on the aerosol dispersion performance of TOB:PLS and AZI:PLS. At 
present, it is not clear why TOB:PLS and AZI:PLS particles performed differently. 
The interfacial properties of antimicrobial compounds have been extensively 
explored[194-200]. Therefore, tobramycin may possibly compete with surface-active 
phospholipids for the air/methanol interface on droplets during spray drying. 
Moreover, tobramycin has a smaller molecular weight compared to phospholipids 
(e.g., tobramycin: 467g/mol vs DPPC: 734g/mol and DPPG: 745g/mol). This may 
suggest that tobramycin possibly had a faster molecular diffusion. Therefore, it could 
be reasonably suggested that significant amount of tobramycin is present on the 
surface of particles.  
Azithromycin may also possess interfacial activity. The molecular weight of 
azithromycin is approximately equal to that of the phospholipids (e.g. azithromycin: 
749g/mol vs DPPC: 734g/mol and DPPG: 745g/mol). Moreover, the hydrophobic 
nature of azithromycin would possibly indicate azithromycin may interact through 
favorable hydrophobic interactions with the hydrophobic chains on the phospholipids 
molecule. The interaction of azithromycin and phospholipids have been reported in 
the literature[174] suggesting that these two different molecules could co-localize on 
particle surface. However, during spray drying, phospholipids would possibly 
undergo main phase transition from gel phase to liquid crystalline phase as the 
temperature (such as outlet temperature of spray drying (To)) (Table 3.2 in Chapter 3) 
was higher than main phase transition temperature of phospholipid bilayer (Tm) 
(Table 4.3 in Chapter 4). After phase transition, sticky phospholipids (due to 
increased molecular mobility) on particle surface would possibly facilitate the 
irreversible formation of particle aggregation. This lowered the aerosol dispersion 
performance of AZI:PLS compared to SD pure AZI, while the FPF values of 
AZI:PLS were still regarded as high. 
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5.4.3 Effect of Mannitol on Spray-Dried Drug:Phospholipids:Mannitol 
When compared with TOB:PLS formulations, aerosol dispersion performance of 
TOB:PLS:MAN decreased with increasing amount of manntiol. For 
TOB:PLS:MAN=1:0.5:0.1, MMAD increased significantly from 1.7µm to 2.2µm. For 
TOB:PLS:MAN=1:0.5:0.5, RF decreased significantly from 82.5% to 66.8% and 
MMAD increased significantly from 1.7µm to 2.6µm. As for 
TOB:PLS:MAN=1:0.5:1, the FPF and RF were significantly lowered from 47.4% to 
38.1%, and from 82.5% to 60.6%, respectively. Moreover, MMAD and GSD 
increased significantly from 1.7µm to 2.7µm, and from 1.9 to 2.2, respectively. With 
incorporation of mannitol in TOB:PLS:MAN, ED overall increased from 86.9% to 
91.7% or higher. 
The mannitol effect on aerosol dispersion performance for AZI:PLS:MAN differed 
with compositions. Based on aerosol dispersion performance parameters, 
AZI:PLS:MAN=1:0.5:0.1 and 1:0.5:0.5 did not improve aerosol dispersion 
performance compared to AZI:PLS=1:0.5. As for AZI:PLS:MAN=1:0.5:0.1, only 
MMAD was affected, increasing significantly from 2.2µm to 3.2µm. In addition, FPF 
and RF of AZI:PLS:MAN=1:0.5:0.5 decreased significantly from 37.4% to 32.6%, 
and from 72.4% to 48.6%, respectively. Moreover, the GSD increased significantly 
from 2.1 to 2.7. However, in AZI:PLS:MAN=1:0.5:1, sharply elevated FPF and RF 
from 27.1% to 60.4%, and 62.4% to 96.1%, respectively, were observed. With 
AZI:PLS:MAN=1:0.5:0.1 and 1:0.5:1 unchanged, the ED of 
AZI:PLS:MAN=1:0.5:0.5 increased. 
In summary, addition of mannitol did not appear to improve the aerosol dispersion 
performance of TOB:PLS:MAN. However, the effect of incorporation of mannitol on 
the aerosol dispersion performance of AZI:PLS:MAN is composition dependent. As 
discussed in Section 5.4.2.1, mannitol may possibly play a same role in 
three-component systems such as all TOB:PLS:MAN formulations, 
AZI:PLS:MAN=1:0.5:0.1, and AZI:PLS:MAN=1:0.5:0.5. Other mechanism(s) (such 
as particle density change[201], surface energetics change[202], and etc.) may have 
contributed to the sharp increase in aerosol dispersion performance of 
AZI:PLS:MAN=1:0.5:1.  
 
5.5 Conclusions 
The aerosol dispersion performance of spray-dried particle was studied employing the 
next generation impactor (NGI) with the HandiHaler® at adult air flow rate (60 
L/min). It was demonstrated that the validated gravimetric method was sufficient to 
assess the azithromycin component distribution on the NGI stages. In almost all cases, 
spray-dried inhalable multi-component particles exhibited mass median aerodynamic 
diameter (MMAD) less than 5µm suitable for deep lung deposition. In general, based 
on the obtained aerosol dispersion performance parameters, addition of mannitol did 
not improve aerosol dispersion performance of spray-dried particles except for 
AZI:PLS:MAN=1:0.5:1. The effect of addition of phospholipids was mainly 
dependent upon the drug properties. 
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Chapter 6 Storage Stability 
 
6.1 Introduction 
Stability in pharmaceutics is defined as the ability of a drug substance or a 
pharmaceutical product to resist specific physical, chemical, and biopharmaceutical 
alterations during the product shelf-life. Therefore it is essentially important to 
consider formulation stability during early drug formulation development. The 
chemical and physical stability of the dry powder formulation could be affected by 
moisture content and hygroscopicity of the formulation[64, 155, 156], chemistry of 
the excipient and carrier particles[64, 203-205], interparticulate forces within the 
formulation[64, 206], particle size (including size distribution) and surface 
morphology[64, 207, 208]. Moreover, the storage conditions, such as relative 
humidity (RH) and temperature, could often affect the physical and chemical stability 
of a dry powder formulation, leading an unsuccessful delivery to the lungs of patients. 
There are three recommended storage test conditions[209] from Food and Drug 
Administration (FDA): 25 ± 2oC and 60 ± 5% RH (long-term conditions); 30 ± 2oC 
and 60 ± 5% RH (intermediate conditions); 40 ± 2oC and 70 ± 5% RH (accelerated 
conditions). In this storage stability study, we examine the effect of relative humidity 
on spray-dried (SD) particles at 40oC. Three different RH % represents low (11%), 
medium (40%), and high (75%) in practical storage conditions. By x-ray powder 
diffraction (XRPD) and thermal analysis such as differential scanning calorimetry 
(DSC), the storage stability of SD powders is studied during the storage. It would be 
expected that the component, lacking of long-range molecular order, in SD powders 
may possibly be subjected to phase transition(s) during storage. With the occurring of 
phase transition(s), the aerosol dispersion performance of SD powders could be highly 
impeded due to possible solid-state bridging. Therefore, after storage, the aerosol 
dispersion performance of SD powders is examined by using the next generation 
impact (NGI).  
  
6.2 Materials and Methods 
6.2.1 Materials 
The fresh spray-dried (SD) tobramycin (TOB) formulations (including pure TOB, 
tobramycin:mannitol (TOB:MAN)=1:0.5, tobramycin:phospholipids 
(TOB:PLS)=1:0.5, and tobramycin:phospholipids:mannitol 
(TOB:PLS:MAN)=1:0.5:0.5) and azithromycin (AZI) formulations (including pure 
AZI, azithromycin:mannitol (AZI:MAN)=1:0.5, azithromycin:phospholipids 
(AZI:PLS)=1:0.5, and azithromycin:phospholipids:mannitol 
(AZI:PLS:MAN)=1:0.5:0.5) were selected for storage stability test. All the studied 
particles were generated employing a 50% pump rate during spray drying. Lithium 
chloride (ACS, 99% min) and potassium carbonate (ACS, 99% min) were purchased 
from Alfa Aesar (Massachusetts, USA). Sodium chloride (≥ 99.5%) was received 
from Fisher Scientific (USA). Incubator (Napco, Model 320) (USA) was used as 
temperature controller in sample storage. HP clear, size 3 capsule (Quali-V®) was 
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received from Qualicaps (Spain). Aluminum foil (624 heavy duty; food-service) was 
obtained from Reynolds® (made in China; packed in USA).  
 
6.2.2 Methods 
Each capsule was filled with ~10mg pre-weighed powder. A piece of uniformly cut 
aluminum foil (3 x 3cm) was used to wrap each capsule containing powder. Several 
filled capsules from the same formulation were stored in a pin-holed sandwich bag. 
Three sandwich bags containing the same formulation were placed in three glass 
desiccators with pre-equilibrated relative humidity (RH) by making saturated lithium 
chloride, potassium carbonate, or sodium chloride solutions in DI water. The three 
glass desiccators were stored in an incubator at 40 ± 1oC. At equilibrium, the RH of 
saturated solution lithium chloride, potassium carbonate, and sodium chloride were 
11%, 40%, and 75%, respectively, at 40oC.[210] In addition to differential scanning 
calorimetry (DSC) and thermal gravity analysis (TGA), the physicochemical 
properties of SD powders were examined by x-ray powder diffraction (XRPD) at 
pre-determined time points of 2 weeks, 1 month, 2 months, and 3 months of storage. 
The in vitro aerosol dispersion performance was conducted by using the next 
generation impactor (NGI) only after 3 months storage. The experimental conditions 
of XRPD, DSC and TGA are reported previously in Chapter 4. The experimental 
conditions of in vitro aerosol dispersion performance are described previously in 
Chapter 3. 
 
6.3 Results 
6.3.1 X-Ray Powder Diffraction (XRPD) 
Figure 6.1 to 6.4 shows the XRPD data of stored SD pure TOB, TOB:MAN=1:0.5, 
TOB:PLS=1:0.5, and TOB:PLS:MAN=1:0.5:0.5, respectively. The SD tobramycin 
particles stored at 11% RH and 40oC exhibited non-crystalline XRPD patterns (Figure 
6.1a to 6.4a, respectively) similar to that of the corresponding fresh samples. These 
results suggested there was no significant change in physical form of the component(s) 
in formulations upon storage. The appearance of crystalline peaks of TOB component 
from the SD tobramycin particles were observed when the particles were stored under 
conditions of either RH of 40% or 75% at 40oC. In addition, these particles also 
exhibited a color change, indicating a potential chemical stability issue. A 
representative picture of SD pure TOB (Figure 6.5) shows that the powder changed 
from colorless to yellow stored at conditions of 40% and 75% RH. It was also noticed 
that a small crystalline peak from beta form of mannitol emerged at ~ 23o of 2 Theta 
(Appendix I) from TOB:MAN=1:0.5 (Figure 6.2b-c) stored at RH of 40% and 75%. 
Supported by differential scanning calorimetry (DSC) data (endothermic peak at 69oC 
indicative of main phase transition of phospholipid bilayer in Figure 6.6a), the 
phospholipid bilayer structure showed a characteristic crystalline peak at range from 
20o to 23o of 2 Theta in XRPD in phospholipid containing TOB formulations (Figure 
6.3-6.4) under all studied storage conditions. 
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(a) 
 
(b) 
 
(c) 
Figure 6.1. XRPD patterns of SD pure tobramycin (offset by 500 counts between 
patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during storage. 
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(a) 
 
(b) 
 
(c) 
Figure 6.2. XRPD patterns of SD tobramycin:mannitol=1:0.5 (offset by 500 counts 
between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during 
storage. 
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(a) 
 
(b) 
 
(c) 
Figure 6.3. XRPD patterns of SD tobramycin:phospholipids=1:0.5 (offset by 500 
counts between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during 
storage. 
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(a) 
 
(b) 
 
(c) 
Figure 6.4. XRPD patterns of SD tobramycin:phospholipids:mannitol=1:0.5:0.5 
(offset by 500 counts between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) 
at 40oC during storage. 
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Figure 6.5. Photograph of capsules of SD pure tobramycin stored at three different 
RH % and 40oC for 2 weeks. 
 
 
(a) 
 
(b) 
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(c) 
Figure 6.6. DSC thermograms of main phase transition of 
tobramycin:phospholipids=1:0.5 (a) and azithromycin:phospholipids=1:0.5 (b) after 3 
months storage at 11% RH and 40oC; DSC thermogram of SD pure tobramycin (c) 
after 3 months storage at 75% RH and 40oC. 
 
As no new XRPD peaks, compared to freshly-prepared material, were observed, SD 
pure AZI and AZI:MAN=1:0.5 were physically stable in solid phase under the storage 
conditions as shown in Figure 6.7 and 6.8, respectively. Supported by DSC data (two 
possibly separated peaks, at 60oC and 68oC, of main phase transition of phospholipid 
bilayer in Figure 6.6b), AZI:PLS=1:0.5 (Figure 6.9) and AZI:PLS:MAN=1:0.5:0.5 
(Figure 6.10) maintained the phospholipid bilayer structure with the presence of a 
characteristic crystalline peak at range from 20o to 23o of 2 Theta in XRPD under all 
the studied conditions. However, the AZI component in these two formulations 
started to crystallize into its dihydrate crystalline form (with the appearance of 
characteristic peaks at 7.4o, 9.4o and 9.5o of 2 Theta; Figure 4.1b in Chapter 4) after 1 
month storage at conditions of 75% RH and 40oC in temperature (Figure 6.9c and 
Figure 6.10c, respectively). The crystalline peaks from mannitol were not observed in 
all SD AZI formulations. In addition, there was no observed color change in SD AZI 
particles. 
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(a) 
 
(b) 
 
(c) 
Figure 6.7. XRPD patterns of SD pure azithromycin (offset by 500 counts between 
patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during storage. 
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(a) 
 
(b) 
 
(c) 
Figure 6.8. XRPD patterns of SD azithromycin:mannitol=1:0.5 (offset by 500 counts 
between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during 
storage. 
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(a) 
 
(b) 
 
(c) 
Figure 6.9. XRPD patterns of SD azithromycin:phospholipids=1:0.5 (offset by 500 
counts between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during 
storage. 
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(a) 
 
(b) 
 
(c) 
Figure 6.10. XRPD patterns of SD azithromycin:phospholipids:mannitol=1:0.5:0.5 
(offset by 500 counts between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) 
at 40oC during storage. 
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6.3.2 Aerosol Dispersion Performance 
On this Section, the aerosol performances of stored formulations were examined. 
Aerosol dispersion performance parameters have been described in Section of 5.2.2.1 
in Chapter 5. The SD tobramycin particles stored at 40% and 75% RH formed 
aggregates through particle crystallization with a color change precluding their use in 
aerosol pulmonary delivery. Therefore, only the particles stored at 11% RH and 40oC 
were used to conduct aerosol dispersion performance. Studies were carryout 
employing the next generation impactor (NGI) with the Handihaler® after 3 months of 
storage. The aerosol particle deposition of SD tobramycin particles on each stage in 
the NGI is depicted for both fresh formulations (Figure 6.11a) and stored formulations 
(Figure 6.11b). Fresh particles deposited less than stored particles on stage 1. In 
addition, it was observed that fine particle deposition mode was on stage 4 or 5 for 
fresh particles. However, the fine particle deposition mode was not evident for stored 
particles. The stored particles had a relatively even deposition on stages 2-7 with 
approximately less than 10% particle deposited on each stage.  
The aerosol dispersion performance parameters of the tobramycin formulations are 
summarized in Table 6.1. The aerosol dispersion performance parameters (i.e. FPF 
and RF) of the stored SD tobramycin formulations were significantly lowered, 
resulting in higher values of MMAD (>5µm) compared to their corresponding 
freshly-prepared powder. However, only stored TOB:PLS=1:0.5 and 
TOB:PLS:MAN=1:0.5:0.5 resulted in higher GSD values compared to the fresh 
powder. The GSD values were not significantly different for fresh and stored SD pure 
TOB and TOB:MAN=1:0.5. Overall, the fresh and stored SD tobramycin powders 
resulted in similar ED values. 
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(a) 
 
(b) 
Figure 6.11. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for: (a) fresh SD tobramycin powders; 
and (b) stored SD tobramycin powders at 11% RH and 40oC (mean ± SD, n=3). 
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The NGI aerosol particle deposition results of SD pure AZI, AZI:MAN=1:0.5, 
AZI:PLS=1:0.5, and AZI:PLS:MAN=1:0.5:0.5 are shown in Figures 6.12, 6.13, 6.14, 
and 6.15, respectively. The fresh particles deposited less on stage 1 than stored 
particles except for the formulation of AZI:PLS:MAN=1:0.5:0.5. For AZI (Figure 
6.12) and AZI:MAN=1:0.5 (Figure 6.13), the fine particle deposition was lowered 
after storage, especially on stage 4-7. On the other hand, for stored AZI:PLS=1:0.5 
(Figure 6.14), the fine particle deposition mode shifted from stage 5 to stage 4 or 2, 
indicating a growth in particle size. However, AZI:PLS:MAN=1:0.5:0.5 particles 
from storage conditions of 11% and 40% RH exhibited a fine deposition mode on 
stage 4 (Figure 6.15). In contrast, AZI:PLS:MAN=1:0.5:0.5 particles from storage 
conditions of RH 75% shifted fine particle deposition mode from stage 4 to stage 3.  
Listed in Table 6.2 are the aerosol performance parameters of the AZI formulations. 
SD pure AZI and AZI:MAN=1:0.5 aerosols exhibited a decrease in FPF and RF 
values with storage RH % increased. MMAD and GSD values increased as storage 
RH % increased. However, all MMAD values remained about ≤5µm after storage. 
Overall, AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 exhibited a lowered aerosol 
dispersion performance with increased storage RH %. At RH of 11% and 40%, the 
MMAD values increased (but remained about ≤5µm) compared to the values from 
fresh samples. The MMAD values dramatically increased (>5µm) when 
AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 were stored at 75% RH and 40oC. In 
general, there was no observed trend for FPF and RF values when comparing fresh 
and stored samples under the conditions of 11% and 40% RH.  
 
 
Figure 6.12. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for fresh and stored SD pure 
azithromycin at three different RH % and 40oC (mean ± SD, n=3). 
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Figure 6.13. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for fresh and stored SD 
azithromycin:mannitol=1:0.5 at three different RH % and 40oC (mean ± SD, n=3). 
 
 
 
Figure 6.14. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for fresh and stored SD 
azithromycin:phospholipids=1:0.5 at three different RH % and 40oC (mean ± SD, 
n=3). 
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Figure 6.15. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for fresh and stored SD 
azithromycin:phospholipids:mannitol=1:0.5:0.5 at three different RH % and 40oC 
(mean ± SD, n=3). 
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Table 6.1. Aerosol dispersion performance parameters of SD tobramycin powders (fresh vs stored at 11% RH and 40oC) (mean ± SD, n=3). 
Definition: ED[%]=emitted dose fraction; FPF[%]=fine particle fraction; RF[%]=respirable fraction; MMAD[µm]=mass median aerodynamic 
diameter; GSD=geometric standard deviation. 
 
System 
(Molar Ratio) Treatment 
Aerosol Dispersion Performance Parameters 
ED[%] FPF[%] RF[%] MMAD[µm] GSD 
Pure TOB 
fresh 96.2±0.5 28.5±3.4 43.7±4.2 5.0±1.1 3.3±0.5 
stored @11% RH 93.6±2.1 20.3±3.5 30.3±4.3 10.6±2.8 3.6±0.4 
TOB:MAN 
(1:0.5) 
fresh 90.7±6.7 25.0±3.2 39.6±6.5 6.1±1.6 3.8±0.2 
stored @11% RH 94.7±3.1 17.7±5.0 26.0±6.2 14.9±5.3 3.7±0.0 
TOB:PLS 
(1:0.5) 
fresh 86.9±1.0 47.4±3.4 82.5±6.5 1.7±0.1 1.9±0.1 
stored @11% RH 91.3±1.9 28.0±0.7 37.8±2.0 6.6±1.0 3.3±0.3 
TOB:PLS:MAN 
(1:0.5:0.5) 
fresh 93.0±0.9 42.7±3.8 66.8±6.4 2.6±0.3 2.1±0.2 
stored @11% RH 95.2±2.9 11.5±5.1 17.3±7.5 28.4±15.1 4.0±0.2 
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Table 6.2. Aerosol dispersion performance parameters of SD azithromycin powders (fresh vs stored at three different RH % and 40oC) (mean ± 
SD, n=3). Definition: ED[%]=emitted dose fraction; FPF[%]=fine particle fraction; RF[%]=respirable fraction; MMAD[µm]=mass median 
aerodynamic diameter; GSD=geometric standard deviation. 
 
System 
(Molar Ratio) Treatment 
Aerosol Dispersion Performance Parameters 
ED[%] FPF[%] RF[%] MMAD[µm] GSD 
Pure AZI 
fresh 90.3±5.9 47.0±3.3 68.1±4.8 2.3±0.3 2.3±0.2 
stored @11% RH 93.7±1.1 30.3±1.6 46.1±3.7 4.0±0.7 3.0±0.3 
stored @40% RH 95.1±2.4 29.7±2.6 44.5±3.4 4.6±0.5 3.2±0.1 
stored @75% RH 94.9±1.4 27.4±1.2 41.4±1.9 5.1±0.5 3.2±0.1 
AZI:MAN 
(1:0.5) 
fresh 88.1±1.3 46.4±1.0 72.7±0.7 2.0±0.1 2.1±0.1 
stored @11% RH 92.2±2.4 34.9±4.3 51.3±3.1 3.3±0.2 2.6±0.2 
stored @40% RH 87.9±1.4 32.6±4.0 46.7±4.3 4.4±0.8 2.9±0.4 
stored @75% RH 92.5±2.3 29.2±2.2 41.9±5.5 5.2±1.5 2.9±0.4 
AZI:PLS 
(1:0.5) 
fresh 95.1±1.0 37.4±3.5 72.4±8.2 2.2±0.3 2.1±0.2 
stored @11% RH 89.7±2.1 38.8±1.6 57.0±1.9 4.4±0.3 2.6±0.1 
stored @40% RH 89.2±1.9 35.4±1.8 52.5±2.2 5.3±0.3 2.8±0.0 
stored @75% RH 95.3±1.1 19.2±2.4 29.9±2.2 14.7±2.2 3.5±0.7 
AZI:PLS:MAN 
(1:0.5:0.5) 
fresh 96.7±0.2 32.6±0.6 48.6±1.8 4.9±0.3 2.7±0.1 
stored @11% RH 95.0±2.9 36.7±4.3 65.3±3.7 3.5±0.3 2.0±0.1 
stored @40% RH 94.5±1.3 31.1±3.6 53.2±1.8 4.3±0.1 2.2±0.1 
stored @75% RH 100.1±1.3 14.3±1.4 25.0±2.7 14.6±2.3 3.0±0.3 
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6.4 Discussion 
 
Moisture may have a significant impact on the physical and chemical stability of 
aerosol particles, particular for small particles due to their high surface area to volume 
ratio and the presence of large interstitial space[41]. Moisture may cause irreversible 
particle agglomeration, leading to failure to generate aerosol particles in respirable 
size[45]. Individual particles may also undergo changes in crystallinity and 
polymorphism[41]. Chemical instability could be a potential issue when particle 
component is hygroscopic[155, 156]. 
Spray-dried sugar excipients (trehalose and raffinose)[211] and spray-dried sodium 
cromoglicate[212] aerosol particles have been studied for physical stability under 
various conditions. The particles were placed in open jars stored in glass chambers, 
maintained either at 60% RH at 25oC or contained silica gel at 25oC and 4oC. At 
different time intervals, samples were assessed by SEM, XRPD, DSC and 
aerosolization. The spray-dried particles, stored at silica gel/25oC or 4oC, exhibited no 
significant change in particle morphology, physical phase (amorphous), and 
aerosolization. However, stored at 60% RH/25oC, the spray-dried particles collapsed 
with a disappearance of porous particle structure, leading to a decrease in the aerosol 
performance. Singh et al.[213] studied room temperature (60% RH & 25oC for 12 
months) and accelerated (75% RH & 40oC for 6 months) stability tests of terbutaline 
sulfate-loaded chitosan microspheres for pulmonary delivery. At specified time 
intervals, samples were evaluated for drug content, particle size, FPF. These stability 
tests were conducted with the powder directly exposed to studied RH %.  It was 
found that the fine particle fraction was slightly decreased at both storage conditions, 
due to an increase in moisture content and a subsequent increase in particle size after 
storage. In addition, no significant change in drug content was observed in this study. 
El-gendy et al.[214] reported on HPMC capsules preloaded with budesonide 
nano-cluster dry powder stored at conditions of shelf-life (60% RH & 25oC for 
12months) and accelerated (75% RH & 40oC for 6month) stability conditions. The 
results suggested that the chemical and physical stability were unchanged during 
storage. The MMAD and GSD values appeared to be constant. FPF of particles at 
accelerated conditions exhibited no significant change compared to fresh powder. 
Only a slight decrease in FPF was observed for particles stored at shelf-life storage 
conditions. Pilcer et al.[215] hand-filled spray-dried tobramycin powder into capsules 
sealed in aluminum/aluminum blisters. Using moisture-protective packaging, this test 
method was close to the compliance from FDA guideline on stability test of dry 
powder for inhalation. The stability study was conducted at 75% RH/40oC, 65% 
RH/30oC, and 60% RH/25oC. The data revealed that the spray-dried powders 
remained unchanged in physical phase, drug content, particle size distribution, and 
FPF. 
FDA recommends that stability tests should be performed on the drug product with 
the packaging configuration (i.e., primary, secondary or additional protective) 
intended for marketing under the appropriate test storage conditions[209]. As an 
alternative to packaging suitable for marketing, we employed aluminum foil as a 
moisture-protective wrapping. Three different RH % were chosen to represent low 
(11%), medium (40%), and high (75%) values to encompass a range of practical 
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storage conditions. In order to have at least one standard storage test conditions (75% 
RH & 40oC; accelerated storage conditions), the temperature of 40oC was chosen in 
this study. We used XRPD and the NGI to correlate the physical phase stability and 
aerosol dispersion performance of the particles during storage. 
Under the storage stability test conditions of 40% and 75% RH at 40oC, the SD 
tobramycin formulations partially crystallized into agglomerates (Figure 6.1-6.4) and 
underwent a color change (on surface layer of agglomerates) as shown in Figure 6.5 at 
times as short as 2 weeks. The XRPD data (Figure 6.1 to 6.4) indicate that the 
crystallized component was probably from tobramycin. The hygroscopic nature of 
tobramycin along with a high tendency to crystallize was also shown in GVS data 
(Figure 4.13-4.16 in Chapter 4). The color change of the particles strongly indicated 
that tobramycin chemically degraded. The chemical degradation pathway of 
tobramycin has been reported[216]. However, another possibility for color change 
could arise from the presence of a different polymorph for TOB by phase transition 
(e.g. ROY[217] polymorphs with striking feature in color of red, orange, and yellow). 
Pilcer et al.[215] suggested no degradation of tobramycin was observed over 12 
months by HPLC when the capsule-containing foil blisters were stored at 75% RH 
and 40oC. As expected, the results in Figure 6.5 clearly suggested that moisture could 
penetrate into the capsules hand-wrapped with aluminum foil. The storage stability 
data for SD pure mannitol (not shown) indicate that the hand-wrapped aluminum foil 
probably delayed rather than prevented moisture penetration into the capsule. As 
shown in Figure 6.2, the mannitol component possibly partially crystallized into beta 
polymorphic crystal form in TOB:MAN=1:0.5 at conditions of 40% and 75% RH. 
However, it was not observed for TOB:PLS:MAN=1:0.5:0.5. These results were 
possibly due to the mannitol component being enriched in TOB:MAN=1:0.5 
compared to TOB:PLS:MAN=1:0.5:0.5. In addition, the possible interaction between 
phospholipids and mannitol in TOB:PLS:MAN=1:0.5:0.5 may impede mannitol 
crystallization. A similar mechanism of hydrogen-bonding interaction between 
trehalose and phospholipids has previously been cited in the literature[218].  
Based on XRPD data (Figure 6.1 to 6.4), there was no evident crystal formation in SD 
tobramycin particles stored at 11% RH and 40oC. However, in comparison to 
freshly-prepared samples, the aerosol dispersion performance of stored samples 
significantly decreased. The MMAD values for stored particles were all above 5µm 
(Table 6.1). This indicated the stored tobramycin particles would not be able to reach 
deep lung regions at adult airflow rate using the Handihaler®. Given in the simplified 
Equation 6.1, the aerodynamic diameter of a particle is the product of particle 
diameter and square root of particle density. 
 
             (Equation 6.1)  
Where dae is the aerodynamic diameter of a particle, d is the spherical particle 
diameter, and ρp is the particle density.  
The increased geometric size (d) and/or density (ρp) of particles could potentially 
decrease the aerosol dispersion performance of dry powder formulations[41]. It was 
not likely the RH as low as 11% (comparable to the RH % maintained by desiccants 
in real DPI products) caused the decrease in aerosol dispersion performance of the 
dd pae ρ=
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powders. Although the storage temperature 40oC was below the glass transition 
temperatures (~45 to 50oC) of SD tobramycin formulations, the drug could still be 
susceptible to crystallization. For instance, the DSC thermogram (Figure 6.6c) of 
stored SD pure tobramycin exhibited similar characteristics to that of the as received 
tobramycin rather than that of the SD pure tobramycin. As a classical drug model, 
amorphous indomethacin has clearly been shown to exhibit sufficient molecular 
mobility to trigger crystallization over a period of days at temperature 30oC below its 
Tg[219]. Therefore it is possible that stored SD pure tobramycin may partially 
crystallize through the storage period, however, at a level not detected by XRPD. It is 
also possible that the partially crystallized SD pure tobramycin particles may form 
particle aggregation through solid-solid bridging (between particles). It has been 
reported that storage of the excipient (mannitol) crystallization resulted in increased 
particle size (e.g., interparticle growth) and adverse effects on the aerosol dispersion 
performance of spray dried protein powders[192]. Moreover, the crystallized 
aggregates were expected to have a higher density than fresh particles due to the loss 
of free volume in particles after crystallization with more organized molecular 
packing. Similar to SD pure tobramycin particles, the possible partial crystallization 
process was also noticed in other tobramycin containing particles under storage at 11% 
RH and 40oC. 
The XRPD data (Figure 6.7 to 6.8) shows that SD pure AZI and AZI: MAN=1:0.5 
lacked long-range molecular order after storage at all conditions through three months. 
As seen from Table 6.2, the aerosol dispersion performance was lowered with 
increased RH % after three-month storage for the two formulations. It is well known 
that interparticulate forces that influence particle interactions during the dispersion of 
powder aerosols include van der Waals, electrostatic, capillary, and mechanical 
interlocking forces[41, 63, 64]. The capillary force arises from moisture condensation 
which form high tensile liquid bridge in the gap between two contiguous surfaces, and 
becomes dominant as the relative humidity increases[41, 64]. Therefore, capillary 
force is highly expected to play a key role in aerosolization efficiency for the two 
formulations exposed to various RH %. Moisture content of the formulations was not 
measured after storage.  
As seen from Figure 6.9 to 6.10, the phospholipid bilayer structure was retained for 
AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 during storage. In addition, the 
mannitol component appeared to lack long-range of molecular order in 
AZI:PLS:MAN=1:0.5:0.5. After one month storage, the crystalline peaks of AZI 
dihydrate (identical to XRPD of as received AZI, but with a lower intensity) were 
observed for AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 only at conditions of 75% 
RH and 40oC. These results suggest that the phospholipid component decreased the 
physical phase stability of azithromycin component in AZI:PLS=1:0.5 and 
AZI:PLS:MAN=1:0.5:0.5 under these conditions possibly by the association of water  
molecules with hydrophilic head groups of phospholipids[167]. Presumably, the 
azithromycin could interact with absorbed water molecules to form azithromycin 
dihydrate. The hand-wrapped aluminum foil wrapping slowed the rate of physical 
phase inter-conversion, but did not ultimately stop the process (Figure 6.9 to 6.10). 
On the other hand, the GVS data (Figure 4.14-4.16 in Chapter 4) did not directly 
support this hypothesis, although the experimental temperature of DVS (25oC) and 
stability test (40oC) were different. Both water vapor sorption isotherms of 
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AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 were lower than SD AZI:MAN=1:0.5 
(no azithromycin crystallization was observed).  
With MMAD values of about ≤5µm, the FPF value of AZI:PLS=1:0.5 and 
AZI:PLS:MAN=1:0.5:0.5 stored at 11% and 40% RH, respectively, was relatively 
comparable to the corresponding fresh samples. However, after the partial 
crystallization of azithromycin into dihydrate form in particles, the aerosol dispersion 
performance of stored AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 at 75% RH was 
poor as evident by MMAD values of ~15µm. Similar to the discussion in aerosol 
dispersion performance of SD tobramycin particles, the effect of irreversible 
crystallization of azithromycin on the particle dispersion may possibly be explained 
by the hypothesized mechanisms, such as particle aggregation and formation of 
densified particles. 
 
6.5 Conclusions 
 
An indicated, possible chemical degradation of tobramycin by a color change was 
observed in SD tobramycin particles stored at 40% and 75% RH (at 40oC). Compared 
to the corresponding freshly-prepared particles, tobramycin particles stored at 11% 
RH and 40oC exhibited decreased the aerosol dispersion performance. The decreased 
in aerosol dispersion performance was possibly caused by a low level of partial 
crystallization of tobramycin in formulations. Possibly due to enhanced capillary 
force, the aerosol dispersion performance was lowered with increasing RH % for the 
stored SD pure AZI and AZI: MAN=1:0.5. Stored AZI:PLS=1:0.5 and 
AZI:PLS:MAN=1:0.5:0.5 from conditions of 11% and 40% RH (at 40oC) showed 
relatively comparable aerosol dispersion performance to the corresponding fresh 
samples. The aerosol dispersion performance of phospholipids-containing 
azithromycin formulations stored at 75% RH (40oC) was highly impeded due to 
partial crystallization of azithromycin. In addition, the phospholipid bilayer structure 
was retained in all formulations. Mannitol component was lacking in long-range 
molecular order in all formulations expect for TOB:MAN=1:0.5 stored at 40% and 75% 
RH (at 40oC). 
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Chapter 7 in vitro Drug Release 
 
7.1 Introduction 
 
The proposed lung surfactant-mimic phospholipids (dipalmitoylphosphatidylcholine 
(DPPC):dipalmitoylphosphatidylglycerol sodium (DPPG) in 4:1 molar ratio; PLS) 
and mucolytic agent mannitol (MAN) were selectively incorporated into spray dried 
(SD) azithromycin (AZI) particles. Despite the advantages from a pharmacological 
perspective by incorporating PLS and MAN into SD AZI particles, the impact of 
incorporation of PLS or/and MAN on in vitro free drug release profiles of SD AZI 
particles needs to be assessed.  
There are no specific pharmacopoeial methods used for testing in vitro drug release 
from inhaled powders delivered to the respiratory tract[220]. Several in vitro drug 
release methods were reported for pulmonary drug delivery formulations[221-231]. 
O’Hara et al.[224] reported the suspension of dispersed rifampicin loaded 
microspheres was centrifuged and an aliquot sample was taken from the supernatant. 
After the aliquots were removed, the entire supernatant was replenished in order to 
maintain sink condition. However, it was not clear if the centrifugal force was 
sufficient to sediment small particles, especially for nano-sized particles. Additionally, 
it was not experimentally demonstrated that sink condition was maintained by 
replenishing the supernatant at each time point. In another study, diffusion cell was 
employed to assess the release of terbutaline sulphate from microspheres into release 
medium[223]. A membrane (pore size of 0.45µm) was chosen to allow free diffusion 
of the drug into the receiver and prevent entry of microparticles. Nonetheless, it may 
have limited use for in vitro drug release of SD AZI particles. The SD particles 
(micro- and nano-sized) and thereafter the possible AZI-containing liposomes 
(formed from PLS released from SD AZI particles incorporated with PLS) may be 
sufficiently small to pass through the membrane during the experiment. Moreover, 
simulated interstitial lung fluid (SILF) and simulated surfactant lung fluid (SSLF) 
were used as alternative release medium[232-234] besides phosphate buffer, which 
may make complicate the in vitro drug release mechanism.  
The in vitro drug release method used in this Chapter was relatively simple to carry 
out. It examined free AZI drug release from SD particles in PBS at pH of 7.4 and 
temperature of 37oC with initial drug loading below the apparent solubility of SD pure 
AZI particles. A sink condition[235], defined as the volume of medium at least three 
times greater than that required to form a saturated solution of a drug substance, was 
not used mainly due to the detection limit of AZI by high performance liquid 
chromatogram (HPLC) assay. In addition, without replacing refresh release medium 
during studies may potentially reduce experimental procedures and minimize 
experimental errors. Due to the small size and lacking in long-range molecular order 
of AZI component, it is expected that SD AZI particles may exhibit a relatively fast 
initial drug release with application of rotation force. The effect of phospholipid 
bilayer structure with low integrity on significantly lowering drug release rate would 
not be anticipated for SD AZI particles. Moreover, the drug release of SD AZI 
particles would possibly be enhanced with the potential presence of molecular 
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interaction between AZI and MAN components in the SD AZI particles.  
 
7.2 Materials and Methods 
7.2.1 Materials 
The spray-dried (SD) formulations of pure azithromycin (AZI), 
azithromycin:mannitol (AZI:MAN)=1:0.5, azithromycin:phospholipids 
(AZI:PLS)=1:0.5, 1:1, and 1:2, azithromycin:phospholipids:mannitol 
(AZI:PLS:MAN)=1:0.5:0.5 and 1:2:2 (in molar ratio) were selected for in vitro drug 
release. The selected formulations were all generated from spray drying employing a 
50% pump rate (15 ml/min). Phosphate buffered saline (PBS) tablets were purchased 
from Sigma (USA). The phosphate buffer with concentration of 0.01M was prepared 
by dissolving 1 tablet in 200ml of water. The organic solvents (methanol, chloroform, 
and acetonitrile) used were all HPLC grade. Methanol and chloroform were obtained 
from Fisher Scientific (USA). Acetonitrile was obtained from Acros (USA). Millipore 
deionized water was used in this study. 
7.2.2 Methods 
The in vitro drug release of selected formulations was conducted in polyethylene (PE) 
vials (anti-static, 20ml; PerkinElmer, USA). In order to achieve initial drug loading 
below the apparent solubility of SD pure AZI particles, certain amount of SD powder 
equal to ~8mg of pure AZI were suspended in 20ml preheated PBS (37oC) in PE vials. 
The suspensions were kept rotated by using Labquake tube shaker (Barnstead 
Thermolyne). The in vitro drug release was conducted at 37oC in a temperature 
well-controlled incubator (Precision, USA). At each planned time point, 0.5ml of drug 
release medium was taken from PE vials. Sufficient sample of free AZI was collected 
in filtrate after passing through a regenerated cellulose membrane of Amicon® Ultra 
(Millipore Corporation, USA) with 30K molecular weight cutoff (MWCO) by using 
Eppendorf centrifuge 5417R (USA) at 14,000g (based on the recommended method 
from the manufacturer of filters) for 1min. The concentration of free AZI was 
determined by using high performance liquid chromatogram (HPLC) with UV 
detector at 210nm of wavelength. The HPLC chromatograms were acquired by 
Shimazu CLASS-VP V5.032. All formulations were done in triplicate. 
 
7.3 Results 
7.3.1 Validations  
7.3.1.1 Linearity of HPLC Assay for Azithromycin  
The employed high performance liquid chromatogram (HPLC) system was consisted 
of an LC compact system (Shimadzu, Japan), and equipped with an autosampler 
(SIL-10AD VP), a binary pump (LC-10AD VP), and a UV detector (SPD-10A VP). 
The HPLC analysis for AZI concentration determinination was slightly modified from 
a previously published method[236]. The column was a Luna C18(2) (5µ, 100A, 
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250×4.60mm) (Phenomenex, USA) operated at 30oC. The analytical mobile phase, 
composed of potassium phosphate dibasic-acetonitrile (35/65%, v/v), was passed 
through the analytical column at a flow rate of 1.0 mL/min with the UV detector 
wavelength set at 210nm. The pH of potassium phosphate dibasic (0.05 mole/L) was 
adjusted to 8.2 with 20% phosphoric acid. 30µL sample was injected into HPLC. 
To validate the HPLC assay, three independent groups of standard solutions were 
prepared with concentration of 1000, 400, and 100 µg/mL, respectively. A typical 
chromatogram of AZI parent compound is shown in Figure 7.1. The coefficients of 
variation (CV) for the peak height and peak area for the successive injections of a 
single standard were 3.1% and 3.1%, respectively. Peak carry-over was not observed. 
The mean and CV of mean response factors for the standard concentrations are shown 
in Table 7.1. The student t-tests for linearity were performed to compare the mean 
response factors of standard solutions with different concentrations. At degrees of 
freedom of 4, the t statistic values for 1000 vs 400 µg/mL, 1000 vs 100 µg/mL, and 
400 vs 100 µg/mL were 0.783, 1.471, and 0.838, respectively. This suggests that there 
was no statistically significant difference between the two mean response factors at 
the p=0.025 significant level (degree of freedom: 4, t0.975=2.776).  
 
Figure 7.1. A representative HPLC chromatogram of a standard azithromycin 
solution. 
Table 7.1. The mean response factor and coefficient of variance for each standard 
azithromycin solution. 
Standard Concentration 
(µg/mL) 
Mean Response Factor 
(mL/µg) 
Coefficient of Variance 
(%) 
100 1959 3.4 
400 1919 2.6 
1000 1884 3.1 
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2 4 6 8 10 12 14 16 18 20 22 24
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0.025
0.050UV VIS (210nm)
A-2 Calibration
A-2 Calibration
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7.3.1.2 Stability Indicating Capability of HPLC Assay for Azithromycin  
The HPLC assay validated in Section 6.3.1.1 was tested for ability to resolve 
degradation products from the parent compound of AZI. A 1:5 dilution of stock 
solution (5 mg/mL in methanol) in (a) 0.1N HCl, (b) 0.1N NaOH, and (c) deionized 
H2O were prepared. The storage condition was 25oC for all solutions. Additionally, a 
H2O solution at 37oC was studied. All samples were light-protected during the study. 
There were 5 vials in each study condition. At planned time points, samples were 
withdraw and analyzed by the same HPLC assay. 
The data indicated that the validated HPLC assay was able to differentiate the AZI 
parent molecule and its degradation products, which is similar to the report[236]. A 
typical chromatogram of AZI is shown in Figure 7.2. The retention time of 
azithromycin parent molecule peak was ~16min, while the retention times of 
azithromycin degradation products ranged from ~5 to 7min. The stability indicating 
assay suggests that ~21%, ~24%, ~8%, and ~3% of AZI degraded in HCl (25oC), 
NaOH (25oC), H2O (37oC), and H2O (25oC), respectively.  
 
Figure 7.2. A representative HPLC chromatogram of an azithromycin solution in 
stability indicating assay. 
 
7.3.1.3 Selection of Centrifugal Filter Unit 
The centrifugal filter units with three different molecular weight cutoff (MWCO) 
sizes (3K, 10K, and 30K, respectively) were used to assess possible drug adsorbance 
on the filter membrane (regenerated cellulose). Three independent AZI standard 
solutions with concentration of ~300 µg/mL were used in this assay. Three centrifugal 
filter units of each MWCO size filled with each standard solution were immediately 
centrifuged. The filtrates were analyzed by HPLC assay. In addition, the standard 
solutions were directly analyzed by HPLC assay as a control group. The data are 
summarized in Table 7.2.  
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Volts
-0.02
-0.01
0.00
0.01
0.02
Vo
lts
-0.02
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Table 7.2. The azithromycin adsorbance data for centrifugal filter units. 
Standard Solution 
No. 
Control 
(µg/mL) 
3K 
(µg/mL) 
10K 
(µg/mL) 
30K 
(µg/mL) 
1 295 201 - 292 
2 299 181 280 286 
3 297 185 305 - 
Mean 297 189 293 289 
SD 1.9 10.6 17.7 4.5 
 
The differences between the mean AZI drug concentration in solution filtered through 
from 10K and 30K (one value missing from each group) and control group were not 
statistically significant (t-test, alpha=0.05). The results of the 3K filter unit group 
suggests high drug adsorbance on regenerated cellulose since the mean concentration 
in the filtrate was significantly lower than the control. The high total membrane 
surface area of 3K, compared to 10K and 30K, may be responsible for the decreased 
concentration after filtration. The 30K filter unit was selected for the AZI in vitro 
drug release study due to its low adsorbance variability compared to 10K filter unit. 
 
7.3.1.4 Selection of Release Medium Container 
In order to choose a suitable type of drug release medium container, the 20ml glass 
scintillation and polyethylene (PE) vials were compared for their potential drug 
adsorbance. Two vials of each type were filled with a standard AZI solution with 
concentration of ~ 507 µg/mL and rotated in Labquake tube shaker at 37oC. At time 
points of 3h and 24h, samples were withdrawn and analyzed by HPLC assay.  
The data are shown in Table 7.3. Apparently PE vials adsorbed less of the drug (~3 to 
4%) at each time point compared to glass scintillation vials. Therefore, PE vials were 
chosen for AZI in vitro drug release studies. The reason why two type vials behaved 
differently was not explored. 
Table 7.3. The azithromycin absorbance data for release vials. 
Vial Type Time Points Concentration (µg/mL) 
Percentage  
(%) 
PE Vial 3h 487 96.0 24h 492 97.0 
Scintillation Vial 3h 353 69.7 24h 256 50.4 
 
7.3.2 Release Data 
Figure 7.3 shows the in vitro apparent release profile of SD pure AZI formulation. 
There was a fast burst observed with ~45% of drug being release at 5min. The 
relatively high variation of drug release at first 40min was possibly due to poor 
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dispersion of SD pure AZI powder in the release medium and due to the sampling 
frequency. Thereafter particles continuously released the drug until 60min with ~92% 
released. The drug release profile appeared to approach a plateau after 1h. 
 
 
Figure 7.3. The apparent in vitro release profile of SD pure azithromycin formulation 
in PBS at 37oC. 
 
7.3.2.1 Effect of Phospholipids on Apparent in vitro Release of Azithromycin 
Compared to SD pure AZI, the effect of PLS on in vitro drug release was studied in 
the formulations of AZI:PLS=1:0.5, 1:1, and 1:2 for up to 24h. The AZI:PLS 
formulations released AZI in similar fashion with approximately ~85% release in the 
first 30min (Figure 7.4b). The formulations reached highest release percentage 
(average of ~94%) at 3h and, thereafter, followed by a slight loss of drug up to 13h 
(Figure 7.4a). Incorporation of PLS into SD particles significantly enhanced initial 
release in the first 5min (Figure 7.4b). Within AZI:PLS formulations, AZI:PLS=1:1 
had statistically relatively higher release percentage in the first 10min, followed by 
AZI:PLS=1:2 and AZI:PLS=1:0.5, respectively (Figure 7.4b). 
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(a) 
 
(b) 
Figure 7.4. The apparent in vitro release (a) full profiles and (b) first 60min profiles 
of azithromycin:phospholipids vs azithromycin in PBS at 37oC. 
 
7.3.2.2 Effect of Mannitol on Apparent in vitro Release of Azithromycin 
To examine the effect of MAN on in vitro AZI release, AZI vs AZI:MAN=1:0.5, 
AZI:PLS=1:0.5 vs AZI:PLS:MAN=1:0.5:0.5, and AZI:PLS=1:2 vs 
AZI:PLS:MAN=1:2:2 were paired, respectively. The MAN component appeared to 
have no significant effect on the both corresponding formulations of SD pure AZI 
(Figure 7.5a) and AZI:PLS=1:2 (Figure 7.5c). However, the comparison of 
AZI:PLS=1:0.5 vs AZI:PLS:MAN=1:0.5:0.5 (Figure 7.5b) revealed that the 
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incorporation of MAN component statistically significantly enhance the AZI release 
for the up to 30min. After 30 minutes, there was no difference in the release profiles. 
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(c) 
Figure 7.5. The apparent in vitro release profiles of (a) azithromycin vs 
azithromycin:mannitol=1:0.5, (b) azithromycin:phospholipids=1:0.5 vs 
azithromycin:phospholipids:mannitol=1:0.5:0.5, and (c) 
azithromycin:phospholipids=1:2 vs azithromycin:phospholipids:mannitol=1:2:2 in 
PBS at 37oC. 
 
7.4 Discussion 
7.4.1 Validation of Release Assumptions 
Several assumptions are made in the in vitro drug release study: 1) degradation of AZI 
does not affect release profiles; 2) only free drug concentration of AZI is determined 
in release study; 3) three components are all in one particle. In order to validate the 
assumptions, several experiments or calculations were conducted to validate the 
results shown in Figure 7.3-7.5. 
7.4.1.1 Validation of Degradation of AZI Does Not Affect Release Profiles 
As Section 6.3.1.2 suggested, AZI may degrade under conditions in in vitro drug 
release. In order to assess the degradation effect on drug release profiles, the 
degradation rate constant needs to be obtained. The degradation rate constants of AZI 
(at 25oC and 37oC) were estimated based on the findings in the report[236] and by 
using Arrehenius equation (Equation 7.1). 
lnkobs = lnA −
Ea
RT
  (Equation 7.1) 
Where A is the frequency factor, Ea is the energy of activation, R is the universal gas 
constant, and T is the absolute temperature. Assuming the degradation reaction 
mechanism (base catalysis with positive slope) is the same at pH value of 6.3 and 7.4 
(Figure 3 in [236]) and given that the values of Ea (96.8 kJ/mol at pH value of 6.3) and 
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k80 (9.37*10-4min-1 at pH value of 7.4 and at 80oC) (recalculated from the value from 
Figure 3 in [236]), the reaction rate constants of k25 (at 25oC) and k37 (at 37oC) were 
calculated to be ~2.13*10-6min-1 and ~9.66*10-6min-1, respectively.  
C =  C0 e−kt   (Equation 7.2) 
The exponential decay equation for the integrated first-order rate law is shown in 
Equation 7.2. Where C and Co are the concentrations of drug at time t and time 0 
(initial time), e is exponential number, k is first-order reaction rate constant, and t is 
release time. 
To determine if putative degradation had any effect on the release profiles, the values 
for AZI (Figure 7.3) were modified according to Equation 7.2. The two corrected 
profiles were named as “one-correction” profile and “two-correction” profile, 
respectively. The one-correction profile was carried out to correct for the possible 
degradation of AZI during in vitro drug release using k37 (at 37oC) and collection time 
during the study. The two-correction method was used to correct for possible 
degradation of AZI both in the time of in vitro drug release by using k37 (at 37oC) and 
the time between the samples were collected and analyzed by HPLC using k25 (at 
25oC). The data suggest that there were no significant differences between the 
apparent, “one-correction” and “two-correction” profiles. Similar results were 
validated for other AZI formulations with release up to 24h. These results suggest that 
no excessive degradation of AZI occurred during the time of release assay. Therefore, 
only the apparent in vitro drug release profiles of formulations were plotted in Results 
Section. 
 
7.4.1.2 Validation of Only Free Drug Concentration of AZI Is Determined in 
Release Study 
It has been assumed that only free AZI was present in the filtrate. In order to 
determine if phospholipids-associated AZI was also present in the filtrate, the ability 
of the filter to prevent passage of phospholipids was studied. In order to detect the 
presence of the phosphatidylcholine (PC) headgroup irrespective of hydrophobic 
chain type for PLS content in filtrate, AZI:PLS=1:1 formulation was assessed by 
HPLC using an evaporative light scattering detector (ELSD) as previously reported by 
Modi et al.[237]. At 24h in vitro drug release, the release medium was collected and 
centrifuged at 5,000g for 5min through a 30K filter unit of 15ml to obtain 10mL 
filtrate. The filtrate was immediately dried by nitrogen gas and reconstituted in 1mL 
chloroform. The precipitated phosphate salt (from PBS release medium) was filtered 
through polytetrafluoroethylene (PTFE) syringe filter (organic solvent resistant, 
0.22µm pore size; Tisch Scientific, USA) and a gas-tight glass syringe. The standard 
DPPC and DPPG solutions were prepared by dissolving known amounts of DPPC and 
DPPG in chloroform, based upon solubility limit and ELSD assay calibration range 
for distearoylphosphatidylcholine (DSPC)[237]. The final concentrations for DPPC 
and DPPG in each standard solution were prepared as 0.3 mg/mL and 0.05 mg/mL, 
respectively. The pure chloroform, chloroform through PTFE filter, and AZI solution 
in chloroform were also used as negative controls.  
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Shown in Figure 7.6, is the ELSD chromatograms (last two chromatograms at bottom) 
for the pure chloroform and chloroform through the PTFE syringe filter. No 
significant peaks were detected. AZI standard showed a peak with a retention time of 
approximately 1.75min. The DPPG standard showed no peak over 10min, suggesting 
that the concentration may be below the limit of detection. The DPPC standard 
exhibited a peak with a retention time at ~3min. 
On the representative chromatogram of AZI:PLS=1:1 (named as A:L=1:1 in Figure 
7.6) with high injection volume (50µL), the first peak (with retention time of ~1.9min) 
and the second peak (with retention time of ~2.5min) were possibly from the parent 
AZI and the degradation product(s) of the parent AZI. With low volume injection (et. 
~2µL; data not shown), the possible degradation product(s) peak was not detected by 
this assay. These results demonstrate that the DPPC, the major phospholipid in the 
formulation, was not detected in the AZI:PLS=1:1. Therefore, there was no PLS 
penetrated into filtrate and the AZI concentration analyzed by the HPLC assay was 
only from free drug.  
 
Figure 7.6. The representative HPLC chromatograms of the samples in phospholipids 
assay. 
7.4.1.3 Validation of Three Components Are All in One Particle 
It is interesting to know that whether all three component (AZI, PLS, and MAN) are 
all in one particle. Due to limitation of particle size (approximately > 2µm), it is 
difficult to verify it with current available techniques. However, it is still reasonable 
to assume that all three components are present in one particle. The starting solution 
was prepared by dissolving all three components in methanol spray drying. Therefore 
it is expected that, in the process of atomization, each of the droplets generated should 
possess all three components since they were in uniform methanol dilute solution. 
Thus the solid-state particle was highly expected to possess the three components 
after the droplet was dried. 
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7.4.2 Drug Release 
It was noticed that there was ~90 to 100% of drug release from formulations that was 
achieved in in vitro drug release in PBS at 37oC. The degradation and absorbance of 
the drug were not likely to be the reasons to explain why there was drug remaining 
during release study as we have discussed. AZI has limited intrinsic solubility with 
~200 µg/mL at 25oC[238, 239]. A water solubility of 514 µg/mL of AZI was also 
predicted[240]. Our preliminary data of as-received AZI (in dihydrate rich) and SD 
pure AZI showed solubility of ~225 and ~490 µg/mL in water at 25oC, respectively. 
The preliminary data highly agreed with reported values. The SD pure AZI particles 
were amorphous rich and was expected to have extremely high surface area. 
Therefore, the apparent solubility of SD pure AZI was much higher than its intrinsic 
solubility of crystalline AZI. The AZI loading with 400 µg/mL was selected for SD 
AZI formulations in the study. Although the selected drug loading (400 µg/mL) was 
lower than the apparent solubility (~490 µg/mL), it was higher than the intrinsic 
solubility (~200 µg/mL). Moreover, the solubility of azithromycin at 37oC was 
reported to be slightly lower than the one at 25oC[239]. Therefore, the remaining 
percentage of AZI loading possible either was not dissolved or precipitated after being 
dissolved during release. 
 
7.4.2.1 Effect of Phospholipids on Apparent in vitro Drug Release of 
Azithromycin 
In Section 6.4.1., compared to SD pure AZI, relatively statistically significant fast 
initial (at 5min) free drug burst was observed for the SD AZI particles containing PLS 
components. This result was somewhat surprising as it was expected that the presence 
of phospholipids might slow the release process. At present, it is only possible to 
speculate about the mechanism driving these results. Surfactants are well known to 
have wetting effect[241] on hydrophobic drug particles. It was observed that the PLS 
incorporated SD AZI particles were well suspended in release medium in comparison 
to the particle floating issue for SD pure SD AZI, especially at the initial time points. 
This possibly resulted in a fast burst release for SD AZI with PLC incorporated with 
~72% at 5min. In addition, it could also be reasonably assumed that high fraction of 
AZI molecules located on the particle surface, although drug release is an indirect 
means of attempting to assess component location and direct methods would need to 
be used to assess surface components. To help understand the proposed effect of PLS 
on AZI release, Figure 7.7 illustrates three possible particle structures. 
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Figure 7.7. The proposed scenarios of location of azithromycin drug molecules and 
phospholipid bilayer in SD azithromycin:phospholipids particles. 
Two extreme particle structures with phase separation are shown by structure (a) and 
(b) in Figure 7.7. The AZI phase either surrounds phospholipid bilayer structure 
(structure (a)) or is covered by phospholipid bilayer structure in particle (structure (b)). 
The possibility of phase separation particle structure was ruled out by DSC (Table 4.3 
& 4.4 in Chapter 4) and XRPD (Figure 4.3 & 4.4 in Chapter 4) data. The data 
suggests that the integrity of phospholipid bilayer structure was diminished compared 
to intact one from pure SD PLS particles. In addition, no delay at early time points in 
drug release profiles further indicates the possible AZI:PLS phase separation in 
particle structure (Figure 7.7b) was not likely to be the case. As shown in Figure 7.7c, 
the in vitro drug release data of AZI:PLS might suggest the possibility that the 
phospholipid bilayer is uniformly distributed in the SD particle and AZI molecules are 
predominately located on or close to the particle surface. However, it is equally 
possible that AZI and PLS are both evenly distributed within the particle, possibly 
supported by the confocal Raman microscopy data (not shown).  
Other factor might also influence the rate of AZI release. SEM micrograph of the SD 
AZI:PLS=1:2 particles (Figure 3.4d in Chapter 3), with aerodynamic diameter >5µm 
(Table 5.6 in Chapter 5), appeared to show fused aggregates. The formation of 
aggregates would dramatically decrease the area-to-volume ratio especially for 
particles under micron-sized. AZI:PLS=1:1 and 1:0.5 particles with better particle 
formation (Figure 3.4e & 3.4f in Chapter 3) released more AZI for the first 10min. 
Perhaps the relatively lower area-to-volume ratio of AZI:PLS=1:2 may offset the 
wetting effect from PLS. Thus the apparent drug release profile of AZI:PLS=1:2 
appeared to be somewhere between AZI:PLS=1:0.5 and 1:1 rather than exhibiting 
fastest initial release (up to 10min). The slight loss of drug after 3h could be attributed 
to partition of released drug into the liposomes in PBS from the released PLS, or into 
the PLS matrix in dispersed particles. The similar slopes for drug loss were not well 
understood given the fact that SD particles had different PLS content. Apparently the 
slight loss of drug ended at 24h could possibly suggest the equilibrium among the 
release of free AZI from SD particles, the formation of liposomes, and the partition of 
free azithromycin molecules into liposomes or into PLS matrix in SD particles had 
been reached. This study may also indicate the release of AZI and the release of PLS 
from particles may follow different release modes with time. 
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7.4.2.2 Effect of Mannitol on Apparent in vitro Drug Release of Azithromycin 
The addition of MAN to AZI:PLS=1:0.5 significantly enhanced MAN release in 
timescale up to 30min. Similar primary particle size (AZI:PLS=1:0.5 vs 
AZI:PLS:MAN=1:0.5:0.5) (SEM: Figure 3.4f vs Figure 3.5h in Chapter 3; Size: Table 
3.7 vs Table 3.8 in Chapter 3) suggests the enhanced dissolution of free AZI may 
result from another factor. One possibility is an increased amorphous fraction of AZI 
in the MAN-containing sample. MAN has been reported to exhibit intermolecular 
hydrogen bonding in solid dispersion[242, 243]. The possible increased amorphous 
fraction could arise from the hydrogen bonding interaction between AZI and MAN in 
the SD AZI:PLS:MAN=1:0.5:0.5 particles. Support for this hypothesis is the 
observation of an increase in glass transition temperature of AZI from ~76 to ~85oC 
was observed by adding MAN to AZI:PLS=1:0.5. This change in glass transition 
temperature could be possibly attributed by an increased amorphous phase of AZI in 
AZI:PLS:MAN=1:0.5:0.5 compared to AZI:PLS=1:0.5. The addition of MAN had no 
significant effect on the profiles of in vitro AZI release to SD pure AZI and 
AZI:PLS=1:2. In addition, AZI:PLS=1:2 and AZI:PLS:MAN=1:2:2 formulations 
were excipient abundant. Therefore, the addition of MAN to AZI:PLS=1:2 had no 
significant effect on the amorphous content of AZI component in particles. However, 
as discussed in Section 6.5.2.1, it could not be ignored that the effect of MAN on 
apparent in vitro drug release could essentially originate from how particle wettability 
is changed. 
 
7.5 Conclusions 
In general, the SD azithromycin formulations had a burst release (~50 to 80% at 5min) 
and approached a plateau (until ~30 to 60min) in PBS at 37oC in vitro drug release 
profiles. The AZI:PLS containing phospholipids exhibited a faster initial release (at 
5min) in comparison to SD pure AZI particles. At the expense of increased particle 
size, the increased wetting effect from increased phospholipids in AZI:PLS could be 
minimized in the drug release profile. Data indirectly suggest that AZI may possibly 
predominantly locate on the surface of particle with a uniform distribution of 
phospholipid bilayer structure in particle. However, it is equally possible that AZI is 
uniformly distributed with PLS as confocal Raman microscopy data may indicate. As 
mannitol incorporated into particles, a relatively faster initial drug release could be 
achieved. This could possibly result from the increase fraction of azithromycin 
amorphous phase existing in particles with hydrogen bonding interaction between 
mannitol and azithromycin in solid dispersion. Overall the in vitro drug release of 
azithromycin was mainly dependent upon the particle composition and corresponding 
particle size. 
 
 
 
Copyright © Xiaojian Li 2014 
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Chapter 8 Summary and Conclusions 
 
8.1 General Conclusions 
The work in this dissertation showed that multi-component dry powder aerosols of 
(non-destructive) mucolytic agent, antimicrobial drug, and lung surfactant mimic 
phospholipids have been successfully produced by spray drying from organic solution. 
In general, the microparticulate and nanoparticulate (typically 0.5 to 2 µm) 
multi-component respirable aerosol particles possessed essential particle properties 
suitable for deep lung penetration by sedimentation and diffusion, respectively. The 
essential particle properties (e.g., narrow size distribution (typically 0.5 to 2 µm), 
spherical particle and smooth surface morphologies, and low water content (or water 
vapor sorption)) are expected to minimize interparticulate forces such as van der 
Waals forces, electrostatic forces, mechanical interlocking, and capillary forces. As a 
result of these properties, the majority of spray-dried (SD) multi-component aerosols 
(including two-component and three-component systems) exhibited ability of deep 
lung penetration with values of mass median aerodynamic diameter (MMAD) and 
fine particle fraction (FPF) being approximately less than 5.0 µm and above 30.0% up 
to 60.4%, respectively. 
In the studied formulation compositions of multi-component particles with 
phospholipid incorporation, phospholipid bilayer structure was retained after spray 
drying. It was observed that the intensity of phospholipid bilayer structure was mainly 
dependent upon the biophysical properties of incorporated antimicrobial drug. A 
relatively lower intensity of phospholipid bilayer structure was observed for 
azithromycin formulations compared to tobramycin formulations. This may possibly 
explain the observed in vitro drug release profiles of phospholipid-containing 
azithromycin formulations with no characteristics of extended drug release under the 
conditions studied and using the particular in vitro release method described. In fact, 
phospholipid-containing azithromycin formulations exhibited an enhanced burst 
release likely due to the wetting effect from phospholipids in the particles.  
The other components in SD multi-component particles are shown to lack long-range 
molecular order. Partial crystallization of azithromycin (starting after one-month 
storage at 40oC) in (phospholipid-containing) particles stored at 75% relative 
humidity (RH) strongly impeded aerosol dispersion performance of the SD powder. 
However, the SD azithromycin particles stored at conditions of 11% and 40% RH 
retained the ability of deep lung penetration. Tobramycin in SD multi-component 
particles were chemically unstable with an indication of color change at 40% and 75% 
RH. Although no evident phase transition was detected, SD tobramycin 
multi-component particles stored at 11% RH exhibited MMAD > 5 µm. This may be 
caused by the well-known hygroscopic nature of tobramycin. Mannitol in SD 
multi-component formulations remained unchanged in physical phase after storage at 
all studied conditions. 
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8.2 Future Work 
To further support the specific application of SD multi-component aerosol particles 
for chronic infection diseases in the deep lungs, some future studies might need to be 
carried out. 
1) Expand the molar ratio for SD multi-component particles 
In this dissertation, high (antimicrobial) drug loading formulation was focused on 
with the goal of achieving high local concentrations while reducing the aerosol 
treatment burden and the potential for causing bacterial resistance in the lungs. 
Patients with chronic infections in deep lungs may have various conditions during 
disease progress[244, 245]. Therefore, there are some demands on tailoring 
formulation compositions specifically treat individual patient with certain disease 
conditions in various stages. However, expansion of the formulation compositions 
may possibly have a significant change in physicochemical properties of the 
formulations, affecting aerosol dispersion performance, storage stability, and in vitro 
drug release profiles of the powders. Therefore, physicochemical evaluation and 
formulation performance for SD multi-component formulations with expansion in 
molar ratios are important to be studied. 
2) Equilibrium spreading pressure of phospholipid-containing SD particles by using 
Langmuir surface biophysical analysis 
Pulmonary surfactants can lower the surface tension of interfacial layer. Studies has 
been shown that pulmonary surfactants promote the displacement of particles from air 
to mucus or aqueous phase and that the extent of particle immersion depends on the 
surface tension of the surface active film[246-249]. The data showed that a greater 
immersion of the latex particles into the subphase of an alveolar lining layer could be 
achieved by lowering the surface tension of the layer. The enhancement in particle 
penetration into mucus would potentially help decrease bacteria (such as 
Pseudomonas aeruginosa colonized in mucus with formation of biofilm[250]) density 
in mucus as particles could release antimicrobial drug to the sites where bacteria 
reside. The enhancement of particle penetration into mucus may only benefit for the 
subsequent dosing in our study. The equilibrium spreading pressure[251-253] (πe = γ0 
- γeq; γ0 and γeq are the surface tension before and after adding formulation, 
respectively), a measure of surface tension change, will be examined with 
phospholipids-containing SD particles. The method has been established by our 
research group[251, 253] using Langmuir surface analysis. In addition, surface 
tension in deep lung region may play a critical role in respiratory control, regulation 
of pulmonary immunity, and etc.[9, 10]. Therefore, it will be also necessary to 
monitor the surface tension (γeq) of air-liquid interface as SD multi-component 
particles release phospholipids. The studies will be conducted on the mucus from 
patients with chronic infections in deep lungs (or phosphate buffer saline (PBS) at PH 
7.4, and in vitro model of lung fluid[233]) at 37oC. 
3) in vitro release of mannitol and phospholipids from SD multi-component particles 
Mannitol and phospholipids (dipalmitoylphosphatidylcholine 
(DPPC):dipalmitoylphosphatidylglycerol (DPPG)=4:1 (molar ratio)) are proposed to 
act as (non-destructive) mucolytic agent and lung surfactant mimic phospholipids for 
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the treatment of chronic deep lung infection diseases, respectively. Therefore, the 
release patterns of mannitiol and phospholipids from SD multi-component particles 
needs to be studied. A dry powder for inhalation (DPI) formulation of mannitol as a 
marketed pharmaceutical product (BronchitolTM) is approved in Europe and has been 
very recently approved for clinical trials in the US.[44] It is used as an osmotic agent, 
also known as non-destructive mucolytic agent, to dilute mucus density.[108] In 
addition, a similar release pattern of DPPC and DPPG from the particles would be 
beneficial to maintain a constant ratio of DPPC to DPPG. The release study can be 
conducted in PBS at PH 7.4 (or in vitro model of lung fluid[233], and mucus from 
patients with chronic infections in the deep lungs). The concentration of mannitol and 
phospholipids could be determined by high pressure liquid chromatography (HPLC) 
equipped with a refractive index detector[254] and a evaporative light scattering 
detector[255], respectively. 
4) in vivo animal study of SD multi-component particles 
It is important to examine whether the respiratory functions of in vivo animal model 
with chronic infections in the deep lungs can be improved after administration of the 
multi-component powders. The diseases such as cystic fibrosis (CF) could be possibly 
studied. The mice, pigs or ferrets CF models[256] could be used for this study. The 
larger animal models (pigs and ferrets) have phenotypes that appear to closely 
resemble human CF disease seen in newborns. Formulation with different 
compositions could be tested. The initial dosing of aerosol particles to animals would 
be determined for eliciting bacterial killing on infected sputum from CF patients, 
quantifying the bacterial killing concentrations needed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Xiaojian Li 2014 
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Appendices 
 
This section contains the following additional information: 
 
Appendix A: Spray-Dried Mannitol Aerosols 
Appendix B: Spray-Dried Trehalose Aerosols 
Appendix C: Spray-Dried Itraconazole Aerosols 
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Abstract 
Background: The purpose was to design and characterize inhalable 
microparticulate/nanoparticulate dry powders of mannitol with essential particle 
properties for targeted dry powder delivery for cystic fibrosis mucolytic treatment by 
dilute organic solution spray-drying, and, in addition, to tailor and correlate aerosol 
dispersion performance delivered as dry powder inhalers (DPIs) based on 
spray-drying conditions and solid-state physicochemical properties. Methods: 
Organic solution advanced spray drying from dilute solution followed by 
comprehensive solid-state physicochemical characterization and in vitro dry powder 
aerosolization was used. Results: The particle size distribution of the spray-dried (SD) 
powders was narrow, unimodal, and in the range of ~500 nm to 2.0 µm. The particles 
possessed spherical particle morphology, relatively smooth surface morphology, low 
water content and vapor sorption (crystallization occurred at exposure above 65% 
relative humidity), and retention of crystallinity by polymorphic interconversion. The 
emitted dose, fine particle fraction (FPF) and respirable fraction (RF) were all 
relatively high. The mass median aerodynamic diameters were below 4 µm for all SD 
mannitol aerosols. Conclusion: The in vitro aerosol deposition stage patterns could be 
tailored based on spray-drying pump rate. Positive linear correlation was observed 
between both FPF and RF values with spray-drying pump rates. The interplay 
between various spray-drying conditions, particle physicochemical properties, and 
aerosol dispersion performance was observed and examined, which enabled tailoring 
and modeling of high aerosol deposition patterns. 
 
Keywords: cystic fibrosis, aerosol performance modeling; osmotic agent; respiratory; 
lung; confocal Raman chemical imaging; DPI; particle engineering design; solid-state 
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Introduction 
 
Cystic fibrosis (CF) is the most common life-shortening, chronic hereditary disease 
among the Caucasian population, affecting approximately 60,000 individual 
worldwide[116]. CF leads to accumulation of thick and sticky mucus that affects the 
lungs. This lung disease is characterized by a cycle of bacterial infection and lung 
damage, causing death in early ages for CF patients[257]. Pulmonary delivery of 
therapeutic dose to local lung has tremendous advantages over other administration 
routes[69]. Pulmonary drug delivery systems include nebulizers, pressurized 
metered-dose inhalers (pMDIs), soft-mist inhalers (SMIs), and dry powder inhalers 
(DPIs). Within each class further differentiation is based on metering, means of 
dispersion, or design. DPIs have unique advantages including high dose delivery, 
higher chemical stability relative to the liquid state, and the potential to tailor particle 
properties in the solid-state. The performance of DPI formulations is influenced by 
several particle properties including size, size distribution, morphology, and particle 
surface properties (i.e. surface morphology and interparticulate forces including van 
der Waals, mechanical interlocking, electrostatic, and capillary forces), as described 
in detail by the authors[68, 69, 184, 258-263]. 
There are several methods available to make respirable particles, including 
micronization, precipitation, freeze drying, and spray drying[68-70]. Spray drying is a 
high-throughput process with the ability to produce particles in a more controlled 
manner, such as directing particle size and size distribution, and particle morphology, 
which are important particle features for pulmonary dry powder drug delivery by 
inhalation. As the chronic lung infection of CF resides in lower respiratory tract and 
small peripheral airways[133] where disease progression starts[264, 265], the 
microparticulate and nanoparticulate aerosols (~0.5-2µm in diameter)[134-136] have 
particle deposition by sedimentation and diffusion[266] mechanisms, respectively.  
 
The advantages of particle engineering by spray drying for the design of DPI 
formulations are related to the optimization of important particle properties such as 
surface morphology, particle morphology, particle size, and size distribution by 
controlling and tailoring spray-drying parameters such as feeding solution conditions 
(i.e. solvent type, concentration, and feeding rate) and drying gas conditions (i.e. gas 
type, inlet and outlet temperatures, and flow rate)[68, 70]. Organic solution advanced 
spray drying in closed-mode for pulmonary applications as DPIs has been reported in 
our previous studies[161-164]. The essential particle properties for targeted delivery 
to smaller airways and deep lung region include microparticulate/nanoparticulate size 
range with relatively narrow unimodal sizing distribution (enhance dosing 
reproducibility), spherical particle morphology with relatively smooth surface 
morphology (reduce mechanical interlocking, van der Waal and electrostatic forces), 
and low water content (lower capillary condensation)[41, 63]. 
 
D-mannitol is a non-reducing sugar alcohol that is used as an osmotic agent[267]. 
D-mannitol has also been used as sugar carriers in carrier-based dry powder for 
inhalation[46]. Dry powder mannitol, when inhaled, creates an osmotic gradient that 
facilitates an efflux of water into the airway lumen by which it increases the water 
content in the airway surface liquid (ASL) and promotes the clearance of mucus by 
ciliary movement and cough action. The detailed mechanisms are described in 
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literature[108, 268-272]. A DPI formulation of mannitol as a marketed 
pharmaceutical product (BronchitolTM) is approved in Europe and has been very 
recently approved in the United States. The polymorphic system of D-mannitol has 
been well documented[175, 273].  
 
In this comprehensive and systematic study, the organic solution closed-mode 
advanced spray-drying technique was employed using organic solvent (i.e. an alcohol) 
to minimize the residual water content and reduce the primary particle size in the solid 
state. In addition, inhalable mannitol aerosol powders were designed and optimized to 
target the lung regions where excess viscous mucus is present in CF lungs. In this 
study, the interplay between spray-drying conditions, mannitol polymorphic 
interconversion behavior, physicochemical properties in the solid-state, and their 
influence on in vitro aerosol dispersion performance deposition patterns as high 
performing microparticulate/nanoparticulate DPIs are reported for the first time.   
 
 
Materials and Methods 
 
Materials 
 
Raw D-mannitol (C6H14O6; M.W.: 182.17 g/mol) was from Sigma-Aldrich (St. Louis, 
Missouri). Methanol (HPLC grade, ACS-certified grade, purity 99.9%) and 
chloroform (HPLC grade, ACS-certified grade, purity 99.9%) were obtained from 
Fisher Scientific (Fair Lawn, New Jersey). HYDRANAL@-Coulomat AD was from 
Sigma-Aldrich (St. Louis, Missouri). AQUA STAR methanol was from EMD 
chemical Inc. (Gibbstown, New Jersey). Raw D-mannitol was used as received and 
stored under room conditions. Ultra-high purity (UHP) nitrogen gas (Scotts Gross, 
Lexington, KY) was used for all experiments. 
 
Methods 
 
Preparation of Spray Dried Particles by Organic Solution Advanced 
Spray-Drying (no water) in Closed-Mode 
Organic solution advanced spray-drying process in the absence of water using dilute 
drug solutions was performed in closed-mode using a Büchi B-290 Mini Spray Dryer 
with a high performance cyclone and UHP dry nitrogen gas as the atomizing drying 
gas, and connected to the B-295 Inert Loop (Büchi Labortechnik AG, Flawil, 
Switzerland). The feeding solution was prepared by dissolving mannitol in methanol 
to make a dilute drug solution with a concentration of 0.1% w/v. The following 
optimized conditions, as reported in our previous studies[161-164], were used during 
spray drying: atomization rate, 600 L/h; aspirate rate, 35 m3/h; pump rate (%): 3 
ml/min (10%) (low pump rate), 15 ml/min (50%) (medium pump rate), and 30 ml/min 
(100%) (high pump rate). The inlet temperature was set at 150oC. The corresponding 
outlet temperatures for each spray-dried (SD) mannitol formulations were 
summarized in Table A.1. The stainless steel nozzle diameter was 0.7mm. SD 
mannitol particles were separated from the nitrogen drying air in the cyclone and 
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collected in a sample collection vial. All SD powders were carefully stored in sealed 
glass vials that were stored in sealed glass desiccators over indicating 
Drierite/DrieriteTM desiccant at -20oC under ambient pressure.  
  
Table A.1. Summary of organic solution advanced spray drying in closed-mode 
conditions. 
Chemical agent Pump Rate (%) Inlet Temperature (oC) 
Outlet Temperature 
(oC) 
Mannitol 
10 150 82 
50 150 58 
100 150 38 
 
Scanning Electron Microscopy (SEM) 
 
Using conditions previously reported,[161-164] visual imaging and analysis of 
particle size, morphology, and surface morphology were achieved by SEM using a 
Hitachi S-800 microscope (Tokyo, Japan). Samples were placed on double-sided 
adhesive carbon tabs (TedPella, inc.) which were adhered to aluminum stubs 
(TedPella, inc.) and were coated with gold/palladium alloy thin film using a Hummer 
VI sputtering system from Technics. The coating process operated at 10mA in AC 
with 8kV of voltage for 3min. The electron beam with an accelerating voltage of 
20kV was used at a working distance of 30mm. SEM images were captured by Evex 
NanoAnalysis. Several magnification levels were used. 
Laser Light Diffraction Particle Sizing and Size Distribution  
 
Using conditions previously reported,[161-164] the mean size and size distribution of 
SD mannitol particles in chloroform suspension were determined by ultraviolet laser 
diffraction of nano particle size analyzer SALD-7101 (Shimadzu Scientific 
Instruments, Japan) as reported[161-164]. Samples were dispersed in chloroform and 
ultrasonicated for 10s in water bath ultrasonicater Branson 5210 (Danbury, 
Connecticut) before measuring particle size. Sample particle dispersion was 
immediately transferred to particle size measuring cell and kept stirring during 
measuring in nano particle size analyzer. The low refractive index 1.60-0.10 was used. 
A volume-based dimension of particle amount distribution was obtained for samples. 
DV10, DV50, and DV90 were used as particle size characterization parameters. The span 
value was calculated using the equation defined as [(DV90-DV10)/DV50]. All 
experiments were done in triplicate (n=3). 
 
X-Ray Powder Diffraction (XRPD) 
 
Using conditions previously reported,[161-164] XRPD patterns of mannitol samples 
were collected with a Rigaku X-ray diffractometer (Japan) with Cu Kα radiation 
(40kV, 44mA, and λ=1.5406Å) between 5.0 – 60.0º (2θ) with a scan rate of 2.00o/min 
at ambient temperature as reported[161-164]. The sample was placed on a quartz plate 
in an aluminum sample holder without further grinding. 
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Differential Scanning Calorimetry (DSC) 
 
Using conditions previously reported,[161-164] thermal properties of mannitol 
samples were measured using a TA Q200 DSC (TA Instruments, New Castle, DE, 
USA) equipped with T-Zero® technology and an automated computer-controlled 
RSC-90 cooling accessory as reported[161-164]. Approximate 2mg sample was 
packed into hermetic anodized aluminum T-Zero® DSC pan which was then 
hermetically sealed with the Tzero hermetic sealer (TA Instruments, New Castle, DE, 
USA). An empty hermetically sealed aluminum pan was used as the reference pan. 
UHP nitrogen was used as a purging gas at a rate of 50 ml/min. The sample was 
heated from 10-200oC at a scanning rate of 5.00oC/min. All experiments were done in 
triplicate (n=3). 
 
Hot-Stage Microscopy (HSM) Under Cross-Polarizers 
 
Using conditions previously reported,[161-164] HSM studies were performed under 
OLYMPUS BX51 polarized microscope (Olympus, Japan) equipped with INSTEC 
STC200 heat unit and INSTEC HCS302 hot stage (Boulder, Colorado) as 
reported[161-164]. The polarized light was filtered by γ 530nm U-TP530 (Olympus, 
Japan). Mannitol samples were mounted on cover glass and heated from 25oC (room 
temperature) to 200oC at a heating rate of 5.00oC/min. The heating program was 
controlled by WinTemp software. Pictures of the samples were captured by a SPOT 
insight digital camera (Diagnostic Instruments, Inc.). 
Karl Fischer (KF) Coulometric Titration  
 
Using conditions previously reported,[161-164] the water content of mannitol 
powders was assessed by KF coulometric titration. The measurements were 
performed with a 737 KF Coulometer coupled with 703 Ti Stand (Metrohm Ltd., 
Antwerp, Belgium) as reported[161-164]. Around 6 to 7mg of sample was dissolved 
in AQUA STAR methanol with a 5mL volumetric. The sample solution was injected 
into reaction cell filled with HYDRANAL KF reagent. The water content of sample 
was obtained from simple calculation. The experiments were done in triplicate (n=3). 
Gravimetric Vapor Sorption (GVS) 
 
Using conditions previously reported,[161, 162, 164, 165] water vapor sorption 
isotherms were measured gravimetrically using an automated microelectronic balance 
coupled to a computerized VTI SGA-CX symmetric vapor sorption analyzer (Hialeah, 
Florida). All measurements were taken at 25oC using a sample size of ～1.0 to 1.5mg. 
Samples were subjected to drying treatment at 25oC under 0% relative humidity (RH) 
(nitrogen gas purging) for up to a maximum of 7h with equilibrium criterion of weight 
change less than or equal to 0.0001% in 10min interval. At the end of the drying cycle, 
the samples were exposed to a sequence of increasing RH with increment of 5% RH 
on each step, which started at 5% RH until 95% RH. The criterion used to establish 
equilibrium during adsorption was a weight change of less than or equal to 0.03% in 
10min interval for up to 3h. The data point was acquired at every 2min or 0.01% 
weight change. The standby temperature was set as 25oC. 
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Confocal Raman Microscopy (CRM) and Spectroscopy for Chemical Imaging 
and Mapping 
 
CRM has demonstrated utility in the non-invasive and non-destructive 
microspectroscopic analysis of DPI aerosol formulations as described in detail by the 
authors[274, 275]. Using conditions previously reported[163, 275], dispersive Raman 
spectra and mapping images of mannitol samples were obtained using an Aramis 
confocal Raman spectrometer and fluorescence microscope system (Horiba Jobin 
Yvon, Edison, NJ, USA). The system is equipped with an Olympus BX41 confocal 
optical microscope, an Olympus U-LH 100W Hg lamp, and U-RFL-T power source 
used for fluorescence excitation and brightfield illumination (Olympus America, Inc., 
Chester Valley, PA). Raman spectra were obtained using both a 785nm diode laser 
and a 633nm HeNe laser. Raman spectral maps were obtained using a ×10 objective 
with the stage moved in increments of 5 to 10µm. Each map point was acquired using 
32 to 128 accumulations each with 2s of detector exposure time. A confocal hole of 
500µm, a grating of 600-900 grooves/mm, and a slit width of 100µm were used. 
Spectra were subjected to baseline correction and smoothing prior to further analysis. 
 
Fourier-transform Raman (FT-Raman) experiments were performed using a Nicolet 
FT-Raman 960 spectrometer equipped with InGaAs and Ge detectors (ThermoFisher 
Scientific, Madison, WI). Samples were analyzed using a 180° collector or a 
horizontal video-controlled stage with a 50µm spot size, and 32 to 1024 co-added 
scans were collected at 4cm-1 resolution. A 1.064µm laser was used with a power 
setting of 0.6W. 
 
Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy 
(ATR-FTIR) 
 
A Varian FTS-7000e FTIR spectrometer (Varian Inc., CA) equipped with a DTGS 
detector and a PIKE MIRacle ATR ZnSe accessory was used for all experiments. 
Each spectrum was collected for 32 scans at a spectral resolution of 8cm-1 over the 
wavelength number range of 4,000-700cm-1. A background spectrum was done under 
the same experimental conditions and was subtracted from each sample spectrum. 
Spectral data were acquired with Varian Resolutions Pro software. 
 
In Vitro Aerosol Dispersion Performance by the Next Generation Impactor 
(NGI) 
 
In accordance with United States Pharmacopeia (USP) Chapter <601> specifications 
on aerosols[178] and using conditions previously reported[161, 163], the aerosol 
dispersion performance of SD mannitol was conducted using the next generation 
impactor (NGI; Corporation, Shoreview, MN) with a stainless steel induction port (i.e. 
USP throat) attachment (NGI Model 170, MSP Corporation), equipped with 
specialized stainless steel NGI gravimetric insert cups (MSP Corporation) and the 
HandiHaler® (a high shear stress DPI device, Boehringer-Ingelheim Inc., Germany). 
The airflow rate (Q) of 60 L/min (adult airflow rate) was adjusted and measured 
before each experiment by a Copley DFM 2000 flow meter (Copley Scientific, United 
Kingdom). The NGI was coupled with a Copley HCP5 vacuum pump (Copley 
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Scientific) and a Copley TPK 2000 critical flow controller (Copley Scientific). The 
aerosolization was experimentally designed by Design Expert 8.0.7.1 software 
(Stat-Ease Corp., MN). The mass of powder deposited on each stage was quantified 
by gravimetric method using type A/E glass fiber filters with diameter 55mm (PALL 
Corporation, NY). Each HP-clear size 3 capsule (Quali-V®) (QUALICAPS, Spain) 
contained about 10 mg of powder. Three capsules were used in each experiment. In 
vitro aerosolization experiments were conducted in triplicate under ambient 
conditions. 
For the NGI Q=60 L/min, the effective cutoff diameter (Da50) for each NGI stage was 
calibrated by the manufacturer and stated as: stage 1 (8.06μm); stage 2 (4.46μm); 
stage 3 (2.82μm); stage 4 (1.66μm); stage 5 (0.94μm); stage 6 (0.55μm); and stage 7 
(0.34μm). The emitted dose (ED) was determined as the difference between the initial 
mass of powder loaded in the capsules and the remaining mass of powder in the 
capsules following aerosolization. The emitted dose fraction (ED[%]; Equation A.1) 
was used to express the percentage of ED based on the total dose (TD) used. The fine 
particle dose (FPD) was defined as the dose deposited on stage 2 through 7. The fine 
particle fraction (FPF[%]; Equation A.2) was expressed as the percentage of FPD to 
ED. The respirable fraction (RF[%]; Equation A.3) was used as the percentage of 
FPD to total deposited dose (DD) on all impactor stages. 
 
Emitted dose fraction (ED[%]) =  ED
TD
x 100%       (Equation A.1) 
Fine particle fraction (FPF[%]) =  FPD
ED
x 100%      (Equation A.2) 
Respirable fraction (RF[%]) =  FPD
DD
x 100%      (Equation A.3) 
 
In addition, the mass median aerodynamic diameter (MMAD) of aerosol particles and 
geometric standard deviation (GSD) calculated by using a mathematic program 
written by Dr. Warren Finlay[183]. All experiments were done in triplicate (n=3). 
 
Data and Statistical Analysis  
All experiments were performed in at least triplicate. The results were analyzed 
statistically using Microsoft Office Excel 2007 (Microsoft Corp., WA, USA). The 
results are expressed as mean ± standard deviation. The aerosolization studies were 
experimentally designed using design of experiments by Design Expert™ 8.0.7.1 
software (Stat-Ease Corp., MN). The level of statistical significance was performed at 
0.05.  
 
Results 
 
Scanning Electron Microscopy (SEM) 
 
Three different batches of SD mannitol particles were successfully produced by using 
low (10%), medium (50%), and high (100%) pump rates from dilute organic solution 
advanced spray drying. The detailed spray-drying conditions were introduced in 
Methods sections and Table A.1. The particle morphology and surface structure of the 
mannitol samples were visualized via SEM in Figure A.1. The particle shape of raw 
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D-mannitol (Figure A.1a) was irregular. The particle size of raw D-mannitol was far 
beyond the respiratory size for dry powder inhalation (DPI) which is less than 10µm. 
Generally, the smooth and spherical mannitol particles (Figure A.1b-d) were produced 
at each spray-drying condition. However, as the pump rate increased from 10% (low) 
to 100% (high), the surface of SD mannitol particles became slightly rougher. In 
addition both nanoparticles and microparticles of SD mannitol (linear geometry) were 
produced by spray drying under optimized conditions. 
 
 
 
   
(a)                            (b) 
   
(c)                             (d) 
Figure A.1. SEM micrographs of raw (magnification 100X) and SD mannitol 
particles (magnification 10,000X) for: (a) Raw D-mannitol; (b) SD mannitol (10%P); 
(c) SD mannitol (50%P); (d) SD mannitol (100%P). 
 
 
 
 
156 
 
Laser Light Diffraction Particle Sizing and Size Distribution 
 
The laser sizing data of SD mannitol particles are summarized in Table A.2. The 
particle size distributions of SD mannitol were all in unimodal distribution by laser 
light diffraction. The median diameter (DV50) increased from 0.486µm to 0.702µm for 
SD mannitol as spray-drying pump rate increased from 10% (low) to 100% (high). 
The D90 was slightly above micro-size with 1.147~1.302µm for SD mannitol particles. 
Therefore, the majority of SD mannitol particles were under micro-size range. The 
span value for SD mannitol was between 1 and 2. 
Table A.2. Laser sizing of SD mannitol particles (mean ± SD, n=3). 
Particles Pump Rate  (%) 
DV10 
(µm) 
DV50 
(µm) 
DV90 
(µm) Span Value 
Mannitol 
 
10 0.346±0.002 0.486±0.006 1.147±0.205 1.646±0.398 
50 0.354±0.003 0.521±0.016 1.302±0.101 1.819±0.145 
100 0.482±0.132 0.702±0.141 1.247±0.016 1.156±0.498 
 
X-Ray Powder Diffraction (XRPD) 
 
X-ray powder diffraction patterns (Figure A.2) of raw D-mannitol showed sharp and 
intensive peaks indicating the existence of long-range molecular order. SD mannitol 
samples remained peaks after spray-drying process. The XRPD data reflected that raw 
D-mannitol and SD mannitol samples were in crystalline phase. However the peaks 
positions and intensity varied with samples. 
 
Figure A.2. X-ray powder diffraction patterns for raw and SD mannitol particles. 
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Differential Scanning Calorimetry (DSC) 
 
The thermograms obtained from mannitol samples are shown in Figure A.3 and the 
detailed values of melting peak enthalpy and temperature are tabulated in Table A.3. 
It was seen that raw D-mannitol had one sharp endotherm with peak temperature at 
~166.4oC and enthalpy of 303.4J/g in Figure A.3a. Interestingly, the endothermic 
temperature and enthalpy of SD mannitol samples decreased from ~165.3oC, 164.7oC, 
and 164.3oC and ~304.2J/g, 288.7J/g, and 282.4J/g as the spray drying pump rates 
increased from 10% (low) to 100% (high), respectively.  
 
     
(a)                                 (b) 
     
(c)                                  (d) 
Figure A.3. DSC thermograms of raw and SD mannitol particles for: (a) Raw 
D-mannitol; (b) SD mannitol (10%P); (c) SD mannitol (50%P); (d) SD mannitol 
(100%P). 
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Table A.3. DSC thermal analysis of raw and SD mannitol particles (mean ± SD, n=3). 
Samples Enthalpy (J/g) 
Melting Point (oC) 
Onset Peak 
Raw 303.40±2.21 165.04±0.03 166.41±0.19 
SD 10%P 304.23±9.06 163.69±0.03 165.34±0.04 
SD 50%P 288.67±10.47 162.66±0.04 164.68±0.06 
SD 100%P 282.43±4.45 161.40±0.45 164.29±0.14 
 
Hot-Stage Microscopy (HSM) Under Cross-Polarizers 
 
Raw and SD mannitol (from 50% (medium) pump rate as a representative sample) 
powders were visualized under cross-polarized light microscopy as a function of 
increasing temperature for the presence/absence of birefringency. There were no 
obvious differences at room temperature (25oC) and physiologic temperature (37oC) 
in terms of morphology or shape for both samples in Figure A.4. The raw D-mannitol 
crystal was highly crystalline as seen from HSM pictures in Figure A.4a. The evident 
phase transition (thermodynamic melting phase transition) of D-mannitol initialized 
from 181oC with subtle change in birefringency and finished at 182oC, which was in a 
relatively narrow temperature range. The SD mannitol had phase transition of melting 
at a slightly lower temperature (178oC) than the raw D-mannitol. As raw D-mannitol, 
the melting temperature range for SD mannitol was narrow as well. 
 
25 oC             37 oC            181 oC           182 oC 
(a) 
 
25 oC             37 oC            178 oC           179 oC 
(b) 
Figure A.4. HSM micrographs of raw and SD mannitol (50%P) particles for: (a) raw 
D-mannitol; (b) SD mannitol (50%P). 
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Karl Fischer (KF) Coulometric Titration  
 
The residual water content in the powders is summarized in Table A.4. It was noted 
that the water content of raw D-mannitol had a lower value (~0.53% (w/w)) than its 
SD counterparts. The water content for SD mannitol increased with spray-drying 
pump rates from low to high and was higher than raw D-mannitol. However, the 
water content values were all below 2% (i.e. very low) which is significantly 
important for chemical and formulation stability. The low water content value ruled 
out the possibility of hemihydrates of mannitol[276].  
 
Table A.4. Water content of raw and SD mannitol particles (mean ± SD, n=3). 
Samples Water Content (% (w/w)) 
Raw 0.53±0.26 
SD (10% pump rate) 1.16±0.04 
SD (50% pump rate) 1.69±0.08 
SD (100% pump rate) 1.96±0.32 
 
 
Gravimetric Vapor Sorption (GVS) 
 
The dynamic water vapor sorption profiles are plotted in Figure A.5 for raw and SD 
mannitol (from 50% (medium) pump rate as a representative sample). Overall the 
mass of raw mannitol almost did not change across the whole RH range from 0% to 
95% RH. The SD mannitol followed the same behavior upon RH increments except 
the small increase at 95% RH. This was in agreement with the fact that mannitol is the 
least hygroscopic of polyols and does not start to sorb moisture until the RH is over 
90%[277]. However, there was a small weight loss observed from the RH range of 65% 
to 90%. 
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Figure A.5. Water vapor sorption isotherms at 25oC for raw and SD mannitol (50%P) 
particles (Weight Change % vs RH). 
 
Confocal Raman Microscopy (CRM) and Spectroscopy for Chemical Imaging 
and Mapping 
 
Raman spectroscopy is highly sensitive to the polymorphic form of mannitol, as 
shown by the FT-Raman spectra of bulk samples of each phase in Figure A.6a 
obtained using a 1.064µm laser. The bulk samples of alpha, beta, and delta mannitol 
were prepared by rapid evaporation from water, slow evaporation from water, and 
lyophilization, respectively, and were checked by XRPD. As shown in Figure A.6a, 
the Raman spectral region between 2850 and 3000cm-1 was particularly specific for 
each polymorphic form. These results can be compared to the spectra obtained by 
CRM of a mapped region (2910 to 2940cm-1) of SD mannitol from a 50% (medium) 
pump rate experiment, as shown in Figures A.6b and A.6c. The CRM spectra were 
obtained using a 633nm laser as mannitol shows minimal fluorescence. From 
examination of the map and spectra in Figures A.6b and A.6c, the material was seen 
to be primarily the alpha polymorph of mannitol. No indication of heterogeneity was 
observed in the map in Figure A.6b for bands in the 2910 to 2940cm-1 region 
associated with alpha mannitol, with the only trend observed being the result of 
sample topology differences. Spectra taken from three individual points in this map 
were compared in Figure A.6c, highlighting the lack of significant differences 
observed and the close similarity with the reference spectrum of the alpha phase 
shown in Figure A.6a. A similar analysis of Raman bands in the region of 860 to 
900cm-1 (not shown), which are also selective for D-mannitol polymorphic form, 
yielded the same result. 
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(a) 
 
 
(b) 
 
(c) 
 
Figure A.6.  (a) FT-Raman spectrum of bulk phases of mannitol; (b) CRM map of a 
region of flattened SD mannitol (50%P) particles obtained using a ×50 objective, 
showing Raman band intensity between 2910 and 2940 cm-1 as blue intensity; (c) 
Expanded CRM spectra of three points on the map in (b). 
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Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy 
(ATR-FTIR) 
 
Figure A.7 shows the FT-IR spectra of mannitol particles. Differences were mainly 
detected in the band range of 1500-1200cm-1, indicating the differences of C-H 
deformation vibration. These were attributed to different mannitol polymorphs[278]. 
 
 
 
Figure A.7. ATR-FTIR spectra for raw and SD mannitol particles. 
 
 
In Vitro Aerosol Dispersion Performance by the Next Generation Impactor 
(NGI) 
 
Figure A.8 shows SD particle deposition profiles on each of the NGI stage at airflow 
rate (Q) of 60 L/min. As indicated in the profile, the SD mannitol powder produced 
from high spray-drying pump rate exhibited low particle deposition on stage 1 
(effective cutoff diameter of 8.06µm) and high particle deposition on stages 2-4. 
However, compared to the other two formulations, particle deposition fraction was 
reduced for particles generated from high pump rate on stages 5-7 that was in the 
aerodynamic nanometer size range. The aerosol dispersion performance parameter 
values are listed in Table A.5. The FPF and RF of SD mannitol particles exhibited 
high, while having similar ED, as pump rates increased for spray drying. All SD 
mannitol powder had MMAD <4µm from the HandiHaler® under Q of 60 L/min. 
However, the GSD decreased, indicating aerodynamic size distribution being 
narrower, as the pump rates increased from 10% to 100%.  
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Figure A.8. In vitro aerosol dispersion performance using the NGI under an airflow 
rate (Q) of 60 L/min with the HandiHaler® DPI device for SD mannitol (n=3). 
 
Table A.5. Aerosol dispersion performance parameters of SD mannitol particles 
(mean ± SD, n=3). 
SD Mannitol Aerosol Dispersion Performance Parameters 
Pump Rate 
(%) 
ED  
(%) 
FPF 
(%) 
RF 
(%) 
MMAD 
(µm) GSD 
10 85.07±2.13 36.02±3.70 60.54±5.77 3.16±0.47 2.57±0.18 
50 83.72±2.58 44.18±2.77 65.67±1.74 2.76±0.09 2.32±0.12 
100 82.33±10.61 54.84±4.84 80.95±6.36 3.49±0.36 1.85±0.08 
 
Discussion 
 
The present work clearly demonstrated that mannitol micro/nanoparticulate aerosols 
can be successfully produced by advanced spray drying dilute organic solutions. By 
using advanced spray-drying technique with low concentration of organic solvent 
solution, the microparticulate/nanoparticulate aerosols were successfully produced 
with narrow particle size distribution, low water content, suitable particle shape and 
morphology. The narrow particle size distribution is essentially critical for pulmonary 
dry powder inhalation, as it enables the aerosols to target a specific lung region 
without spreading the dose in the whole lungs. Targeted aerosols lower the 
therapeutic dose and toxic effects. Therefore they enhance the therapeutic outcome. 
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More importantly microparticulate/nanoparticulate aerosols ensure particle 
penetration to middle and deep lung regions of CF patients where excessive mucus 
locates. In addition, particle engineering process of spray drying can optimize particle 
size, shape, as well as morphology, which will result in better aerosol dispersion 
performance given as dry powder formulations. Low water content (< 6% w/w) of 
particles slows down chemical degradation process via hydrolysis and, in addition, 
decreases capillary forces between particles.  
In general the majority of SD mannitol particle was in nanoparticulate primary size 
range of ~0.5-1µm (Table A.2), which is beneficial for deep lung penetration by 
diffusion of particle deposition mechanism, while the particles with size range of 
~1-2µm would have particle deposition by sedimentation. On the other side, the 
narrow particle size distribution with span value of 1-2 (Table A.2) theoretically 
indicates reproducible aerosol particle aerodynamic performance, which is clinically 
important for therapeutic reproducibility. 
As pump rates in spray-drying process increased from 10% (low) to 100% (high), the 
DV50 increased from ~0.486µm to ~0.702µm for SD mannitol. The increased particle 
size (DV50 in Table A.2), particle surface roughness (Figure A.1b-d), and water 
content (Table A.4) of SD mannitol were attributed to the formation of larger droplet 
size of solution as pump rates increased during atomization given at same primary 
drying temperature and period in spray drying.  
From the XRPD patterns (Figure A.2), it can be seen that SD mannitol particles 
presented many intensive peaks in their patterns, indicating SD particles retained 
long-range molecular order/crystalline phase. Mannitol polymorphic behavior has 
been previously reported[175, 273]. The simulated X-ray diffractograms of alpha, 
beta, and delta forms (thermodynamic stability order: beta>alpha>delta) of anhydrous 
mannitol are shown in Figure A.9. Interestingly, the beta form has highest melting 
point and lowest enthalpy value, while delta form has lowest melting point and 
highest enthalpy value. The characteristic peaks of each polymorph in diffractograms 
were symboled for identification purpose. The alpha form was identified using the 
peaks at 13.6o and 17.2o 2θ. The peaks at 14.6o and 23.4o 2θ were used to label the 
beta form. The delta form was validated using a peak at 9.7o 2θ. Based upon the 
XRPD patterns in Figure A.2, it indicated that the raw D-mannitol was in the beta 
polymorphic form that was the most thermodynamic stable form verified by DSC data 
(Figure A.3a and Table A.3) and in agreement with the literature[279]. The SD 
mannitol powders were a mixture of different polymorphs. As the pump rate 
increased, the alpha and beta polymorphic content decreased along with increasing 
polymorphic delta form content based on intensity of characteristic peaks of each 
polymorph. According to the XRPD data (Figure A.2), SD mannitol from low to high 
pump rates consisted of beta and alpha polymorphic forms (10% pump rate), a 
majority of alpha polymorph (50% pump rate), and alpha and delta (100% pump rate) 
polymorphs, respectively. This observed trend of polymorphic composition was also 
supported by melting temperature data in Table A.3 since their meting peak 
temperatures descended as more metastable mannitol crystalline forms were present. 
On the other hand, the enthalpy data in Table A.3 also suggested that a small amount 
amorphous phase may remain in SD mannitol and the content of amorphous phase 
may increase with pump rate. Contrastingly, Michiko Kumon[280] et al. reported that 
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SD mannitol was in the beta polymorph form under their spray-drying condition 
which is different from the spray-drying conditions reported here. The CRM results in 
Figure A.6 for the 50% (medium) pump rate sample indicated the presence of 
homogeneous alpha mannitol, supported by XRPD results showing dominant alpha 
form in Figure A.2. In addition, the comparison the FT-IR spectrum of SD mannitol 
from 50% (medium) pump rate (as shown in Figure A.7) with the literature data[278] 
suggested the existence of mainly the alpha form of mannitol.  
 
Figure A.9. Reference X-ray patterns of different polymorphs of mannitol obtained 
from Cambridge structure database program of ConQuest 1.10 (The Cambridge 
Crystallographic Data Center, UK). The symbol, , indicates characteristic peaks of 
alpha, beta, and delta mannitol, respectively, which were used for identification in this 
study. 
The small weight loss of raw and SD mannitol from 65% to 90% RH may suggest 
crystallization of mannitol. It is reported that SD composited formulation of salmon 
calcitonin and mannitol had a weight loss at 60% RH due to the crystallization of 
mannitol in GVS at 25oC[158]. Upon storage, amorphous mannitol transformed to the 
delta polymorphic form during RH exposure at 51%, which crystallized further into 
alpha polymorphic form at 69% RH[158]. A solution-mediated transformation was 
suggested based on their findings. The deliquescence point of the delta polymorphic 
form is approximately 85% RH, above which beta polymorph may form. The 
stoichiometric plot of water vapor sorbed/dry compound vs relative humidity (RH) 
(Figure A.10), translated from the gravimetric water vapor sorption equilibrium data 
(Figure A.5), provides insightful molecular information. The SD mannitol reached 
~0.5 mole/mole ratio at equilibrium of 95% RH. It suggested that SD thermodynamic 
metastable microparticulate/nanoparticulate mannitol particles [50% (medium) pump 
rate] with more surface area and higher surface energy took up a high percentage of 
moisture at 95% RH level, or this may simply indicate the formation of mannitol 
hemihydrate[276]. Due to the increased surface area/energy[145] the SD mannitol had 
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slightly higher water content than raw D-mannitol (Table A.4), but they were all 
under 2% (i.e. very low). The low water vapor sorption (Figure A.5) and water 
content (Table A.4) of SD mannitol is critical for formulation stability issues such as 
chemical stability[281], polymorphic interconversion[282] and interparticulate 
capillary forces[41, 63]. 
 
 
Figure A.10. Water vapor sorption isotherms at 25oC for raw and SD mannitol (50%P) 
particles (Water Vapor Sorbed/Dry Compound mole/mole vs RH). 
 
Excellent aerosol dispersion performance of SD mannitol particles was achieved at Q 
of 60 L/min (adult airflow rate) with the HandiHaler® which gave low particle 
deposition on stage 1 (below 40% deposition) as in Figure A.8. The HandiHaler® is a 
high shear stress DPI device[283]. The particles on stage 1 would be predicted to 
deposit in larger airways (i.e. bronchi) in vivo[64]. The respiratory aerosol 
formulation with ability to effectively reach the smaller airways (i.e. bronchioles) or 
even the bronchioalveolar regions penetration is crucial for enhanced effective 
treatment of CF[134-136]. As demonstrated here for the first time, the SD mannitol 
particles from different pump rates and organic solution (closed-mode) had a 
significant effect on their aerosol dispersion performance. High pump rate (100%) 
particles exhibited FPF ~55% and RF ~81%. The MMAD values for all aerosols were 
suitable for efficiently targeting the smaller airways as inhaled dry powder aerosols. 
Interestingly, positive linear correlation of FPF and RF with spray drying pump rates 
(Figure A.11a and A.11b) exhibited excellent linear regression correlation values of 
r^2 of 0.9998 and 0.9543, respectively. 
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(a) 
 
(b) 
Figure A.11. Linear correlation plots of (a) FPF and (b) RF vs spray drying pump 
rates for SD mannitol. 
 
The difference in aerosol dispersion performance among SD mannitol particles may 
arise from the presence of different polymorphic composition after organic solution 
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resulting in distinctive physicochemical properties (thermal properties, XRPD, water 
vapor sorption, etc.) of aerosols and particle properties (water content, sizing, etc.). 
SD mannitol particles from medium and particularly from low pump rate exhibited 
higher particle deposition on stage 1. Those deposited particles on stage 1 represented 
the aerosolized agglomerates (not primary particles)[284]. However, for all aerosols, 
the primary particles or reduced aggregates were entrained and deposited on stages 
5-7 which have lower Da50 cutoffs into the nanometer aerodynamic size. It is known 
that the interparticulate forces (i.e. interfacial forces) increase as particle size 
decreases because the surface area per volume increases[64], the SD 
microparticulate/nanoparticulate particles do aerosolize, as shown from deposition 
profiles on stages 5-7 in Figure A.8. The excellent aerosol dispersion properties of 
such particles can be advantageous in the treatment of CF and other pulmonary 
diseases by DPIs.  
 
Conclusions 
 
This study has demonstrated for the first time that the SD 
microparticulate/nanoparticulate DPI aerosols of mannitol were successfully produced 
at three pump rates (high, medium, and low) from dilute mannitol solution (methanol) 
using organic solution advanced spray drying in closed-mode. The primary SD 
mannitol particles possessed necessary particle and surface properties that minimize 
the interparticulate interactions and provide excellent aerosol performance as DPIs. 
Comprehensive physicochemical characterization of SD mannitol particles indicated 
that crystallinity was retained following organic solution advanced spray drying due 
to polymorphic interconversion. The type of crystalline polymorphs present was 
correlated with spray drying pump rate. As high-performing DPIs, aerosol deposition 
patterns for all three pump rates were distinct. Positive linear correlation between 
aerosol dispersion parameters (FPF and RF) and spray drying pump rate revealed this 
interplay.  
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Abstract  
 
Novel advanced spray dried inhalable trehalose microparticulate/nanoparticulate 
powders with low water content were successfully produced by organic solution 
advanced spray-drying from dilute solution under various spray-drying conditions. 
Laser diffraction was used to determine the volumetric particle size and size 
distribution. Particle morphology and surface morphology was imaged and examined 
by scanning electron microscopy (SEM). Hot-stage microscopy (HSM) was used to 
visualize the presence/absence of birefringency before and following particle 
engineering design pharmaceutical processing, as well as phase transition behavior 
upon heating. Water content in the solid-state was quantified by Karl Fisher (KF) 
coulometric titration. Solid-state phase transitions and degree of molecular order were 
examined by differential scanning calorimetry (DSC) and X-ray powder diffraction 
(XRPD), respectively. Scanning electron microscopy showed a correlation between 
particle morphology, surface morphology, and spray drying pump rate. All advanced 
spray-dried (SD) microparticulate/nanoparticulate trehalose powders were in the 
respirable size range and exhibited a unimodal distribution. All spray-dried powders 
had very low water content, as quantified by KF. The absence of crystallinity in 
spray-dried particles was reflected in the X-ray powder diffractograms and confirmed 
by thermal analysis. DSC thermal analysis indicated that the novel advanced spray 
dried inhalable trehalose microparticles and nanoparticles exhibited a clear glass 
transition (Tg). This is consistent with the formation of the amorphous glassy state.  
Spray-dried amorphous glassy trehalose inhalable microparticles and nanoparticles 
exhibited vapor-induced (lyotropic) phase transitions with varying levels of relative 
humidity as measured by gravimetric vapor sorption (GVS) at 25oC and 37oC.  
 
Keywords: microparticulate/nanoparticulate inhalable powders; non-reducing sugar 
excipient; organic solution advanced spray drying; Respiratory delivery; trehalose 
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Introduction 
 
Pulmonary inhalation drug delivery offers attractive advantages in delivering high 
concentrations of drug directly to the disease site in lungs while minimizing systemic 
bioavailability[69]. Many mortal lung infectious diseases such as cystic fibrosis reside 
at both mid and low airway regions[91, 285-287]. Therefore, local drug delivery for 
treatment can be enhanced through the use of microparticles and nanoparticles[288, 
289] in pulmonary delivery[70]. These particles can efficiently deposit in the lungs by 
physical sedimentation and diffusion of particle deposition mechanism, 
respectively[290]. Three main delivery systems have been utilized for the inhalation 
of aerosolized drugs, namely, nebulizers, pressurized metered-dose inhalers (MDIs) 
and dry powder inhalers (DPIs)[68, 69]. Various interparticulate interactions[291] 
influence DPI dispersion performance and include  intermolecular van der Waals 
force, capillary force, and electrostatic force[64, 261, 262].  
 
Freeze drying and spray drying are two most common processes which allow the 
conversion of the formulation from liquid state to solid state particularly for dry 
powder inhalation formulation design and development[68]. Nevertheless, freezing 
and thermal stresses associated with both processes are often observed. Therefore, 
cryoprotectants[292] and thermoprotectants[73] are frequently incorporated in the 
formulation for the purpose of protection of drug stability. Carbohydrates[293, 294] 
are commonly used as cryoprotectants and thermoprotectants. Trehalose can be 
successfully included in inhalation formulations that contain biotherapeutic drugs 
(biologics)[295], including aqueous solution spray-freeze dried formulations to 
produce large trehalose particles for nasal vaccination delivery[296]. It has many 
advantages over other sugars, such as less hygroscopicity, an absence of internal 
hydrogen bounds that allows more flexible formation of hydrogen bonds with drugs, 
low chemical reactivity and high glass transition temperature[297]. Moreover, 
trehalose dihydrate has notable similarities to the pulmonary sugar carrier, lactose 
monohydrate, as both are crystalline disaccharides and both are hydrates. Notable 
differences with lactose monohydrate are that trehalose dihydrate is a non-reducing 
sugar, and hence, it is not susceptible to the solid-state chemical degradation Mallaird 
reaction. Additionally, it is not metabolized by bacteria due to its non-reducing 
property. Freeze-dried trehalose[298-300] and aqueous solution spray-dried 
trehalose[300-302] have been reported for non-inhalation dry powder dosage forms. 
 
Exploring alternative sugar carriers for pulmonary inhalation formulation is of 
considerable interest[303]. It has been demonstrated that trehalose can effectively 
improve dry powder aerosolization by increasing the fine particle fraction (FPF)[304]. 
Recently, trehalose dihydrate as an aerosol drug carrier for dry powder inhalation 
delivery has been systematically studied and was found to be an effective alternative 
to lactose monohydrate carrier[46]. Additionally, trehalose has been used as a 
lyoprotectant stabilizing excipient in dry powder inhalation aerosol 
formulations[274]. 
 
The unique features of spray drying involve the ability of particle design, formation 
and drying in a continuous single-step that starts with a liquid and ends with the 
powder formulation. It provides the theoretical framework for a rational design of 
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structured aerosol particles[68, 70, 305]. Typically, the spray drying process consists 
of atomization of feed into a spray, spray-air contact, solvent evaporation of the spray, 
and separation of the dried particles from the drying air[306]. However, particle 
engineering requires a deeper understanding of particle formation processes since 
many process and formulation variables need to be tuned correctly to achieve the 
desired structured particles for inhalation. 
 
By using organic solvent in feedstock with no water present, much lower moisture 
content and significantly smaller particle size can be achieved down to ~400 nm.  
The non-aqueous nature and inherently lower surface tension of an organic solvent 
combined with a low (dilute) solute concentration enables particle production in the 
solid-state down to the inhalable nanometer size range while maintaining a unimodal 
and narrow particle size distribution in the solid-state. To the authors’ knowledge, this 
study is the first to use and report this novel approach to rationally design and produce 
inhalable dry powder microparticles/nanoparticles for pulmonary delivery. These 
novel particles are produced by organic solution advanced spray drying from dilute 
solution under rationally chosen spray drying conditions. The goal of this study was to 
produce and optimize low water content trehalose microparticles and nanoparticles to 
be suitable for pulmonary delivery as dry powder inhalers (DPIs) and to 
comprehensively and systematically investigate the physicochemical and particle 
properties of spray-dried and raw trehalose particles.  
 
Materials and Methods 
Materials 
 
The chemical structure of D-(+)-trehalose dihydrate (C12H26O13; Molecular Weight: 
378.33 g/mol; ≥98.5% purity, Sigma-Aldrich Inc., St. Louis, MO) is shown in Figure 
B.1 (ChemDraw Ultra 10.0, ChemOffice, Cambridge, MA) and its molecular model 
has been previously reported by Mansour and Hickey[274]. Methanol (HPLC grade) 
and chloroform were obtained from Fisher Scientific (Fair Lawn, New Jersey). 
HYDRANAL@-Coulomat AD was from Sigma-Aldrich (St. Louis, Missouri). AQUA 
STAR methanol was from EMD chemical Inc. (Gibbstown, New Jersey). 
 
Figure B.1. The chemical structure of D-(+)-trehalose dihydrate 
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Methods 
Organic Solution Advanced Spray-Drying from Dilute Solution 
 
The advanced spray-drying process was performed using the Büchi Mini Spray Dryer 
B-290 (Büchi, Switzerland) coupled with the Inert Loop B-295 (Büchi, Switzerland) 
and the high performance (HP) cyclone (Büchi, Switzerland). The spray drying 
process was in closed mode. The feeding solution was prepared by dissolving 
D-(+)-trehalose dihydrate in methanol to form a dilute solution with a concentration 
of 0.3% w/v. The following spray-drying conditions were rationally chosen and used: 
atomization gas flow rate was 600 L/h; aspiration rate was 35 m3/h; three different 
pump rates were rationally chosen to represent the “high”, “medium” and “low” pump 
rates which were 100% (30 mL/min), 50% (15 mL/min), and 10% (3 mL/min), 
respectively. The inlet temperature was set at 150oC and this represents the 
temperature maintained the first drying process. The corresponding outlet temperature 
for the secondary drying process at the three different pump rates were 39oC (high 
pump rate), 45oC (medium pump rate), and 53oC (low pump rate). The nozzle 
diameter of the stainless steel nozzle was 0.7mm. The spray-dried (SD) particles were 
separated from the hot nitrogen drying gasin a cyclone and collected in a sample 
collector. Ultra-high purity grade compressed nitrogen gas from Scott-Gross 
(Lexington, Kentucky) was used as the spray-drying gas during closed mode 
spray-drying. 
 
All spray-dried powders were carefully stored in sealed glass vials that were stored in 
sealed glass desiccators over Indicating Drierite/DrieriteTM desiccant at 25oC under 
ambient pressure.   
 
 
Laser Light Diffraction Particle Sizing and Size Distribution 
 
The mean size and size distribution of the particles in chloroform suspension were 
determined by ultraviolet laser diffraction of nano particle size analyzer SALD-7101 
(Shimadzu, Japan). Using the method previously reported by Mansour et al[46], 
powders were dispersed in chloroform and ultrasonicated for 10 s (Branson 5210 
Ultrasonicator Bath, Danbury, Connecticut) to break up the agglomerates without 
reducing the primary particle size before particle size measurements were carried out. 
Sample particle dispersion was immediately transferred to the particle size measuring 
quartz glass cell under stirred conditions. The low refractive index 1.60-0.10 was used. 
Number-based dimension of particle amount distribution was obtained for samples. In 
addition to acquiring the particle size distributions, the Dv10, Dv50, and D90 parameters 
were measured.  The Span value was calculated using the equation defined as 
[(Dv90-Dv10)/Dv50]. 
 
 
Scanning Electron Microscopy (SEM) 
 
The shape and surface morphology of particles was evaluated by SEM, using a 
Hitachi S-800 microscope (Tokyo, Japan). Samples were placed on double-sided 
adhesive carbon tabs (TedPella, Inc.) which were adhered to aluminum stubs 
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(TedPella, inc.) and were coated with gold/palladium alloy thin film using a Hummer 
VI sputtering system from Technics. The coating process was operated at 10 AC mA 
for 3 min. The electron beam with an accelerating voltage of 20 kV was used at a 
working distance of 30mm. SEM images were captured using Evex NanoAnalysis 
software. Several magnification levels were used. 
 
 
X-ray Powder Diffraction (XRPD) 
 
XRPD patterns of powder samples were measured by a Rigaku Multiflex X-ray 
diffractometer (Japan) with a slit-detector Cu Kα radiation (40 kV, 44 mA, and 
λ=1.5406 Å) source. Scan range was 5.0 – 50.0 (2θ) º with a scan rate of 2.00o/min at 
ambient temperature. The sample was placed on a horizontal quartz glass sample 
holder plate. 
 
 
Differential Scanning Calorimetry (DSC) 
 
Thermal analysis and phase transition measurements were carried out using a TA 
Q200 DSC system (TA Instruments, New Castle, Delaware) equipped with T-Zero® 
technology and an automated computer-controlled RSC-90 cooling accessory (TA 
Instruments, New Castle, Delaware). Approximately 3 mg of powder was carefully 
weighed into hermetic anodized aluminum T-Zero® DSC pans (TA Instruments 
T-Zero®, New Castle, Delaware) and were sealed with the T-Zero® hermetic sealer 
(TA Instruments New Castle, Delaware). Ultra-high purity (UHP) nitrogen gas (Scotts 
Gross, Lexington, KY) was used as the purging gas at a purge rate of 50 mL/min. The 
heating range was 10-250oC at a heating scan rate of 5.00oC/min. 
 
Karl Fisher (KF) Coulometric Titration 
 
The water content of all powders was chemically quantified by Karl Fisher (KF) 
coulometric titration. The measurements were performed with a 737 KF Coulometer 
coupled with 703 Ti Stand (Metrohm Ltd., Antwerp, Belgium). Approximately 10 mg 
of powder was dissolved in AQUASTAR® anhydrous methanol in a 5-mL volumetric 
flask. The sample solution was injected into the reaction cell that contained 
HYDRANAL® KF reagent. The water content was then calculated. 
 
Gravimetric Vapor Sorption (GVS) 
 
Water vapor absorption isotherms were measured gravimetrically using an automated 
ultra-high sensitivity Cahn microelectronic balance (Thermoscientific Instruments) 
coupled to a computerized VTI SGA-CX symmetric vapor sorption analyzer (VTI 
Corporation, Hialeah, Florida). All measurements were taken at 25oC and 37oC (ie. 
biological temperature) at using a sample size of 1.0-1.5 mg. Samples were subjected 
to drying treatment at 25oC (for absorption at  25oC) and at 37oC (for absorption at 
37oC) under ultra-high purity (UHP) nitrogen gas (Scotts Gross, Lexington, KY) for 7 
h. At the end of the drying cycle, the samples were exposed to an automated 
computerized sequence of increasing relative humidity (RH) in steps of 5% RH. The 
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RH range was from 0% RH to 95% RH. Sample data acquisition was collected in 
2-minute intervals. The equilibrium criterion was a weight change of ≤0.03% (w/w) in 
a 10-minute interval, per manufacturer recommendations and as reported previously 
by Mansour and Zografi[167]. 
 
Hot-stage Microscopy (HSM) under Cross-Polarizers 
 
HSM studies were performed under OLYMPUS BX51 polarized microscope 
(Olympus, Japan) equipped with an INSTEC STC200 heating unit and an INSTEC 
HCS302 hot stage (Boulder, Colorado). The polarized light was filtered by a γ 530nm 
U-TP530 (Olympus, Japan) filter lens. Powder samples were mounted on a cover 
glass and heated from 25oC to 250oC at a heating rate of 5oC/min. The heating 
program was controlled by WinTemp software. Images were digitally captured by a 
SPOT Insight digital camera (Diagnostic Instruments, Inc.). 
 
Results 
 
Laser Light Diffraction Particle Sizing and Size Distribution 
 
The particle sizing data and calculated span values are tabulated in Table B.1. The 
particle size distributions for all spray-dried powders were unimodal with narrow 
particle distribution, as reflected in the span values. The raw trehalose dihydrate had a 
large volume-median particle size of ~60µm as tabulated in Table B.1. Great 
reduction of particle size was achieved by organic solution advanced spray drying 
from dilute solution to create microparticulate/nanoparticulate powders that are in the 
respirable size range. 
 
Table B.1. Particle size parameters of spray-dried (SD) trehalose and raw trehalose 
dihydrate particles (mean ± SD, n=3) 
    Pump rate D10 (µm) 
D50 
(µm) 
D90 
(µm) 
Span Value 
SD  
10% 0.549±0.003 0.752±0.008 1.177±0.012 0.836±0.010 
50% 0.710±0.006 0.993±0.013 1.544±0.019 0.840±0.030 
100% 0.646±0.109 0.947±0.071 1.648±0.228 1.080±0.455 
Raw 35.139±2.602 59.854±3.296 110.460±1.568 1.263±0.122 
 
 
Scanning Electron Microscopy (SEM) 
 
The particle morphology and surface morphology (ie. surface roughness) of the 
samples were visualized and analyzed using SEM. As shown in Figure B.2, smooth 
and spherical particles were produced by 10% SD pump feeding rate. However, as the 
pump % feeding rate approached 100% (high), the surface roughness increased and 
the proportion of irregular particles also increased. Interestingly, raisin-like dimpled 
particles were produced at the high pump % feeding rate of 100%. SEM analysis of 
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the particle size agreed with the laser sizing data in that all spray-dried powders were 
in the suitable size range for inhalation delivery, in addition to having suitable particle 
morphology. Contrastingly, the raw trehalose dihydrate particles were much larger 
(too large for pulmonary inhalation delivery) and non-spherical with a smooth but 
rectangular shape which are not suitable for inhalation delivery. 
 
    
(a)                               (b) 
    
(c)                               (d) 
Figure B.2. SEM photographs of spray-dried (SD) trehalose and raw trehalose 
dihydrate particles. (A) SD trehalose from 10% pump feeding rate, magnification 
20,000X; (B) SD trehalose from 50% pump feeding rate, magnification 20,000X; (C) 
SD trehalose from 100% pump feeding rate, magnification 20,000X;  (D) raw 
D-(+)-trehalose dihydrate, magnification 1,000X. 
 
X-ray Powder Diffraction (XRPD) 
X-ray powder diffraction patterns (Figure B.3) indicated that the organic solution 
spray drying process produced amorphous phase trehalose particles, as exemplified by 
the absence of sharp peaks and the presence of the characteristic non-crystalline “halo” 
which can be attributed to the loss of crystal character following the loss of the two 
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bound water molecules (ie. tightly bound to the crystal lattice by thermodynamically 
favorable H-bonding) during the organic solution advanced spray drying process from 
dilute solution. In contrast, the raw trehalose dihydrate had many intense peaks 
indicative of the presence of long-range molecular order due to crystallinity. The 
peaks represented that the raw trehalose dihydrate was highly crystalline which is in a 
good agreement with the University of Cambridge database and by results reported by 
Mansour et al[46]. The loss of characteristic crystalline peaks (“halo”) is in good 
agreement with previous reports on aqueous solution spray-dried trehalose under 
different conditions[307].  
 
 
 
Figure B.3. X-ray powder diffractograms of SD trehalose and raw trehalose dihydrate 
powders. 
 
Differential Scanning Calorimetry (DSC) 
 
The thermograms obtained from raw trehalose dihydrate and SD trehalose are shown 
in Figure B.4. There were three endothermic peaks observed for raw trehalose 
dihydrate which are characteristic for order-to-disorder thermotropic phase transitions. 
Similar DSC thermograms were obtained for single crystals of trehalose 
dihydrate[308] and for raw trehalose dihydrate powder[296]. The two endothermic 
order-to-disorder peaks at ~100oC and 140oC correspond to two dehydration 
processes due to the loss of unbound water at ~100oC (ie. vaporization of unbound 
water) and vaporization of the bound water molecules at 140oC which vaporize at a 
temperature significantly greater than 100oC due to thermodynamically favorable 
H-bonding of the water molecules within the trehalose dihydrate crystal lattice. The 
third endothermic order-to-disorder peak at 210oC represented the fusion of 
anhydrous β form of trehalose[309]. All SD trehalose samples showed an amorphous 
glassy-to-rubbery phase transition, Tg, (ie. characteristic baseline shift) at ~50oC, 
5 15 25 35 45 55
In
te
ns
ity
 
2 Theta (degrees) 
SD trehalose (100% feeding
rate)
SD trehalose (50% feeding rate)
SD trehalose (10% feeding rate)
D-(+)-trehalose dihydrate
179 
 
followed by an exothermic disorder-to-order phase transition near 95oC which 
suggests crystallization at Tc from the amorphous rubbery state. A small endothermic 
order-to-disorder peak was observed in the temperature range of 140-150oC for the 
SD trehalose samples. To the authors’ knowledge, this peak has not been reported 
previously in the literature. The fusion of the β form of trehalose was observed in this 
same temperature range as the raw trehalose dihydrate. 
 
    
           (a)                                (b) 
 
    
(c)                                (d) 
Figure B.4. DSC thermograms of SD trehalose and raw trehalose dihydrate particles 
at a heating scan rate of 5.00oC/minute. (A) raw D-(+)-trehalose dihydrate; (B) SD 
trehalose (10%  pump feeding rate); (C) SD trehalose (50% pump feeding rate); (D) 
SD trehalose (100% pump feeding rate). 
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Karl Fisher (KF) Coulometric Titration 
 
The water content data are plotted in Figure B.5. The mean total water content of raw 
trehalose dihydrate was 9.62% (w/w) with a standard deviation (std. dev.) value of 
±0.08% (w/w). This data is in excellent agreement with the literature[308]. By 
comparing the theoretical minimum water content of raw trehalose dihydrate (9.52% 
(w/w)), it suggested that there was a trace amount of water (0.1% (w/w)) adsorbed to 
its surface, as the sample was stored under ambient conditions (approximately 55% 
RH and 25oC). As stated in the Experimental section, all spray-dried trehalose 
powders were stored in a sealed glass desiccator containing Drierite®/Indicating 
Drierite® desiccant under room temperature of 25oC. The water content values were 
0.73% (w/w) (std. dev. = ± 0.25% (w/w)), 0.86% (w/w) (std. dev. = ± 0.09% (w/w)), 
and 1.51% (w/w) (std. dev. = ± 0.01% (w/w)) for samples produced by 10% (low), 50% 
(medium), and 100% (high) pump feeding rates, respectively.  
 
 
Figure B.5. Water content quantification (% w/w) of SD trehalose and raw trehalose 
dihydrate powders by Karl Fisher coulometric titration. 
 
Gravimetric Vapor Sorption (GVS) 
 
The gravimetric vapor sorption isotherms of the three spray-dried trehalose and raw 
trehalose dihydrate samples are plotted in Figure B.6a. From 0% to 55% of RH, all 
three SD samples underwent a rising curve with respect to their mass changes, 
reflecting an increasing capability of water vapor uptake. Interestingly, a transition 
point of water vapor sorption took place at 30% RH. This may be due to the SD 
trehalose samples passing through the lyotropic vapor-induced glass transition, from 
lower molecular mobility of glassy state to higher molecular mobility of the rubbery 
state. The uptake of water vapor of the sample continued to increase after the 
lyotropic vapor-induced glass transition. The amorphous trehalose relaxed to its more 
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stable crystalline state through crystallization at 55%-60% RH and the water vapor 
sorption capacity decreased sharply over a very narrow RH range followed by a 
plateau in vapor absorption. A slight desorption of water was observed for SD 
trehalose samples after 60% RH followed by the plateau region suggestive of the 
recrystallization process from the amorphous state to the crystalline state. It also 
suggests the transition from unbound water to bound water, as occurs during the 
process of crystallization. 
 
The water vapor sorption isotherms of SD trehalose particles (50% pump feeding rate) 
at 25oC and 37oC were measured as shown in Figure B.6b. The water vapor 
absorption isotherm at 37oC appeared to reach the equilibrium faster than at 25oC in 
terms of RH %. For example, the SD amorphous trehalose reached its highest weight 
change percentage at 50% RH at 37oC vs 55% RH at 25oC. In addition, the SD 
amorphous trehalose exhibited more water vapor uptake at 37oC than at 25oC across 
the whole RH % range studied while retaining the similar isothermal profile trend. 
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(b) 
Figure B.6. Water vapor sorption isotherms of SD trehalose and raw trehalose 
dihydrate particles (weight change (%) vs relative humidity (RH)): (A) Comparison of 
water vapor absorption between SD trehalose and raw trehalose dihydrate particles at 
25oC; (B) Comparison of water vapor absorption of SD trehalose particles (50% 
feeding rate) at 25oC and 37oC.  
 
Hot-Stage Microscopy (HSM) under Cross-Polarizers 
 
The HSM pictures of raw trehalose dihydrate and SD trehalose (50% feeding rate) 
upon heating are shown in Figure B.7. Under cross-polarized light, the birefrigency of 
raw trehalose dihydrate were observed at 25oC and 37oC. The birefrigency of raw 
trehalose dihydrate started to diminish at 108oC and disappeared finished at 116 oC. 
This phase transition may correspond to its first endothermic order-to-disorder phase 
transition, as seen in Figure B.4 for raw trehalose dihydrate. This may be due to the 
first dehydration process ie. loss of unbound water. As seen in Figure B.7, the crystal 
shape was retained during this transition. However, during the second endothermic 
order-to-disorder phase transition, the crystal shape disappeared in the temperature 
range 146-160oC. Subtle birefringency reemerged in the temperature range of 
200-227oC which may suggest a subtle recrystallization event which was not observed 
in the DSC thermogram. Melting was visualized in the temperature range of 
231-234oC as evident by liquid droplet formation.  
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25oC         37oC          108oC         116oC        146oC 
 
160oC        200oC         227oC        231oC        234oC 
Figure B.7. HSM of raw trehalose dihydrate particles 
 
SD trehalose from 50% feeding rate (Figure B.8) showed dark agglomerates lacking 
birefringency at 25oC and 37oC, as would be expected for non-crystalline amorphous 
materials. The recrystallization of SD trehalose with increasing temperature was not 
visually evident due to the small particle size of SD trehalose (Table B.1). The first 
phase transition visualized by HSM appears to correlate with the small 
order-to-disorder endotherm (perhaps due to a metastable phase transition or a 
pretransition), as observed in the DSC thermogram at 140-150oC in Figure B.4c. The 
melting process occurred at higher temperatures as evident by liquid droplet 
formation seen in the micrographs.  
 
 
 25oC         37oC         50oC          95oC        146oC 
 
 158oC        183oC        224oC        234oC        236oC 
Figure B.8. HSM of SD trehalose particles (50% pump feeding rate)  
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Discussion 
 
The present work demonstrates that low water content trehalose microparticles and 
nanoparticles with particle properties necessary for inhalation dry powder delivery 
can be successfully produced by organic solution advanced spray drying from dilute 
solution using rationally selected spray drying conditions. By using low concentration 
of organic solvent solution, the unimodal narrow particle size distribution of SD 
trehalose microparticulate/nanoparticulate powders was achieved. The unimodal 
narrow particle size distribution is critical for pulmonary dry powder inhalation, as it 
enables the particles to target a specific lung region which consequently can lower the 
therapeutic dose. In addition, the water content of final product can be reduced via 
spray drying the organic solution of trehalose instead of water solution. Since the size 
of inhalable particles is small, residual water can have a significant influence on the 
dispersion of dry powder during aerosolization through capillary force[64]. However, 
the water content of SD trehalose increased a bit as the pump rate increased but was 
still at the level that is considered to be low. 
 
The surface morphology, as visualized by SEM, changed with increasing pump 
feeding rates. Specifically, smooth particles and corrugated particles were produced 
by low feeding rate and high feeding rate, respectively. Research studies[141, 263] 
have demonstrated that the particle morphology of dry powder can impact the aerosol 
performance.  
 
From the XRPD and DSC data, they showed that the organic solution advanced spray 
drying process from dilute changed raw crystalline trehalose dihydrate into SD 
amorphous glassy trehalose. The change of pump rate did not significantly affect the 
XRPD and DSC data for SD trehalose particles. However, DSC thermal analysis for 
SD trehalose appears to suggest that amorphous rubbery trehalose crystallizes to a 
relatively more ordered phase at a Tc ~95oC, as seen by the distinct disorder-to-order 
exothermic phase transition present in the thermograms.  
 
Gravimetric vapor sorption study illustrated water vapor lyotropic effect on SD 
trehalose particles microparticulate/nanoparticulate powders. A vapor-induced phase 
transition suggestive of a glass transition occurred at 30% RH, after which point water 
vapor uptake continued to increase up to ~55% RH. The crystallization process 
appeared to occur during vapor absorption in the RH range of 55-60% RH, as evident 
by the sharp decrease in water vapor uptake over a narrow RH range followed by the 
plateau in vapor uptake. It is generally recognized that temperature and RH are two 
important factors on the phase transition behavior and stability on amorphous 
phases[310, 311]. As expected for crystalline hydrate powders, raw trehalose 
dihydrate did not absorb any significant amounts of water vapor over the entire range 
of RH, as it is in its thermodynamically stable state. 
 
Figure B.9 shows water vapor uptake lyotropic phase behavior at 25oC (ambient 
temperature) and 37oC (biological temperature) on a molar basis for stoichiometric 
water content analysis and insight. Figure B.9a shows that the raw trehalose dihydrate 
does not exhibit any significant water vapor uptake on a molar basis. This is expected 
for crystalline materials especially for crystalline hydrate powders, as crystalline 
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materials are in a relatively lower thermodynamic energy state.   
 
All spray-dried trehalose amorphous glassy particles, produced using three different 
pump feeding rates, had similar water vapor sorption profiles but were significantly 
greater than raw crystalline trehalose dihydrate, as shown in Figure B.9a. The 
stoichiometric molar ratio reached to 2.1 (i.e. dihydrate) at 55% RH and remained at 
this level in the plateau region which suggests a lyotropic phase transition from the 
amorphous rubbery state (i.e. higher energy state)  to the thermodynamically stable 
dihydrate crystal (lower energy state). It decreased slightly followed by a plateau 
region. There appears to be a slight ratio decrease for SD trehalose at 25oC starting 
from the crystallization point, reaching to 1.8 moles (i.e. dihydrate) in the plateau 
region. Figure B.9b shows that the SD trehalose particles had a lesser decrease in the 
stoichiometric molar ratio at 37oC (biological temperature) at the recrystallization 
point and was essentially constant at 2 moles (i.e. dihydrate) at higher RH % levels.  
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(b) 
Figure B.9. Water vapor sorption of SD trehalose and raw trehalose dihydrate 
particles (water vapor absorbed/dry sample (mole/mole) vs relative humidity (RH)): 
(A) Comparison of water vapor absorption between SD trehalose and raw trehalose 
dihydrate particles at 25oC; (B) Comparison of water vapor absorption of SD 
trehalose particles (50% feeding rate) at 25oC and 37oC.  
 
Conclusions 
 
This study has demonstrated for the first time that the inhalable trehalose 
microparticles and nanoparticles with different particle morphology were rationally 
designed and successfully produced via organic solution advanced spray drying from 
dilute solution. The use of organic solvent has several important advantages to 
produce unimodal microparticulate/nanoparticulate inhalable powders with greatly 
reduced residual water content which can improve product stability and performance. 
The SD trehalose particles from various feeding rates possessed similar amorphous 
phase and capacity of water vapor sorption. Pharmaceutical processing conditions 
correlated in a meaningful manner with changes in important physicochemical and 
particle properties essential for targeted pulmonary delivery as DPIs. The 
thermotropic and lyotropic phase transition at 25oC and 37oC (biological temperature) 
were correlated with the amorphous glass vs rubbery state and solid-state phase 
transitions. 
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Appendix C Spray-Dried Itraconazole Aerosols 
 
C.1 Materials 
Two itraconazole formulation systems were produced at the same spray-drying 
conditions (50% pump rate) as shown in Section 3.2.2.1 in Chapter 3. The 
itraconazole two-component systems are itraconazole:mannitol and 
itraconazole:trehalose. The itraconazole three-component systems are 
itraconazole:phospholipids:mannitol and itraconazole:phospholipids:trehalose. 
 
C.2 Results 
C.2.1 Spray-dried Itraconazole Two-component Systems  
C.2.1.1 X-ray Powder Diffraction 
The XRPD patterns suggest that SD itraconazole:mannitol (ITR:MAN) (Figure C.1a) 
and SD itraconazole:trehalose (ITR:TRE) (Figure C.1b) were lacking in long-range 
molecular order except for ITR:MAN=1:5. By comparing to the XRPD of mannitol 
(in Appendix A), it suggests that the characteristic peaks correspond to alpha form of 
MAN. 
 
C.2.1.2 In Vitro Aerosol Dispersion Performance 
As shown in Figure C.2a, SD ITR:MAN=1:5 aerosol powder exhibited a relatively 
higher particle deposition on stage 1 compared to the formulations with other ratios. 
The deposition mode of fine particles was on stage 4 and stage 2 for the powders of 
ITR:MAN=1:0.1, 1:0.5, and 1:1, and ITR:MAN=1:5, respectively. Compared to other 
formulations, ITR:MAN=1:5 aerosol particles exhibited an lower value in FPF and 
RF, and an higher value in MMAD  of 14.3µm. The data indicate that 
ITR:MAN=1:0.1, 1:0.5, and 1:1, with a MMAD value being approximately ≤ 5µm, 
could be able to penetrate into deep lung regions. However, ITR:MAN=1:5, after 
partial crystallization, showed a MMAD value far beyond respirable size of 10µm. 
The detailed values are listed in Table C.1. 
SD ITR:TRE aerosol powders (Figure C.2b) shifted fine particle deposition mode 
from stage 4 to stage 5 with increasing amount of TRE. The FPF, RF, and MMAD of 
ITR:TRE aerosol particles ranged from 27.9% to 45.9%, 41.7% to 74.7%, and 2.0µm 
to 4.6µm, respectively. These data suggest that ITR:TRE powders were suitable for 
deep lung penetration. The detailed values are listed in Table C.2. 
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(a) 
 
(b) 
Figure C.1. X-ray powder diffraction patterns for: (a) SD itraconazole:mannitol 
formulations; and (b) SD itraconazole:trehalose formulations. 
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(a) 
 
(b) 
Figure C.2. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for: (a) itraconazole:mannitol powders; 
and (b) itraconazole:trehalose powders (mean ± SD, n=3). 
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Table C.1. Aerosol dispersion performance parameters of SD itraconazole:mannitol 
particles (mean ± margin of error for 95% confidence, n=3). 
 
ITR:MAN Aerosol Dispersion Performance Parameters 
Molar Ratio ED[%] FPF[%] RF[%] MMAD[µm] GSD 
1:0.1 98.1±1.4 28.2±1.0 46.2±1.3 5.2±0.3 3.2±0.4 
1:0.5 97.0±0.4 35.9±1.3 56.1±2.1 3.8±0.3 2.6±0.1 
1:1 97.0±1.4 29.7±2.8 48.5±2.3 5.1±0.4 3.0±0.2 
1:5 98.9±0.4 16.9±1.3 28.8±1.9 14.3±0.3 3.9±0.7 
 
Table C.2. Aerosol dispersion performance parameters of SD itraconazole:trehalose 
particles (mean ± margin of error for 95% confidence, n=3). 
 
ITR:TRE Aerosol Dispersion Performance Parameters 
Molar Ratio ED[%] FPF[%] RF[%] MMAD[µm] GSD 
1:0.1 97.7±1.0 31.5±2.6 53.7±2.9 4.4±0.4 2.6±0.1 
1:0.5 96.3±0.7 45.9±3.5 74.7±3.1 2.7±0.3 2.2±0.1 
1:1 97.0±0.7 27.9±3.6 41.7±5.0 4.6±0.7 3.1±0.2 
1:5 97.7±1.1 39.4±2.1 69.9±5.0 2.0±0.2 2.0±0.1 
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C.2.2 Spray-dried Itraconazole Three-component Systems  
C.2.2.1 X-ray Powder Diffraction 
The XRPD patterns suggest (Figure C.3a) that SD 
itraconazole:phospholipids:mannitol (ITR:PLS:MAN) formulations lacked long-range 
molecular order at molar ratio of 3:1:9. Some characteristic crystalline peaks were 
observed in both ITR:PLS:MAN=3:3:9 and 3:9:9 powders. SD 
itraconazole:phospholipids:trehalose (ITR:PLS:TRE) particles (Figure C.3b) were 
lacking in long-range molecular order. The phospholipid bilayer structure was 
retained after spray drying for both formulation systems. 
 
C.2.2.2 In Vitro Aerosol Dispersion Performance 
As shown in Figure C.4a, SD ITR:PLS:MAN=3:1:9 aerosols exhibited an extremely 
low particle deposition of 2.4% on stage 1 compared to other two partially crystalline 
formulations. The deposition mode of fine particles was on stage 4 and stage 2 for 
aerosol powders of ITR:PLS:MAN=3:1:9, and ITR:PLS:MAN=3:3:9 and 3:9:9, 
respectively. ITR:PLS:MAN=3:1:9 aerosols exhibited FPF, RF, and MMAD as 
66.3%, 97.6%, and 2.8µm, respectively. As shown for MMAD of being from 28.3µm 
to 34.3µm, ITR:PLS:MAN=3:3:9 and 3:9:9 aerosol were not suitable for dry powder 
for inhalation. Therefore, only ITR:PLS:MAN=3:1:9 aerosol powder was suitable to 
be delivered to deep lung regions. The detailed values are listed in Table C.3. 
SD ITR:PLS:TRE (Figure C.4b) aerosol particles exhibited deposition mode of fine 
particles on stage 4 or stage 5. With FPF, RF, and MMAD being of 36.5%, 70.4%, 
and 1.9µm, ITR:PLS:MAN=3:3:9 aerosols appeared to have a superior aerosol 
dispersion performance to the others. ITR:PLS:MAN=3:1:9 and 3:3:9 aerosol 
particles, exhibiting MMAD values ≤ 5µm, were suitable for deep lung delivery. The 
detailed values are listed in Table C.4. 
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(a) 
 
(b) 
Figure C.3. X-ray powder diffraction patterns for: (a) SD 
itraconazole:phospholipids:mannitol formulations; and (b) SD 
itraconazole:phospholipids:trehalose formulations. 
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(a) 
 
 
(b) 
 
Figure C.4. Aerosol dispersion performance using the NGI under an airflow rate (Q) 
of 60 L/min with the HandiHaler® DPI device for: (a) 
itraconazole:phospholipids:mannitol powders; and (b) 
itraconazole:phospholipids:trehalose powders (mean ± SD, n=3). 
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Table C.3. Aerosol dispersion performance parameters of SD 
itraconazole:phospholipids:mannitol particles (mean ± margin of error for 95% 
confidence, n=3). 
 
ITR:PLS:MAN Aerosol Dispersion Performance Parameters 
Molar Ratio ED[%] FPF[%] RF[%] MMAD[µm] GSD 
3:1:9 95.4±0.9 66.3±0.6 97.6±0.8 2.8±0.1 1.8±0.0 
3:3:9 99.4±0.2 12.3±0.9 19.8±1.3 28.3±2.0 4.9±0.2 
3:9:9 99.2±0.4 10.1±2.4 18.5±3.6 34.3±7.8 5.5±2.7 
 
 
Table C.4. Aerosol dispersion performance parameters of SD 
itraconazole:phospholipids:trehalose particles (mean ± margin of error for 95% 
confidence, n=3). 
 
ITR:PLS:TRE Aerosol Dispersion Performance Parameters 
Molar Ratio ED[%] FPF[%] RF[%] MMAD[µm] GSD 
3:1:9 96.7±0.5 23.9±2.3 45.7±4.0 3.6±0.6 2.8±0.2 
3:3:9 93.2±0.9 36.5±3.1 70.4±5.6 1.9±0.1 2.0±0.1 
3:9:9 98.0±0.2 29.6±1.9 46.9±2.2 5.6±0.3 2.9±0.3 
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